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Cover illustration: Dougal Haston on the summit of mount Everest after the first successful ascent of the south-west face, september 25th 1975. Photo courtesy of Doug Scott. "We walked up side by side the last few paces to the top, arriving there together the entire world lay before us. That summit was everything and more that a summit should be. My usually reticent partner became expansive, his face broke out in a broad, happy smile and we stood there hugging each other and thumping each other's backs." 
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Summary 
Tumor hypoxia is a characteristic feature of locally advanced solid tumors which has been 
described in a wide range of tumor types. It is the consequence of the tumor's uncontrolled 
growth and structural and functional abnormalities of its blood vessels. Its presence is 
associated with a negative prognosis and impairs the effectiveness of common anti-cancer 
therapies. Despite the existence of a number of specialized PET tracers for the detection of 
tumor hypoxia, their use is limited. The most widely used PET tracer for tumor detection, 
staging and evaluating therapy response is the glucose analogue [18F]FDG, which exploits the 
inherent dependence of the tumor cell on glycolysis (Warburg effect). As the proteins 
responsible for [ 18F]FDG-uptake are under control of HIF-1, the master transcription factor 
regulating the hypoxic response, the degree of [
18F]FDG-uptake might indirectly reflect the 
level of tumor hypoxia and vice versa. Detection of tumor hypoxia under certain 
circumstances using [ 18F]FDG would obviate the need for more specialized hypoxia 
radiotracers. Additionally, as there are a number of situations where [18F]FDG-PET imaging 
is less than ideal (high physiological uptake, low tumor metabolic rate, high tumor G6P­
levels ), insight into the close relation between tumor hypoxia and tumor metabolism might 
provide opportunities to increase tumor [18F]FDG-uptake and thereby improve imaging. In 
this work the effects of a modification of tumor oxygenation on tumor metabolism and with it 
the possible consequences and benefits for functional imaging using [ 18F]FDG-PET, were 
studied and a new marker of tumor vasculature was validated. In Chapter 2, partim 2.1, the 
effects of an increase in tumor oxygenation on tumor metabolism were studied by 
investigating changes in expression of proteins important for tumor metabolism, survival and 
spread in a rat colorectal xenograft after treatment with rhEPO. This study showed the 
detrimental effects of the combination ofrhEPO treatment with RT. In Chapter 2, partim 2.2, 
the effects of a decrease in tumor oxygenation or a direct HJF-1 activation on tumor 
metabolism were studied by investigating [ 18F]FDG-uptake in an in vitro and in vivo model of 
human colorectal carcinoma. Activation of HIF-1 and subsequent transcription of proteins 
responsible for [ 18F]FDG-uptake, increased [ 18F]FDG-uptake in HT29-cells. Although 
physical induction of hypoxia in an in vivo model of human colorectal carcinoma using 
hydralazine did not result in an increase in tumor [ 18F]FDG-uptake, systemic administration 
of a chemical inhibiting HIF-la breakdown resulted in a significant increase in SUVmax and 
SUVmean. In Chapter 2, partim 2.3, the distribution of the exogenous nitroimidazole hypoxia 9 
marker pimonidazole was compared with the expression of GLUTl and 3, HK2 and CA IX in a spontaneous canine mammary gland tumor and a statistically significant correlation was found between pimonidazole staining and GLUTl expression. In Chapter 2, partim 2.4, a significant correlation was found between SUVmax and SUVmean values of patients suffering from NSCLC and the expression of the endogenous hypoxia marker CA IX. Although our results suggest that [ 18F]FDG-uptake might reflect tumor hypoxia, the use of 
[
18F]FDG as a reliable non-invasive marker of tumor hypoxia seems questionable. Nevertheless, insights into the relationship between tumor hypoxia and tumor metabolism can create opportunities to increase tumor [ 1 8F]FDG-uptake in situations where diagnostic accuracy is suboptimal. In Chapter 3, a new radiotracer (99mTc-(C0)3 His-CNA35) that selectively binds tumor vasculature was evaluated. Our results indicated the convenient preparation of a stable, functional and specific radiotracer that gives a reliable estimate of existing tumor vasculature through the binding of subendothelial collagen IV due to the characteristic leakiness and immatureness of tumor blood vessels in a human HT29 colorectal carcinoma xenograft. Non-invasive detection of tumor vasculature might (i) offer a tool to provide a reliable assessment of tumor vasculature and thus provide a means for the management and planning of anti-angiogenic therapy and (ii) might provide insights into tumor hypoxia. 
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Samenvatting 
Tumorale hypoxie is een karakteristiek fenomeen dat is beschreven in verscheidene tumor 
types. Het is het gevolg van een ongecontroleerde tumorale groei en structurele en functionele 
abnormaliteiten van de tumorale bloedvaten. De aanwezigheid van tumorale hypoxie is 
geassocieerd met een negatieve prognose en vermindert de efficientie van standaard 
oncologische behandelingen zoals radio- en chemotherapie. Ondanks het bestaan van 
verscheidene gespecialiseerde PET tracers voor de detectie van tumorale hypoxie, is hun 
gebruik eerder beperkt. De meest gebruikte PET tracer voor kanker detectie, staging en 
nagaan van therapie respons is het glucose analoog [ 18F]FDG, welke de inherente 
afhankelijkheid van de tumor eel op glycolyse voor z'n energieproductie (Warburg effect) 
uitbuit. Omdat de eiwitten die verantwoordelijk zijn voor [18F]FDG-opname onder de controle 
staan van HIF-1, de centrale transcriptiefactor die de hypoxische respons regelt, zou de mate 
van hypoxie deels worden weergegeven door de mate van [ 18F]FDG-opname en omgekeerd. 
Detectie van hypoxie door middel van [ 18F]FDG zou gespecialiseerde hypoxie tracers 
overbodig maken. Bijkomend zouden in situaties waarin beeldvorming dmv. [ 18F]FDG-PET 
minder ideaal is (hoge fysiologische opname, lage metabole activiteit, hoge tumorale G6P 
activiteit), de inzichten in deze relatie mogelijkheden kunnen bieden om tumorale [18F]FDG­
opname te verhogen en op die manier beeldvorming kunnen verbeteren. In dit werk werden de 
effecten van een modificatie van de oxygenatie op het metabolisme van de tumor nagegaan en 
daarmee de mogelijke gevolgen en voordelen voor functionele beeldvorming dmv. [18F]FDG­
PET. Bijkomend werd een nieuwe merker voor tumorale vasculatuur gevalideerd. In 
Hoofdstuk 2, partim 2.1 werden de effecten van een stijging van de tumorale oxygenatie op de 
expressie van een aantal metabole eiwitten nagegaan. Deze studie toonde de negatieve invloed 
aan van de combinatie van rhEPO - behandeling en radiotherapie. In Hoofdstuk 2, partim 2.2 
werd tumorale [ 18F]FDG opname nagegaan na chemische inductie van hypoxie en chemische 
activatie van HIF-1 in een in vitro en in vivo model van colorectale kanker. Activatie van 
HIF-1 en de daaropvolgende transcriptie van eiwitten die verantwoordelijk zijn voor de 
opname van [ 18F]FDG, leidde tot een stijging van [ 18F]FDG opname in HT29 cellen. Waar 
fysische inductie van hypoxie in een in vivo model van colorectale kanker dmv. hydralazine 
niet resulteerde in een stijging van de tumorale [ 18F]FDG opname, resulteerde systemische 
toediening van geneesmiddelen die de afbraak van HIF-1 inhibeerden, in een significante 
stijging van SUVmax en SUVmean. Deze resultaten geven aan dat, in situaties waar 
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[
18F]FDG-PET beeldvorming minder ideaal is, voorbebandeling met geneesmiddelen die de afbraak van HIF-1 inhiberen, mogelijk tumorale [18F]FDG-opname kunnen doen stijgen. In Hoofdstuk 2, partim 2.3 werd een gelijkaardig expressiepatroon gevonden van eiwitten die verantwoordelijk zijn voor [ 18F]FDG-opname en pimonidazole, een exogene bypoxie merker, in een spontaan borstcarcinoma in honden In Hoofdstuk 2, partim 2.4 werd een significante correlatie gevonden tussen de SUVmax en SUVmean waarden van patienten die lijden aan longkanker en de expressie van CA IX, een endogene merker van hypoxie. Hoewel onze resultaten suggereren dat [ 18F]FDG-opname en hypoxie in hoge mate verbonden zijn, lijkt bet gebruik van [ 18F]FDG als betrouwbare merker voor hypoxie twijfelacbtig. Wei kunnen inzicbten in deze relatie de mogelijkheid bieden om tumorale [18F]FDG-opname te vergroten in situaties waarin de diagnostische accuraatbeid suboptimaal is. In Hoofdstuk 3 werd een nieuwe tracer (99mTc-(CO)3 His-CNA35) geevalueerd, die selectief bindt aan tumorale bloedvaten. Onze resultaten gaven aan dat deze radiotracer gemakkelijk te produceren is, stabiel en functioneel is, en een betrouwbare inscbatting geeft van de bestaande tumorale vasculatuur door de binding van de subendotheliale collageen IV laag als gevolg van de structurele abnormaliteiten van tumorale bloedvaten in een HT29 colorectaal carcinoma xenograft. Niet-invasieve detectie van tumorale bloedvaten kan: (i) een mogelijkheid bieden om op een betrouwbare manier anti-angiogene therapie te plannen (ii) inzicbten bieden in bet proces van tumorale bypoxie. 
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Chapter 1: Introduction and Aims 13 
14 
1. 1 Hypoxia: definition Maintaining a normal oxygen (02) homeostasis is a key prerequisite for the development, growth and normal function of all mammals. In every mammalian cell, 02 is used in aerobic respiration to generate energy in the form of ATP ( adenosine triphosphate) and other energy­carrying molecules. Under normal aerobic conditions, this happens through the succession of glycolysis and Krebs cycle (alternatively known as the TCA (tricarboxylic acid) cycle) where oxidative phosphorylation is completed. The former takes place in the cytosol and does not require 02, the latter takes place in the mitochondria and requires 02. In the absence of 02, the end product of glycolysis (pyruvate) does not enter the Krebs cycle but is broken down (to lactic acid) in a process yielding considerable less energy than aerobic respiration (Lodish et al. 2 004). Oxygen thus ensures an efficient cellular energy production. Normal physiological pOi-values across the body range from 150 mmHg in the upper airway to 66-24 mmHg in different tissues/organs (see Table 1). 
Tissue I Position p02(mmHg) reference Sea level 159 mmHg Upper airway 150mmHg Alveolar blood l00mmHg Stainsby et al., 1988 Arterial blood 95 mmHg Stainsby et al., 1988 Venous blood 4 0mmHg Stainsby et al., 1988 Tissue, organ dependent 66-24 mmHg Vaupel, 1989 Malignancies :S2 0mmHg Vaupel, 1989 Anoxia 0mmHg 
Table 1. pO2-levels across the body. When there is an imbalance between 02 supply and demand, tissue hypoxia arises. It can be caused by a number of factors such as low 02 partial pressure in arterial blood (hypoxemic hypoxia), reduced ability of blood to carry 02 (anaemic hypoxia), reduced tissue perfusion ( circulatory or ischemic hypoxia), deterioration of the diffusion geometry ( diffusional hypoxia), and the inability of cells to use 02 due to intoxication (histotoxic or cytotoxic hypoxia). In normal physiological circumstances, an increase in O2-consumption is matched by an increase in blood flow and, therefore, does not lead to hypoxia (Hocke I et al. 2 001 ). 15 
1.2 Tumor hypoxia: definition and causative factors 
As apposed to normal mammalian cells, tumor cells are characterized by their uncontrolled 
growth due to self-sufficiency in growth signals, insensitivity to antigrowth signals, limitless 
replicative potential, sustained angiogenesis, tissue invasion and metastasis, and evasion of 
apoptosis (Hanahan et al. 2000) .. As a result of this uncontrolled growth, a tumor outgrows the 
vasculature and resources it relies on and intratumoral hypoxia arises. The occurence of 
heterogeneously distributed, clinically relevant areas of hypoxia and/or anoxia is a 
characteristic feature of locally advanced solid tumors which has been described in a wide 
range of tumor types and in approximately 50-60% of all solid tumors. The pretherapeutic 
oxygenation status assessed in cancers of the breast, uterine cervix and head and neck is lower 
than in their respective normal counterpart and is independent of clinical size, stage, 
histology, grade, nodal status and a series of other tumor characteristics or patient 
demographics. Tumor-to-tumor variability in oxygenation is greater than intra-tumor 
variability and there doesn't seem to be a topological distribution of pO2 values within the 
tumor. Local recurrences have a higher hypoxic fraction than the respective primary tumors 
and there is no difference in oxygenation status between primary and metastatic malignancies 
(Vaupel et al. 1989, Hockel et al. 2001, Vaupel et al. 2007). Although no sharp threshold 
exists between hypoxia and normoxia and no single hypoxic treshold is generally applicable, 
a median 02 partial pressure in the tumor of approximately 8-10 mmHg appears to represent a 
critical threshold below which detrimental changes associated with reduced 02 consumption 
have been described and intracellular acidosis, ATP depletion, and a drop in energy supply 
will occur. The threshold 02 partial pressure below which oxidative phosphorylation, and thus 
ATP formation, will cease, is dependent on cell line and experimental setup and is believed to 
lie between 0.5 and 10 mmHg (Hockel et al. 2001). 
Commonly, three major pathogenetic mechanisms involved in the emergence of tumor 
hypoxia are described, respectively chronic hypoxia, acute hypoxia and anaemic hypoxia. 
Chronic or diffusion-related hypoxia is believed to be the result of increased diffusion 
distances between the nutritive blood vessels and the tumor cells or deterioration of diffusion 
geometry. As a consequence, O2-supply (and nutrient supply) for cells distant (> 70µm) from 
nutritive blood vessels, is obstructed. 
Acute or perfusion-related hypoxia is an often transient form of hypoxia which is caused by 
an inadequate blood flow in the tumor and is believed to be the result of an abnormal structure 
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and function of the tumoral microvessels. The formation of these vessels is achieved through the process of angiogenesis in which, through a multistep process that relies on the tumor­driven production of pro-angiogenic factors, new blood vessels are formed from existing ones (Carmeliet et al. 2000). These resulting new blood vessels however, are structurally and functionally deficient when compared to normal ones. Anatomically, tumor blood vessels are disorganized, dilated, tortuous and leaky. Unlike the blood vessels of normal tissue, which have an organized and regular branching order, tumor blood vessels display irregular interconnections and branching, and are heterogeneous in their spatial distribution within the tumor. At the cellular level, the endothelial cells that line the tumor blood vessels have an irregular, disorganized morphology, leading to an incomplete endothelial lining with large inter-endothelial junctions and an increased number of fenestrations (Baluk et al. 2005, Fukumura et al. 2007, Carmeliet et al. 2011 ). In addition, perivascular cells (pericytes and vascular smooth muscle cells), that normally surround and support the endothelium, have an abnormal morphology and a heterogeneous association with tumor vessels. These cells usually lie within the vessel basement membrane and interact closely with endothelial cells to prevent vessel leakage (Baluk et al. 2005, Fukumura et al. 2007, Carmeliet et al. 2011). Finally, the vascular basement membrane in tumor tissue also displays abnormal characteristics. It has a loose association with endothelial cells and is characterized by multiple redundant layers, irregular thickness, focal holes and broad extensions into the tumor stroma (Baluk et al. 2005). These structural and functional deficiencies of tumor vasculature lead to heterogeneous blood flow, hypoxia, acidosis and elevated interstitial fluid pressure (IFP) with a disturbed tumor microenvironment as a result (Fukumura et al. 2007). The molecular mechanisms underlying this abnormal vasculature characteristics are not entirely clear, but an imbalance between pro- and anti-angiogenic factors as the tumor grows, is believed to be a key contributor (Jain et al. 2005). Finally, a third type of hypoxia (anaemic hypoxia) is sometimes described which is the result of reduced 02 transport capacity of the blood due to the presence of disease- or treatment­related anaemia which frequently accompanies cancer (Vaupel et al. 2007). 17 
1.3 Tumor hypoxia: consequences 
Cancer cells adapt to hypoxic conditions by the induction of target genes involved in glucose 
metabolism, angiogenesis, erythropoiesis and apoptosis in an effort to overcome their 
compromised situation. Many of these adaptations are coordinated by the transcription factor 
hypoxia-inducible factor (HIF) - 1, which has been verified as a master regulator of oxygen 
homeostasis under hypoxic conditions (Semenza et al. 2000). HIF-1 is a heterodimer 
consisting of HIF-la and HIF-1�. Its biological activity is determined by the expression and 
activity of HIF-la which is constantly expressed and subsequently rapidly destroyed under 
normal oxygen conditions. This involves a mechanism where post-translational hydroxylation 
of specific proline residues (Pro402 and Pro564) by prolyl hydroxylases (PHD) allows binding 
of the von Rippel-Lindau (VHL) tumor suppressor protein which in turn leads to 
ubiquitination by an E3 ubiquitin-protein ligase and subsequent proteosomal degradation. 
Additionally, factor inhibiting HIF-1 (FIH-1) hydroxylates an asparagine residue (Asn803) 
within HIF-la and thereby blocks its interaction with the co-activators p300 and CBP [CREB 
( cAMP-response-element-binding protein)-binding protein] (Mahon et al. 2001, Lando et al. 
2002). Under hypoxic conditions however, stabilization of HIF-1 a occurs through inactivation 
of the Pl-IDs, allowing it to translocate to the nucleus where it can bind with the constitutively 
expressed HIF-1 � to form a functional transcription factor that will transactivate several target 
genes (Vaupel et al. 2004, Kim et al. 2007, Semenza et al. 2007). These target genes include 
amongst others vascular endothelial growth factor (VEGF), facilitative glucose transporters 
(GLUTs), hexokinases (HKs), erythropoietin (EPO), carbonic anhydrase IX (CAIX), ... The 
resulting adaptive changes in the proteome and genome of the tumor cells are, after selection 
and clonal expansion, believed to lead to a more adapted and aggressive tumor cell 
population. Accordingly, the presence of tumor hypoxia impairs the effectiveness of common 
anti-cancer therapies like radiotherapy (RT) and chemotherapy. Hypoxia-induced 
radioresistance is multifactorial. Besides the above mentioned proteomic and genomic 
changes that most likely contribute to resistance by increasing the number of mutated cells 
that are more resistant to apoptosis or have an increased proliferative and metastatic potential, 
and by causing upregulation of several repair enzymes and stress proteins (Hockel et al. 2001, 
Harrison et al. 2004 ), the main reason for radioresistance is the intrinsic dependence of RT on 
oxygen to cause damage to the tumor cell. As oxygen has a very high electron affinity, it 
stabilizes the DNA-damaging radicals that are formed after the interaction of radiation with 
intracellular water. Additionally, oxygen stabilizes ('fixes') the radicals that are formed after 
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direct interaction of radiation with the DNA (Harrison et al. 2004 ). This effect, widely known 
as the 'oxygen enhancement ratio', implies that the radiation dose needed to acquire the same 
biologic effect is two to three times higher in the absence of oxygen than in the presence of 
oxygen (Gray et al. 1953). Hypoxia has also been shown to reduce chemotherapeutic efficacy 
by causing cells within hypoxic regions to cycle more slowly, and by providing a selection 
mechanism for cells with reduced susceptibility for apoptosis and upregulation of several 
repair enzymes and stress proteins (Hickman et al. 1994, Hockel et al. 2001 ). Also, several 
chemotherapeutic agents like cyclophosphamide, carboplatin and doxorubicin have been 
shown to be oxygen dependent in in vitro and in vivo conditions (Teicher 1990 et al., Hockel 
et al. 2001, Harrison et al. 2004). Additionally, due to limited drug penetration within solid 
tumors, hypoxic regions are often protected from the cytotoxic effects of chemotherapeutic 
agents further reducing drug efficacy (Hockel et al. 2001, Durand et al. 2001 ). All these 
mechanisms together ensure that tumor hypoxia is a negative prognostic factor. Accordingly, 
tumor hypoxia measured with invasive oxygen electrodes has been associated with an 
aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis 
in advanced squamous cell carcinoma of the cervix (Hockel et al. 1996, Fyles et al. 1998), 
head and neck (Nordsmark et al. 1996, Brizel et al. 1997, Nordsmark et al. 2005), and soft­
tissue sarcomas (Brizel et al. 1996). 
In order to increase success of RT and chemotherapy, attempts have been made to reduce 
tumor hypoxia and its effects. A first approach is to directly increase the oxygen supply to the 
tumor. This can be done by the use of hyperbaric oxygen and accelerated fractionated 
radiotherapy combined with carbogen (ARCON) or by the correction of anaemia by blood 
transfusion or the administration of recombinant human erythropoietin (rhEPO). A second 
approach is the development of chemicals that mimic oxygen and sensitize hypoxic cells to 
radiation of which the nitroimidazole compounds are the best known. Further, attempts have 
been made to selectively target hypoxic cells through the use of hypoxia-specific cytotoxins. 
These bioreductive drugs are reduced by biological enzymes to their toxic and active 
metabolites in the absence of oxygen (Hoogsteen et al. 2007). 
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1.4 Tumor hypoxia: detection 
Given its importance in tumor biology and in order to predict outcome and identify patients 
with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo 
measurement of tumor hypoxia is required. Several different approaches exist for the 
detection of tumor hypoxia including invasive ( oxygen electrodes, endogenous markers, 
exogenous markers) and non-invasive methods (MRI, PET-, SPECT-imaging). 
1 .4. 1 Invasive detection of tumor hypoxia. 
At present, the best-known technique for direct in vivo determination of tumor oxygenation is 
the real-time measurement of oxygen tension in tissues with invasive oxygen electrodes such 
as the Eppendorf
M 
polarographic needle electrode (Fyles et al. 1998, Olive et al. 2001, 
Nordsmark et al. 2005) and the OxyLite™ fiber-optic probe (Bussink et al. 2000, Jarm et al. 
2002, Brurberg et al. 2003). Although both have a different mode of action, they allow direct 
measurement of oxygen concentrations at different positions in the tumor. Whereas the 
Eppendorf
M 
polarographic needle electrode consumes oxygen during its operation and is 
moved throughout the tissue during measurements, providing multiple samplings, the 
OxyLite™ fiber-optic probe does not consume oxygen and can be left at one position for a 
longer period of time making it more suitable for the detection of temporal fluctuations in 
pO2. Tumor oxygenation measurements obtained using the Eppendorf
M 
polarographic needle 
electrode correlated well with clinical outcome in several clinical trials (Hockel et al. 1996, 
Brizel et al. 1996, Nordsmark et al. 1996, Brizel et al. 1997, Fyles 1998, Nordsmark 2005). 
As a consequence, this technique has been considered the "gold standard" for oxygenation 
measurements in human tumors. Nonetheless, this technically demanding procedure has a 
number of drawbacks and limitations like its sensitivity for sampling errors, large inter­
observer variability, its invasive nature, failure to distinguish necrotic areas from viable tumor 
tissue and the fact that only easy accessible tumors can be studied. 
Several different proteins that are involved in the hypoxic response, of which the most 
important are HIF-la, CA IX, GLUTl and GLUT3, have emerged as possible endogenous 
markers of hypoxia. 
As a part of the transcription factor HIF-1, HIF-la seems the most obvious choice as an 
endogenous marker of tumor hypoxia. Exposure of HeLaS3 cells to hypoxia for less than 2 
min already revealed nuclear HIF-1 a protein induction. Reoxygenation reduced HIF-1 DNA 
20 
binding within 2 min, and nuclear HIF-1 a protein levels within 4 to 8 min, down to a level 
below the detection limit within 32 min (Jewell et al. 2001). This quick hypoxic response 
would make HIF-la the ideal hypoxic endogenous marker for detection of chronic as well as 
acute hypoxia. Unfortunately, studies trying to identify a correlation between 
immunohistochemical HIF-la expression and electrode measurements have reported only a 
weak (Haugland et al. 2002, Hutchison et al. 2004) or lack of (Mayer et al. 2004) correlation. 
The transmembrane zinc metalloenzyme carbonic anhydrase IX (CA IX) catalyzes the 
reversible hydration of carbon dioxide to carbonic acid and is involved in respiration and 
acid-base balance (Potter et al. 2004). The gene for CA IX has been shown to be the most 
strongly hypoxia-inducible gene of 25504 transcripts on a gene array (Lal et al. 2001). A 
study by Vordermark et al. showed that hypoxia-induced CA IX protein expression was 
delayed ( detectable level of expression after 6h of hypoxia, highest level of expression after 
24h of hypoxia) and that the protein was stable for 96h after reoxygenation in human 
fibrosarcoma and human pharyngeal carcinoma cells (V ordermark et al. 2005). As a results, it 
appears that CA IX is more suited as a marker of chronic hypoxia than as a marker of acute 
hypoxia. Several studies investigated a possible correlation of CA IX expression with 
oxygenation status in several types of cancer with mixed results. Whereas some studies 
reported on a positive correlation between these two (Loncaster et al. 2001, Le et al. 2006, 
Iakovlev et al. 2007), other studies found no such correlation (Hedley et al. 2003, Mayer et al. 
2005, Jankovic et al. 2006). 
Also controlled by HIF-1 and of interest as endogenous markers of hypoxia are the facilitative 
glucose transporters (GLUTs) 1 and 3 which mediate the transport of glucose and other 
monosaccharides across the plasma membrane of mammalian cells. As the timescale for 
GLUTl expression appears to be similar to that of CA IX (Rafajova et al. 2004), GLUTl is 
also expected to be mainly a marker of chronic hypoxia. Again, conflicting results were found 
when comparing GLUTl expression with oxygenation status (Airley et al. 2001, Mayer et al. 
2005, Sakata et al. 2006). 
To date, it remains unclear whether the conflicting results when looking for a correlation 
between the expression of endogenous hypoxia markers and direct tumor oxygenation 
measurements have a methodological or biological cause. Probably, the combination of the 
above mentioned limitations and drawbacks associated with the use of invasive oxygen 
electrodes taken together with the influence of hypoxia-independent microenvironmental 
parameters such as differentiation, pH, glucose availability, oncogene activation, . . . on the 
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expression of proteins downstream of HIF-1, is responsible for the mixed results (Bussink et 
al. 2003). 
The most studied invasive marker for qualitative and quantitative determination of tumor 
hypoxia in experimental and clinical circumstances is the exogenous hypoxia marker 
pimonidazole hydrochloride. This 2-nitroimidazole reagent is reduced under hypoxic 
conditions and the resulting adducts are irreversibly bound to thiol-containing proteins in 
viable hypoxic cells with :functional nitro-reductase enzymes. After it has been reduced and 
bound in tumor tissue, loss of the marker mainly occurs through cell loss (Ljungkvist et al. 
2005). It shows a steep increase in the amount of reduction below a pO2 of 10 mmHg (Gross 
et al. 1995). This was confirmed in a study by Raleigh et al. in which pimonidazole binding 
was compared with micro-electrode pO2 measurements. They found that the correlation was 
strongest when the pimonidazole hypoxic fraction was compared with the percentage of pO2 
values below 10 mmHg (Raleigh et al. 1999). Other studies that compared pimonidazole 
binding with invasive oxygen measurements have yielded inconsistent results (Bussink et al. 
2000, Olive et al. 2001, Nordsmark et al. 2003). Necrosis is thought to be the main 
confounding factor. As pimonidazole staining is usually seen at a distance from blood vessels 
(Janssen et al. 2002), it is believed that it mainly detects chronic ( diffusion-related) hypoxia. 
Although numerous studies reported on correlations between pimonidazole staining and HIF­
l u  expression (Hutchinson et al. 2004, Jankovic et al. 2006, Russel et al. 2009), CA IX 
expression (Hoskin et al. 2003, Jankovic et al. 2006, Shin et al. 2007, Russel et al. 2009) and 
GLUTI expression (Airley et al. 2003, Hoskin et al. 2003) in several tumor types, other 
studies proved negative in this regard (Janssen et al. 2002, van Laarhoven et al. 2006, 
Goethals et al. 2006). Besides analysis of a possible correlation by correlating fractions of 
positively stained areas and intensities, some of these studies performed a more qualitative 
analysis taking into account the degree of colocalization. 
1 .4.2 Non-invasive detection of tumor hypoxia 
In nuclear medicine, the distribution of a previously administered radiolabeled molecule is 
studied by means of specialized instrumentation to assist in the diagnosis and treatment of 
disease. In contrast to anatomical imaging modalities like CT ( computed tomography) and 
MRI (magnetic resonance imaging), which provide morphological information of the studied 
object, nuclear medicine techniques attempt to provide :functional and biological information. 
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A gamma camera or SPECT (single photon emission computed tomography) camera detects scintillations that result from the interaction of SPECT radioisotopes ( e.g. technetium-99m (99mTc), iodine-123 ( 1 231)) emitted gamma rays with a sodium iodide crystal in front of the camera. A lead collimator placed in front of this crystal ensures that only gamma rays that are travelling perpendicularly to the crystal face can enter. In this way a projection of the distribution of the radiopharmaceutical in the body can be obtained. By the use of specific reconstruction algorithms, the planar images that are obtained at different angles by rotating the camera around the patient, are reconstructed to tomographic images (Eberl et al. 1998, Bailey et al. 1998). The same principle is used in PET (positron emission tomography) where images are acquired through the indirect detection of PET radioisotopes ( e.g. fluorine-18 
(
18F), carbon-11 ( 1 1C), oxygen-15 ( 150)) emitted positrons. When positrons emitted from positron emitting molecules interact with an electron in its surrounding, annihilation of both takes place and electromagnetic radiation in the form of two high-energy ( 511 ke V) photons emitted 18 0° away from each other is generated. Simultaneous detection of these photons by detectors on opposite sides of the object allows mapping of the distribution of the annihilations ('coincidence detection') (Meikle et al. 1998). The half-lives of SPECT radioisotopes is usually longer than that of PET radioisotopes, allowing longer acquisition times. This short half-life of PET radioisotopes raises the need for an on-site cyclotron and specialized radiosynthesis facilities, whereas the production of SPECT radiopharmaceuticals is less expensive and less cumbersome. On the other hand, PET cameras have a superior spatial resolution and PET allows more accurate quantification (Van de Wiele 2 006). Nuclear medicine has proven its role in today's clinical practice were it is used for a variety of applications. One of the major applications is in oncology were different radiopharmaceuticals are used for cancer detection, staging and monitoring of response and recurrence in several tumor types. For these purposes, a variety of radiopharmaceuticals are available to allow evaluation of tumor metabolism, cell death, cell proliferation, tumor hypoxia, . . . . Below is an overview of the most important radiopharmaceuticals to detect tumor hypoxia which was published as a review (Molecular imaging of hypoxia with radiolabeled agents. European Journal of Nuclear Medicine and Molecular Imaging. 2 009;36: 1674-1686.) 23 
1 .4.2.1  Non-invasive detection of tumor hypoxia with PET 
1) Nitroimidazole compounds These compounds are reduced into reactive intermediary metabolites by intracellular reductases in a process which is directly related to the level of oxygenation/hypoxia. This causes a gradient which is favourable for detection of hypoxic cells. Subsequently, these metabolites covalently bind to thiol groups of intracellular proteins and thereby accumulate within viable hypoxic cells. When labelled with a PET-tracer, these chemicals can be detected using PET-imaging methods. Several nitroimidazole compounds with different properties and labelled with different PET radionuclides have been described (Lee et al. 2 007, Krohn et al. 2 008). A) [ 1 8F]FMISO ([ 18F]fluoromisonidazole) Preclinical data: Kubota et al. evaluated the tumour imaging potential of [ 18F]FMISO in an AH1 09A tumour rat xenograft and examined the correlation between intratumoural distributions of [18F]FMISO, 14C-2-deoxyglucose and 14C-methionine. Hypoxic and radioresistant tumours could be identified by increased [ 18F]FMISO uptake. A large overlap in the distribution of [18F]FMISO and 14C-2-deoxyglucose and a small overlap in the distribution of [ 18F]FMISO and 1 4C-methionine were observed (Kubota et al. 1999). In a study by Rasey et al., an attempt was made to define the relationship between [ 18F]FMISO uptake and radiobiologically hypoxic fraction in a 36B 1 0  glioma rat xenograft. Although the relationship between classically defined radiobiologically hypoxic fraction and [ 18F]FMISO time-activity data remained to be clarified, [ 18F]FMISO retention provided useful correlations with the degree of hypoxia (Rasey et al. 2 000). Bentzen et al. compared [ 18F]FMISO uptake with invasive Eppendorf electrode pO2 measurements in a C3H mammary carcinoma mouse xenograft and found no direct correlation between both methods (Benten et al. 2 002). A number of studies compared [ 18F]FMISO uptake with immunohistochemical staining techniques. In a study by Dubois et al., [ 18F]FMISO uptake was compared with the exogenous hypoxia marker pimonidazole and the endogenous hypoxia marker carbonic anhydrase IX (CA IX) in a rhabdomyosarcoma rat xenograft. A statistically significant correlation was obtained between the hypoxic volumes defined with [ 18F]FMISO PET and the volumes 
24 
derived from the pimonidazole- and CA IX-stained tumour sections, indicating the value of 
[
1 8F]FMISO PET to measure hypoxia (Dubois et al. 2 004). Troost et al. tried to validate 
[
1 8F]FMISO PET by comparing [ 1 8F]FMISO uptake with pimonidazole staining in several xenograft models in two different studies. Both studies found a correlation between 
[ 
1 8F]FMISO uptake and pimonidazole immunohistochemistry (Troost et al. 2 006, Troost et al. 2 008). In a number of studies [ 1 8F]FMISO uptake was compared with [ 1 8F]FDG uptake. Most of these studies demonstrated the feasibility and utility of [ 1 8F]FMISO PET imaging to identify tumour hypoxia whereas [ 1 8F]FDG PET imaging seemed less suitable for this purpose (Bentzen et al. 2 000, Wyss et al. 2 006, Zanzonico et al. 2 006, Oswald et al. 2 007, Dence et al. 2 008). Clinical data: Valk et al. were the first to demonstrate the feasibility of [ 1 8F]FMISO PET to detect tumour hypoxia in three patients with malignant glioma (Valk et al. 1992). Rasey et al. assessed pretreatment hypoxia in a variety of human tumours using [ 1 8F]FMISO PET and concluded that human tumour hypoxia is widely prevalent and highly variable between different tumours of the same histology and also between regions within the same tumour (Rasey et al. 1996). In a study by Bruehlmeier et al. where hypoxia was measured in eleven patients with various brain tumours, it was concluded that late [ 1 8F]FMISO PET images provide a spatial description of tumour hypoxia which may develop irrespective of the magnitude of perfusion as measured with 1 5O-H2O PET (Bruelmeier et al. 2 004). A number of studies compared [ 1 8F]FMISO uptake with invasive Eppendorf electrode pO2 measurements. In some of these studies, [ 1 8F]FMISO uptake in renal cell carcinoma and head and neck cancer correlated well with pO2 measurements from polarographic needle oxygen electrodes, confirming the use of [ 1 8F]FMISO PET to measure tumour hypoxia (Lawrentschuk et al. 2 005, Zimny et al. 2 006, Gagel et al. 2 007, Gagel et al. 2 004, Bentzen et al. 2 003). Bentzen et al., however found no correlation between [ 1 8F]FMISO uptake and pO2 measurements in human soft tissue tumours (Bentzen et al. 2 003). Some of the above mentioned studies also compared uptake of [ 1 8F]FDG and [ 1 8F]FMISO in patients with head and neck cancer. They found no correlation between [ 1 8F]FDG uptake and pO2 measurements whereas an association between [ 1 8F]FMISO uptake and pO2 measurements existed (27-29). Further comparison of [ 1 8F]FDG and [ 1 8F]FMISO indicated that no correlation exist between both tracers as both represent different tumour characteristics (Rajendran et al. 2 003, Rajendran et al. 2 004, Cherk et al. 2 006, Cher et al. 2 006, Thorwarth et al. 2 006). 25 
Several clinical studies have used [ 18F]FMISO PET as a prognostic indicator in oncology. In a 
study by Rajendran et al., the prognostic effect of pretherapy [ 18F]FMISO PET on survival 
was investigated in 73 patients with head and neck cancer and pretreatment [ 18F]FMISO 
uptake proved to be an independent prognostic factor (Rajendran et al. 2006). Another study 
of 12 patients with head and neck carcinoma who received a preradiotherapy [ 18F]FMISO 
PET scan, concluded that [ 18F]FMISO uptake was predictive of treatment response to 
radiotherapy (Thorwarth et al. 2006). Similarly, in forty patients with advanced head and neck 
cancer and non-small cell lung cancer, outcome after radiotherapy could be predicted on the 
basis of kinetic behaviour of [ 18F]FMISO in tumour tissue (Eschmann et al. 2005). Two 
studies investigating the prognostic significance of [ 18F]FMISO PET in patients with head and 
neck cancer receiving chemoradiation in combination with the hypoxia sensitizer 
tirapazamine concluded that [18F]FMISO uptake can predict prognosis and is associated with 
a high risk of locoregional failure (Hicks et al. 2005, Rischin et al. 2006). Cher et al. showed 
that in patients with malignant glioma, [ 18F]FMISO uptake is prognostic for treatment 
outcome in the majority of patients (Cher et al. 2006). In a study with eight patients with non­
small cell lung cancer receiving chemotherapy and/or radiotherapy, changes in [ 18F]FMISO 
uptake measured early response to therapy and may predict freedom from disease as well as 
overall survival (Gagel et al. 2006). A recent study that was conducted to evaluate the 
reproducibility of [ 18F]FMISO intratumour distribution in 20 patients with head and neck 
cancer showed considerable variability in the intratumour uptake that can occur between 
repeated [ 18F]FMISO PET scans performed 3 days apart (Nehmeh et al. 2008). 
B) [ 1 8F]FAZA ([ 1 8F]fluoroazomycin-arabinofuranoside) 
Preclinical data: Sorger et al. compared the selective uptake of [ 18F]FMISO and [ 18F]F AZA in 
hypoxic cells in vitro and in a Walker 256 rat sarcoma model. The in vitro study showed that 
[
18F]FAZA is able to indicate reduced oxygen supply in the same order of magnitude of 
[
18F]FMISO. The in vivo study however, indicated that [ 18F]FMISO displayed a slightly 
higher standardized uptake value and tumour-to-muscle ratio compared to [ 18F]FAZA though 
the elimination of the latter was much faster (Sorger et al. 2003 ). Two other studies also 
compared [ 18F]FMISO and [ 1 8F]FAZA in various tumour mice xenografts and reported 
superior biokinetics for [ 18F]FAZA compared with [ 18F]FMISO. In both studies [ 18F]FAZA 
displayed higher tumour-to-background, tumour-to-muscle and tumour-to-blood ratios due to 
its more rapid clearance from blood and non-target tissues (Piert et al. 2005, Reischl et al. 
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2007). Beck et al. evaluated the predictive value of [ 18F]FAZA PET for success of 
radiotherapy in combination with tirapazarnine in EMT6 tumour mice xenografts. High 
[
1 8F]F AZA uptake was identified as an independent adverse progriostic factor for tumour 
progression and hypoxia imaging with [ 18F]FAZA PET was able to predict the success of 
radiochemotherapy (Beck et al. 2007). In a study by Busk et al., [ 18F]FAZA uptake was 
compared with Eppendorf electrode measurements and the hypoxia marker pimonidazole. The 
distribution of [ 18F]FAZA proved to be consistent with tumour hypoxia, as identified with the 
Eppendorf electrode measurements and the hypoxia marker pimonidazole (Busk et al. 2008). 
The same group compared the in vitro hypoxia specificity of cellular [ 18F]FDG and 
[
18F]FAZA retention and tested tracer distribution between hypoxic and non-hypoxic areas in 
different mice xenografts. As well the in vitro as the in vivo experiments indicated that 
[
18F]FAZA is an excellent marker for tumour hypoxia, whereas [ 18F]FDG is not (Busk et al. 
2008). 
Clinical data: Souvatzoglou et al. evaluated the feasibility of [ 18F]F AZA PET for the imaging 
of tumour hypoxia in eleven patients with head and neck cancer and concluded that PET 
imaging with [ 18F]F AZA is feasible and that adequate image quality is achieved 
(Souvatzoglou et al. 2007). Another study, that included 18 patients with advanced squamous 
cell head and neck cancer, evaluated the role of [ 18F]FAZA PET imaging to identify hypoxia 
in order to plan radiation treatment. It was concluded that radiation treatment planning and 
intensity-modulated radiotherapy based on [ 18F]F AZA uptake measurements is feasible 
(Grosu et al. 2007). C) [ 1 8F]FETA ([ 1 8F]fluoroetanidazole) 
In a study by Rasey et al., four cultured rodent cell lines were incubated with [ 18F]FETA for 
various times under graded 02 concentrations. The biodistributions of [ 
18F]FETA and 
[
18F]fluoromisonidazole (FMISO) at 2h and 4h postinjection in C3H mice bearing KHTn 
tumours were also compared. [ 18F]FMISO and [ 18F]FETA demonstrated similar oxygen 
dependency of binding in cultured cells. However, differences in biodistribution suggested 
advantages of [ 18F]FETA over [ 18F]FMISO because [ 18F]FETA appeared to be less 
metabolized in vivo than [ 18F]FMISO (Rasey et al. 1999). In another study, the cellular 
transport and retention of [ 18F]FETA was determined in vitro under air and nitrogen and the 
biodistribution and metabolism was determined in mice bearing several different xenografts. 
It was concluded that [ 18F]FETA has suitable physicochemical properties and is stable to non-
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hypoxic degradation in vivo. It was also demonstrated that the tumour retention of the 
radiotracer is related to radiobiological hypoxia and pO2 status as determined with 
polarographic needle oxygen electrodes (Barthel et al. 2004). D) [ 1 8F]FETNIM ([ 18F]fluoroerythronitromodazole) 
Preclinical data: Yang et al. reported on the synthesis and evaluation of [ 18F]FETNIM. Their 
results indicated that at 4h after injection, tumour-to-blood and tumour-to-muscle ratios in 
mammary tumour-bearing rats were significantly higher with [ 18F]FETNIM than with 
[
18F]FMISO (Yang et al. 1995). In a later study by Gronroos et al. where the pharmacokinetic 
properties and metabolite formation of [ 18F]FETNIM were studied, [ 18F]FETNIM showed low 
peripheral metabolism, little defluorination, and possible metabolic trapping in hypoxic 
tumour tissue (Gronroos et al. 2001). In a pre-clinical study by the same group, the hypoxia 
imaging ability of [ 18F]FETNIM was compared with that of [ 18F]FMISO in a C3H mammary 
carcinoma mice xenograft under different oxygenation conditions. Additionally, the 
biodistribution of both markers in normal tissues was assessed under similar conditions. 
Uptake of both tracers correlated with the oxygenation status in the tumours, but 
[
18F]FETNIM showed a low and favourable background signal in normal tissues as compared 
with [ 18F]FMISO (Gronroos et al. 2004). 
Clinical data: Most of the clinical studies with [ 18F]FETNIM were performed in patients with 
head and neck cancer. A study investigating the accurate radiation dosimetry in 27 patients 
with head and neck cancer concluded that the effective dose of [ 18F]FETNIM PET is well 
within the range of several related nuclear medicine procedures (Tolvanen et al. 2002). A lot 
of clinical studies were performed by researchers at the University of Turku in Finland. They 
found that [ 18F]FETNIM uptake in the early phase of tissue accumulation, as measured using 
[ 1 5O]H2O and PET, was highly variable and depended for the most part on perfusion (Lehtio 
et al. 2001 ). Tumour-to-plasma ratio provided the best estimate for tumour hypoxia (Lehtio et 
al. 2004). In another study the radiotherapy response was assessed by hypoxia imaging with 
[ 
18F]FETNIM PET in 21 patients with head and neck cancer and high uptake of [ 18F]FETNIM 
prior to radiation therapy was associated with a trend towards poor overall survival (Lehtio et 
al. 2004). 
28 
In a study by Ziemer et al., the biodistribution of[ 1 8F]EF5 was assessed using hepatoma and 
glioma rodent tumour models. [ 1 8F]EF5 was rapidly and uniformly distributed to all tissues. 
This together with its high drug stability in vivo suggests that [ 1 8F]EF5 is a promising agent 
for the noninvasive assessment of tumour hypoxia (Ziemer et al. 2003 ). Another study 
investigated hypoxia in androgen-dependent, androgen-independent and regressing Shionogie 
tumours using [ 1 8F]EF5. Differences in hypoxia between the different types of tumours could 
be detected with [ 1 8F]EF5 (Yapp et al. 2007). Recently, the first human study with [ 1 8F]EF5 
was performed in 15 patients with squamous cell carcinoma of the head and neck (HNSCC) in 
which the time course of [ 1 8F]EF5 uptake after intravenous injection was evaluated to 
determine the most suitable PET protocol (Komar et al. 2008). 
F) [ 1 8F]EF3 
Preclinical data: In the framework of the preclinical evaluation, Mahy et al. studied the 
pharmacokinetics, biodistribution, metabolism and specificity for hypoxia of [
1 8F]EF3 in 
different tumour bearing C3H mice breathing carbogen (5% CO2, 95% 02), 21 % oxygen and 
10% oxygen. They also compared [ 1 8F]EF3 uptake and EF5 adducts detected by 
irnrnunofluorescence in the same model. [ 1 8F]EF3 upake was inversely correlated with 
oxygen concentration and a significant correlation was found between the [ 1 8F]EF3 tumour­
to-muscle ratio and the fluorescence intensity of EF5 (Mahy et al. 2004, Mahy et al. 2006). 
Pharmacokinetics, biodistribution and metabolism of [ 1 8F]EF3 were assessed and compared 
with [ 1 8F]FMISO uptake in rodent tumour models. It was concluded that both exhibited 
similar pharrnacokinetics, biodistribution and metabolism and that [ 1 8F]FMISO was able to 
detect tumour hypoxia to a similar extent than [
1 8F]EF3, although it seemed less specific than 
the latter tracer (Mahy et al. 2008). The same group tried to increase tumour-to-noise ratio in 
C3H mice by increasing [ 1 8F]EF3 elimination. Several chemicals increasing renal filtration 
rate, decreasing tubular reabsorption or stimulating gastro-intestinal elimination were tested. 
Only phenobarbital induced a trend toward an increase in tumour-to-noise ratio (Christian et 
al. 2007). In another study, [ 1 8F]EF3 was quantitatively compared with [ 1 8F]FMISO in rats 
bearing syngeneic rhabdomyosarcoma tumours. It was showed that [ 1 8F]EF3 is cleared faster 
from the blood compared to [ 1 8F]FMISO. Both had a similar tumour uptake at 4h post 
injection, a similarly fast and uniform distribution in normal tissues and a comparable intra­
tumoural distribution, indicating that [ 1 8F]EF3 is not superior to [ 1 8F]FMISO (Dubois et al. 
2009). 
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Clinical data: In a recent phase I study by Mahy et al., pharmacokinetics, biodistribution and 
metabolism of [ 18F]EF3 were assessed in ten patients with head and neck squamous cell 
carcinoma. Administration of [ 18F]EF3 seemed feasible and safe in head and neck cancer 
patients. Uptake and retention of the tracer was observed in the tumour, indicating the 
presence of hypoxia (Mahy et al. 2007). 
Imaging with this marker was studied in 2 rat tumour types whereby the drug's biodistribution 
was assessed and optimized. [ 18F]EF1 proved an excellent radiotracer for noninvasive 
imaging of tumour hypoxia (Evans et al. 2000). H) [ 1 24I]IAZA ([ 124I]iodoazomycin arabinoside) 
Although IAZA has been frequently labelled with gamma rays-emitting isotopes of iodine 
([
1231] and [ 1251]), several studies report on the use of IAZA labelled with [ 1 241]. In a recent 
study by Reischl et al., the hypoxia imaging capacities of [ 124I]IAZA, [ 1 8F]FAZA and 
[
1 8F]FMISO were compared in female Balb/c nude mice bearing A43 l tumours with a small 
animal PET scanner. [ 18F]FAZA displayed significantly higher tumour-to-background ratio 
compared to [18F]MISO and [ 124l]IAZA. Although tumour-to-background ratio for [ 124I]IAZA 
increased with time, ratios were still lower than these for [ 18F]F AZA at shorter time periods. 
The study demonstrated the superior biokinetics of [ 18F]FAZA compared to [ 18F]FMISO and 
[
124l]IAZA (Reischl et al. 2007). 
Newer agents based on the azomycin-nucleoside structure such as iodoazomycin galactoside 
(IAZG) (Zanzonico et al. 2004, Riedl et al. 2007), iodoazomycin galactopyranoside (IAZGP) 
(Riedl et al. 2008) have been developed and evaluated. Two studies compared [ 124l]IAZG 
uptake with [ 18F]FMISO uptake. Zanzonico et al. studied the use of [ 1 24l]IAZG as a hypoxia 
imaging agent in MCa and Fsall tumour bearing mice using microPET imaging by comparing 
it with [ 18F]FMISO imaging and provided data showing the potential of this tracer for hypoxia 
imaging (Zanzonico et al. 2004 ). A similar study by Riedl et al. in Morris hepatoma 
(RH7777) bearing nude rats however, found that although [ 18F]FMISO localized in the same 
intra-tumoural regions as [ 124I]IAZG, a superior diagnostic image quality was obtained with 
[
18F]FMISO (Riedl et al. 2007). A recent study evaluated hypoxia imaging using [ 124I]IAZGP 
in a Morris hepatoma RH7777 tumour rat model by comparing it with fluorescence fiberoptic 
oxygen probe measurements, pimonidazole and EF5 distribution, and tried to determine the 
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optimal time after injection to depict hypoxia. [ 1 24I]IAZG distribution correlated positively with pimonidazole and EF5 distributions and the optimal ratio between signal intensity and tumour-to-liver contrast occurred 6 hours after tracer administration (Riedl et al. 2 008). 
2) Non-imidazole imaging agents A) [ 18F]FDG (2-Deoxy-2-[ 1 8F]fluoro-D-glucose) [ 1 8F]FDG-PET is a non-invasive functional imaging method that is routinely used for cancer detection, staging and monitoring of response in several tumour types. Because the uptake of [ 1 8F]FDG during FDG-PET imaging relies largely on the expression of proteins that are under control of HIF-1, the degree of [ 18F]FDG-uptake by tumours might indirectly reflect the level of hypoxia. Reports trying to relate [ 18F]FDG-uptake with tumour hypoxia have, however, given inconsistent results. In vitro studies have suggested that FDG should be accumulated in hypoxic cancer cells compared to normoxic cancer cells because of changed metabolism (Oswald et al. 2 007, Busk et al. 2 008, Clavo et al. 1995, Minn et al. 1996, Burgman et al. 2 001, Pedersen et al. 2 001, Hara et al. 2 006). However, in vivo experiments (pre-clinical and clinical) have given conflicting results when showing a correlation between the uptake of [ 1 8F]FDG and the existence of hypoxia in tumours (Bentzen et al. 2 000, Wyss et al. 2 006, Zanzonico et al. 2 006, Dence et al. 2 008, Zimney et al. 2 006, Gagel et al. 2 007, Gagel et al. 2 004, Rajendran et al. 2 004, Cherk et al. 2 006, Cher et al. 2 006, Thorwarth et al. 2 006, Gagel et al. 2 006, Dearling et al. 2 004, Pugachev et al. 2 005, Scigliano et al. 2 008, Obata et al. 2 003, Tanaka et al. 2 006, Dietz et al. 2 008). A recent review by Dierckx et al., addresses this subject matter (Dierckx et al. 2 008). B) Cu-ATSM Another alternative PET agent for hypoxia imaging that holds great promise is based on a metal complex of radioactive copper with ATSM, diacetyl-bis(N4-methylthiosemicarbazone ). Cu(Il)-ATSM is a neutral lipophilic molecule, which is highly membrane permeable. It can undergo reduction by cellular reducing equivalents and can be converted to [Cu(I)-ATSML which becomes entrapped in cells because of its negative charge when cells are hypoxic. There are four different positron-emitting copper isotopes that each have their own decay scheme: 60Cu (t 1 12 = 0,4 0h) , 6 1Cu (t 112 = 3,32h), 62Cu (t 112 = 0, 16h), 64Cu (t 1 12 =12,7h) (Vavere et al. 2 007). 3 1  
Preclinical data: After reports on the use of Cu62 -ATSM to detect hypoxia in hypoxic 
myocardial tissue (Fujibayashi et al. 1997), numerous pre-clinical studies have evaluated and 
validated its use for imaging of hypoxia in tumours. In an in vitro study by Dearling et al., 
several 64Cu-labelled bis(thiosemicarbazone) complexes were prepared and tested for tumour 
hypoxia selectivity by incubation with CHO320 Chinese hamster ovary cells under normoxic 
and hypoxic conditions. A number of molecules, including 64Cu-ATSM, showed significant 
hypoxia selectivity (Dearling et al. 1998). Later, attempts were made to improve the hypoxia 
selectivity of the copper complexes by identification of the physicochemical properties that 
control hypoxia selectivity (Dearling et al. 2002). Lewis et al. evaluated 
64Cu-ATSM in vitro 
in the EMT6 carcinoma cell line under varying pO2 and compared it with [
18F]FMISO and 
further evaluated 64Cu-ATSM in vivo in a murine animal model. 64Cu-A TSM was selectively 
trapped in vitro in EMT6 cells under hypoxic conditions and in vivo in solid EMT6 tumours, 
confirming it's role as an agent to successfully detect tumour hypoxia (Lewis et al. 1999). A 
study by Burgman et al. indicated, after determining the in vitro uptake of 64Cu-ATSM as a 
function of oxygenation conditions and incubation time in several tumour cell lines of rodent 
and human origin, that the uptake and retention of 64Cu-ATSM and their relation to 
oxygenation conditions were cell line dependent (Burgman et al. 2005). The pO2 dependence 
of Cu-ATSM was confirmed in a 9L gliosarcoma rat model by comparison of Cu-ATSM 
uptake with direct oxygen measurements using needle oxygen electrodes while tumour 
oxygen concentration was manipulated (Lewis et al. 2001 ). A study by Yuan et al. on the 
other hand, concluded after comparing the autoradiographic distributions of 64Cu-ATSM with 
the hypoxia markers EF5, pimonidazole and CAIX in R3230 mammary adenocarcinomas, 
fibrosarcomas and 9L gliomas that 64Cu-ATSM is a suitable PET hypoxia marker in most 
tumour types, but not for all (Yuan et al. 2006). 
A number of studies compared 64Cu-ATSM uptake with [ 18F]FMISO uptake and [ 18F]FDG 
uptake in vivo. O'Donoghue et al. reported that the uptake of 64Cu-ATSM 4h after injection in 
an R3327-AT anaplastic rat prostate tumour model did not correlate with [ 18F]FMISO uptake 
and does not reflect the level of hypoxia, as assessed by pimonidazole immunostaining and 
invasive oxygen needle probes. 64Cu-ATSM imaging at 16-20h after injection however, 
corresponded with [ 18F]FMISO uptake and showed a good correlation with the distribution of 
tumour hypoxia. In a FaDu tumour model, early and late 
64Cu-ATSM images were in 
concordance with [ 18F]FMISO imaging, indicating a tumour specific dependence of 64Cu­
ATSM uptake and retention under hypoxic conditions (O'Donoghue et al. 2005). In another 
study 64Cu-ATSM tumour uptake was unable to predictably detect changes in varying 
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amounts of tumour hypoxia when oxygenation levels in SCCVII tumours were modulated, 
whereas [ 18F]FMISO tumour uptake was more responsive to changing levels of hypoxia. 
Tumour hypoxia was also assessed independent using pimonidazole (Matsumoto et al. 2007). 
Two studies comparing 64Cu-ATSM uptake with [ 18F]FDG uptake in different animal models 
concluded that both tracers have a different distribution pattern (Obata et al. 2003, Tanaka et 
al. 2006). 64Cu-ATSM accumulated in hypoxic but viable tumour cells, whereas [
18F]FDG 
uptake was highest in pre-necrotic regions where the cells were believed to lack the necessary 
reductive mechanisms to accumulate 64Cu-ATSM (Obata et al. 2003). It was also shown that 
regions with high 64Cu-ATSM uptake were hypovascular and consisted of tumour cells 
arrested in the cell cycle, whereas regions with high [ 18F]FDG uptake were hypervascular and 
consisted of proliferating cells, as confirmed by histological analysis with Ki67, CD34 and 
TUNEL assay (Tanaka et al. 2006). Finally Dence et al. compared the regional distribution of 
64Cu-ATSM, [18F]FDG and [ 18F]FMISO in 9L gliosarcoma tumours. It was shown that the 
regional distribution of [ 18F]FMISO at 2h correlates highly with the distribution of 64Cu­
ATSM at 10 min or 24h. A poor correlation existed however between 64Cu-ATSM (10 min) 
and [ 18F]FDG (Dence et al. 2008). 
Clinical data: In numerous studies, 6°Cu-ATSM uptake proved to be predictive of tumour 
behaviour and response to therapy in patients with non-small cell lung cancer (Dehdashti et al. 
2003), cervical cancer (Dehdashti et al. 2003, Dehdashti et al. 2008) and rectal carcinoma 
(Dietz et al. 2008). In a study by Dehdashti et al. 14 patients with biopsy proven cervical 
cancer, an arbitrary selected tumour-to-muscle threshold of 3,5 was able to discriminate those 
patients that were likely to develop recurrence so that 6°Cu-ATSM uptake was inversely 
related to progression-free survival and overall survival. Additionally, no correlation was 
found between 6°Cu-ATSM uptake and [ 18F]FDG uptake (Dehdashti et al. 2003). To confirm 
these results, a study with a larger group of patients was performed by the same group. 
Tumour 6°Cu-ATSM uptake (TIM threshold of 3,5) in 38 patients with cervical cancer was 
inversely related to progression-free survival and cause-specific survival. Again, no 
correlation was found between 6°Cu-ATSM uptake and [ 18F]FDG uptake (Dehdashti et al. 
2008). Similar results were obtained in a study where semi-quantitative analysis of the 60Cu­
A TSM tumour-to-muscle ratio in 14 patients with non-small cell lung cancer was able to 
discriminate responders from non-responders. However, there was no significant difference in 
mean tumour SUV of non-responders and responders. Again, no correlation was found 
between 6°Cu-ATSM uptake and [ 18F]FDG uptake (Dehdashti et al. 2003). In a recent study 
an effort was made to predict the response of rectal cancers to neoadjuvant 
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chemoradiotherapy and prognosis in 17 patients. The results of this small pilot study 
suggested that 6°Cu-ATSM tumour-to-muscle ratio may be predictive of survival and, 
possibly, tumour response. Again, no correlation was found between 60Cu-ATSM uptake and 
[
1 8F]FDG uptake (Dietz et al. 2008). To determine if hypoxia-related molecular markers were 
associated with 60Cu-ATSM retention, the PET imaging data of 15 patients with cancer of the 
cervix were compared with the expression of tissue molecular markers, which included 
vascular endothelial growth factor (VEGF), cyclo-oxygenase-2 (COX-2), epidermal growth 
factor receptor (EGFR), carbonic anyhdrase IX (CA-9), and apoptotic index. Hypoxia as 
identified with 60Cu-ATSM imaging was correlated with overexpression of VEGF, EGFR, 
COX-2, CA-9, an increase in apoptosis, and a poor outcome (Grigsby et al. 2007). Chao et al. 
further demonstrated the feasibility to use 60Cu-A TSM imaging to identify the hypoxic 
tumour subvolume through coregistration of CT and 6°Cu-ATSM PET images in order to 
plan a patients' course of radiotherapy and perform intensity-modulated radiation therapy 
(IMRT) (Chao et al. 2001). As most clinical Cu-ATSM studies used the agent with the short­
lived positron-emitting radionuclide of copper, 60Cu, a recent study compared the image 
quality and tumour uptake of 60Cu-A TSM and 64Cu-A TSM in 10 patients with cervical 
carcinoma to evaluate the use of Cu-ATSM with one of the longer-lived positron-emitting 
copper nuclides, 64Cu. It was concluded that 64Cu-ATSM was a safe radiopharmaceutical that 
can be used to obtain high quality images of tumour hypoxia in human cancers (Lewis et al. 
2008). 
1 .4.2.2 Non-invasive detection of tumor hypoxia with SPECT 
1) [123I)IAZA and [125l]IAZA ([1231]/ [125I]iodoazomycin arabinoside) 
Preclinical data: In one of the first studies with IAZA, it's synthesis and labelling with [ 1251] 
was described. It's elimination and biodistribution were also studied in vivo in EMT-6 
tumours in BALB/c mice and it was shown that IAZA undergoes hypoxia-dependent binding 
in EMT-6 cells in vitro (Mannan et al. 1991 ). Moore et al. investigated the oxygenation status 
and tumour perfusion of rats with Dunning R3327-AT tumours who were treated with 
photodynamic therapy (PDT) with [ 1 23l]IAZA and [99mTc]HMPAO. Increased retention of 
[ 1 23l]IAZA was observed in tumours treated with PDT together with an inverse correlation 
34 
between tumour hypoxia as measured with [ 123I]IAZA and tumour perfusion as measured with [99mTc]HMPAO (Moore et al. 1993). Clinical data: The first clinical study assessing hypoxia with IAZA, investigated the uptake of 
[
123I]IAZA in patients with advanced malignancies. Radiotracer avidity was observed in three out of ten tumours and it was concluded that the use of gamma-emitter labelled 2-nitroimidazoles as diagnostic radiopharmaceuticals is feasible and safe and that metabolic binding of [ 123I]IAZA is observed in some, but not all tumours (Parliament et al. 1992). In 22 patients, [ 123I]IAZA uptake showed a significant inverse correlation with the perfusion marker [99mTc ]-HMP AO and severe perfusion deficits were usually associated with an increased uptake of the hypoxic marker (Groshar et al. 1993 ). After observing uptake of radioactivity in the brain after administration of [ 123I]IAZA, a study was undertaken to investigate the proposed metabolites of IAZA in normal and tumour-bearing murine models. Neither of the proposed metabolites' biodistribution did support its involvement in brain radioactivity uptake in patients (Lee et al. 2 000). A study investigating the use of [ 123I]IAZA in 51 human patients with newly diagnosed malignancies demonstrated hypoxia in small cell lung cancer and squamous cell carcinoma of head and neck but not in malignant gliomas. The study did however, demonstrate the feasibility of [ 123I]IAZA imaging in a clinical setting (Urtasun 1996). Stypinski et al. reported the clinical pharmacokinetics of IAZA, the radiopharmacokinetics of [ 123I]IAZA, total radioactivity kinetics and the radiation dosimetry estimates for 6 healthy volunteers and concluded that all supported its clinical use for imaging tissue hypoxia (Stypinski et al. 1999, Stypinski et al. 2 001 ). Newer agents based on the azomycin-nucleoside structure such as iodoazomycin galactoside (IAZG) (Chapman et al. 1996, Iyer et al. 1998), iodoazomycin pyranoside (IAZP) (Mannan et al. 1992), iodoazomycin galactopyranoside (IAZGP) (Iyer et al. 2 001, Saitoh et al. 2 002), iodoazomycin xylopyranoside (IAZXP) (Chapman et al. 1996) have been developed and evaluated. Iyer et al. demonstrated that microelectrode measurements in R3327-AT tumour bearing rats, did not correlate with [ 125I]IAZGP uptake (Iyer et al. 2 001). Furthermore, a study by Saitoh et al. showed high accumulation of IAZGP in FM3A mouse tumours 24h after administration (Saitoh et al. 2 002). 
2) [99mTc] labelled agents 
A) BMS18 1 32 1  35 
This was the first [99mTc]-labelled 2-nitroimidazole to be widely studied for imaging (Linder 
et al. 1994). A number of experimental studies have evaluated the use ofBMS 181321 for the 
detection of ischemic and hypoxic myocardium (Kusuoka et al. 1994, Shi et al. 1995, Rumsey 
et al. 1995, Fukuchi 1996). Ballinger et al. showed selective accumulation in hypoxic cells in 
vitro and in vivo but concluded that BMS 181321 was not optimal for tumour hypoxia 
imaging because of in vitro and in vivo instabilities and a high partition coefficient, resulting 
in slow clearance from the blood and high background levels in normal tissues (Ballinger et 
al. 1996). 
B) BRU59-2 1 
Preclinical data: BRU59-21, previously known as BMS194796, is a second generation 
analogue ofBMS181321 which shows greater stability in vitro and more rapid clearance from 
the circulation in vivo, resulting in higher tumour-to-blood and tumour-to-muscle ratios. It 
showed selective localisation in tumour cells incubated under hypoxic conditions and 
following intravenous injection in animal models representive of poorly perfused tumours 
(Melo et al. 2000). In a study by Zhang et al. BRU59-21 and HL91 were compared directly in 
the same in vitro systems. Both tracers proved suitable for hypoxia imaging (Zhang et al. 
2001). Clinical data: Hoebers et al. assessed the safety and biodistribution of [99mTc]BRU59-
21 in 10 patients with head and neck cancer and correlated uptake in vivo with pimonidazole 
staining. In vivo evaluation of tumour hypoxia with [
99mTc]BRU59-21 appeared to be safe and 
feasible and uptake and retention of the marker seemed to be indicative of tumour hypoxia, as 
confirmed by pimonidazole staining (Hoebers et al. 2002). 
C) [99mTc]HL-9 1 
Preclinical data: Zhang et al. evaluated the efficacy of [99mTc]HL91 as a non invasive marker 
of tumour hypoxia in vitro (Chinese hamster ovary cells) and in vivo (C3H mice bearing 
KHT-C tumours) and observed selective accumulation of [99mTc]HL91 in hypoxic cells and 
hypoxic tumours (Zhang et al. 1998). A similar study assessed the retention of [
99mTc ]HL91 
in mice bearing 3 different tumours under control and enhanced oxygenation conditions and 
correlated these data with the oxygenation status as assessed by Eppendorf pO2 histograph 
measurements. A very good correlation between [99mTc]HL91 retention and hypoxia, as 
measured by the Eppendorfhistograph, was observed (Honess et al. 1998). Yutani et al. found 
that [99mTc]HL91 accumulated to significantly higher levels in hypoxic tumour areas and that 
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[
99mTc]HL91 uptake was strongly correlated with the expression of GLUTl in the viable 
cancer cell area (Yutani et al. 1999). In a study by Tatsumi et al., a dual-tracer 
autoradiography was performed with HL91 and IAP (carbon-14 iodoantipyrine) in Walker 
256 tumour bearing rats to elucidate the relationship between hypoxia and blood flow. The 
study confirmed that high HL91 uptake is related to low blood flow (Tatsumi et al. 1999). 
Kinuya et al. reported on an increase in [99mTc]HL91 uptake after exposure to X-ray radiation 
(Kinuya et al. 2000). Siim et al. examined whether [99mTc]HL91 uptake could be used as a 
marker for the inhibition of tumour blood flow by the antivascular agents DMXAA (5,6-
dimethylxantenone-4-acetic acid) and CA4P (combreastatin A4 phosphate) and observed that 
tumour hypoxia as a result of the acute inhibition of blood flow by anti vascular agents caused 
increased tumour uptake of [99mTc]HL91 (Siim et al. 2000). Another study demonstrated that 
microelectrode measurements in R3327-AT tumour bearing rats, did not correlate with 
[99mTc]HL91 uptake (Iyer et al. 2001). After having determined the biodistribution of [99mTc]HL91 (129), Suzuki et al. investigated the relationship between [99mTc]HL91 uptake 
and tumour response to radiation in athymic mice bearing different human tumours. They 
concluded that [99mTc ]HL91 uptake did not always relate to their sensitivities to radiation 
therapy (Suzuki et al. 2003 ). In a study by Kinuya et al., an attempt was made to determine 
whether oxygenation status affected [99mTc]MIBI (sestamibi) uptake. They observed 
enhanced [99mTc]HL91 accumulation in hypoxic tumour cells after treatment with N2-gas (in 
vitro) and hydralazine (in vivo) (Kinuya et al. 2002). A recent study by Lee et al. investigated 
the selectivity of [99mTc]HL91 for hypoxia in vitro in A549 human lung cancer cells and LL2 
murine Lewis lung cancer cells under varying oxygen concentrations and in vivo in different 
xenogra:ft mouse models after chemically altering the degree of tumour hypoxia with 
hydralazine. The in vitro studies identified hypoxia-selective uptake of [
99mTc]HL91, with 
significantly increased uptake in the hypoxic state compared to the normoxic state. The in 
vivo studies showed that [99mTc]HL91 was markedly increased in mice treated with 
hydralazine compared with controls (Lee et al. 2008). 
Clinical data: Clinical studies concerning the clinical evaluation of [99mTc]HL91 are limited. 
In a pilot study, Cook et al. compared [99mTc]HL91 uptake with [18F]FDG-PET imaging in 10 
patients with a variety of tumours and showed visible [99mTc]HL91 tumour uptake in all 7 
patients where the tumour could be clearly identified with [ 18F]FDG PET (Cook et al. 1998). 
Another phase I pilot study evaluated the usefulness of [99mTc]HL91 imaging for the 
visualization of local recurrence in 9 men with squamous cell carcinoma of the head and neck 
(SCCHN) as compared to CT and biopsy and concluded that [99mTc]HL91 is a safe 
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radioligand and that metabolic binding in a large fraction but not all of local SCCIIN 
recurrences may be expected (Van de Wiele et al. 2001). Finally, in a study with 32 patients 
with non-small cell lung cancer, Li et al. showed that hypoxia imaging with [99mTc]HL91 
before radiotherapy may predict tumour response and patient survival (Li et al. 2006). 
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1.5 Tumor hypoxia and tumor metabolism 
More than 50 years ago, Warburg described that even in aerobic conditions, tumor cells prefer 
to use glycolysis instead of oxidative phosphorylation for their energy/ATP-production 
(aerobic glycolysis or Warburg effect) (Warburg 1953). As a consequence, tumor cells utilize 
far more glucose than their normal counterparts to compensate for the use of glycolysis which 
is inherently inefficient as compared to aerobic degradation of glucose through the Krebs 
cycle and oxidative phosphorylation. Although several explanations exist, the exact 
mechanisms and advantages associated with aerobic glycolysis remain unclear and are 
probably multiple (Bartrons et al. 2007, Kroemer et al. 2008, Denko et al. 2008). This tumor­
specific phenomenon is exploited in [ 18F]FDG-PET (2-Deoxy-2-[ 18F]fluoro-D-glucose 
positron emission tomography) imaging. This non-invasive imaging method which is 
routinely used for cancer detection, staging and monitoring of response in several tumor 
types, is based upon the accumulation of a radiolabeled glucose analogue in tumor cells as a 
consequence of this enhanced glucose uptake and glycolysis. Major factors that are 
considered to play a key role in the higher [ 18F]FDG uptake by malignant cells appear to be 
overexpression of different types of GLUTs, a high HK activity and a low glucose-6-
phosphatase (G6P) activity (Smith et al. 2001, Ong et al. 2008). The precise determinant 
however, remains unclear. Overexpression of several types of GLUTs and HKs is a common 
feature of cancer and has been described extensively (Pastorino et al. 2003, Macheda et al. 
2005). 
Under hypoxic conditions, tumor cells will further increase their glycolytic ATP-production 
to compensate for the hypoxia-induced drop in mitochondrially produced ATP (Pasteur 
effect). The efficiency of the glycolytic response is enhanced by activation of HIF-1 and the 
downstream expression of metabolic proteins. HIF-1 stimulates glycolytic energy production 
by transactivating genes involved in glucose transport and glycolytic enzymes. HIF-1 
increases the rate of glucose uptake through the induction of the facilitative glucose 
transporters GLUTl and GLUT3 (Maxwell et al. 1997, Chen et al. 2001). These transporters 
(solute carriers SLC2A, protein symbol GLUT) mediate the transport of glucose and other 
monosaccharides across the plasma membrane of mammalian cells. HIF-1 also increases 
expression of HK I and II, although it seems that HK.II is more important for modifying 
glucose metabolism under hypoxic conditions (Mathupala et al. 2001 ). Hexokinases convert 
glucose to glucose-6-phosphate and allow the tumor cell to maintain a high rate of glycolysis 
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by maintaining the downhill concentration gradient necessary to move glucose into the cell 
through glucose transporters. Further, expression of lactate dehydrogenase-A (LDH-A), a 
protein responsible for the conversion of pyruvate to lactate, is under control of HIF-1 
(Semenza et al. 1996, Semenza et al. 2007). Besides stimulating glycolytic energy production, 
hypoxia also actively suppresses aerobic glucose metabolism by inducing pyruvate 
dehydrogenase kinase 1 (PDKl) which inactivates pyruvate dehydrogenase (PDH) (Kim et al. 
2006, Papandreou et al. 2006, Semenza et al. 2007). As PDH catalyzes the committed, 
irreversible step in the mitochondria in which pyruvate is broken down into acetyl-CoA and 
CO2, acces of pyruvate into the TCA cycle is inhibited. Further, an effect of HIF-1 on 
mitochondrial biogenesis and function through actions on MXI I and the activity of 
cytochrome c oxidase (COX), has been described (Denko et al. 2008). All these mechanisms 
together result in the glycolytic tumor phenotype. It remains however, difficult to discern 
whether hypoxia and/or HIF-1 activation are a cause or a contributing factor in aerobic 
glycolysis. 
(i) As the proteins responsible for [ 1 8F]FDG-uptake are under control of HIF-1 ,  the degree of 
[
1 8F]FDG-uptake might indirectly reflect the degree of tumor hypoxia, obviating the need for 
more specialized radiopharmaceuticals for hypoxia imaging. Reports trying to find a link 
between [ 1 8F]FDG-uptake and hypoxia have yielded inconsistent results. Numerous in vitro 
studies in different types of cancer cell lines have reported on an increase in [3H]FDG or 
[
1 8F]FDG-uptake after exposure to decreasing oxygen atmospheres (Clavo 1995, Burgman 
2001 ,  Pedersen 2001,  Oswald 2007). In vivo results on the other hand, have proven less 
straightforward and comparisons of [ 1 8F]FDG with more specialized hypoxia tracers have 
questioned the use of [ 1 8F]FDG for hypoxia imaging (see Chapter 1 ,  Partim 1 .4.2). A review 
by Dierckx et al. adresses this subject matter (Dierckx 2008). 
(ii) As the proteins responsible for [ 1 8F]FDG-uptake are under control of HIF-1,  it should be 
possible to modify tumor [ 1 8F]FDG-uptake by modifying tumor oxygenation state or HIF-1 
activation. Despite its widespread use, a number of problems and limitations still exist when 
using [ 18F]FDG-PET imaging. First of all, because glucose is used as an energy substrate 
throughout the body, [ 1 8F]FDG-uptake in benign tissues and certain physiological processes is 
common and complicates its oncological use: high uptake in normal brain tissue complicates 
brain tumor detection, aspecific bladder activity interferes with bladder and prostate cancer 
diagnosis, and inflammation and infection processes are known to be highly [ 1 8F]FDG avid. 
Secondly, some tumors such as prostate carcinoma, mucinous carcinoma and hepatocellular 
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carcinoma display low [ 1 8F]FDG-uptake due to low metabolic rates or elevated glucose-6-phosphatase levels (Kellof et al. 2 005, Endo et al. 2 006). The possibility to increase tumor 
[
1 8F]FDG-uptake in these situations where diagnostic accuracy is suboptimal, is highly attractive. 41 
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1. 7 Outline and objectives 
Given their close interaction, the objective of this work was to explore the relation between 
tumor oxygenation and tumor metabolism and evaluate the possible consequences and 
benefits of this relation for [ 18F]FDG - PET imaging. Furthermore, a new radiotracer of tumor 
vasculature was evaluated. 
Chapter 2 of this work focuses on the relation between tumor oxygenation and tumor 
metabolism and investigates whether or not this relation can be exploited in order to improve 
functional imaging using [ 18F]FDG - PET. In partim 2.1, the effects of an increase in tumor 
oxygenation on tumor metabolism were studied by investigating changes in expression of 
proteins important for tumor metabolism, survival and spread in a rat colorectal xenograft 
after treatment with rhEPO. In partim 2.2, the effects of a decrease in tumor oxygenation or a 
direct HIF-1 activation on tumor metabolism were studied by investigating [18F]FDG-uptake 
in an in vitro and in vivo model of human colorectal carcinoma. In partim 2.3, the distribution 
of the exogenous nitroimidazole hypoxia marker pimonidazole was compared with the 
expression ofGLUTl and 3, HK2 and CA IX in a spontaneous canine mammary gland tumor. 
In partim 2.4, the expression of the endogenous hypoxia marker CA IX was compared with 
[
18F]FDG-PET SUVmax and SUVmean values in patients suffering from NSCLC. 
In Chapter 3 of this work a new radiotracer (99mTc-(CO)3 His-CNA35) that selectively binds 
tumor vasculature subendothelial collagen, was evaluated. As tumor vasculature and tumor 
hypoxia are highly interconnected, non-invasive imaging of tumor vasculature might provide 
insights into tumor hypoxia. In this manuscript, the synthesis, purification, biodistribution, 
dosimetry and in vivo imaging qualities of this new molecule are examined. 
59 
60 
Chapter 2: Tumor Hypoxia and Glucose Metabolism 61 
62 
2.1 Research article: Combined effect of EPO and radiotherapy on the 
expression of endogenous molecular markers of tumour metabolism and 
metastasis. 
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ABSTRACT 
Erythropoietin has been used to correct cancer-related anaemia and to improve tumour 
hypoxia which both adversely affect the clinical condition of cancer patients and response to 
radiotherapy. Data available on the effects of erythropoietin treatment in cancer are, however, 
conflicting. Several clinical studies investigating the influence of erythropoietin treatment 
have given contradictory results as to whether or not this treatment positively influences 
survival. In the light of these conflicting results, we studied the effects of erythropoietin 
treatment either alone or in combination with radiotherapy on tumour oxygenation and on the 
expression pattern of several proteins related to tumour metabolism, survival and spread in a 
rat colorectal cancer model. We found a statistically significant upregulation of hexokinase I, 
N-cadherin, and glucose transporter 3 when erythropoietin treatment was combined with 
radiotherapy. Because these three proteins have distinct functions in protecting the cell in 
compromised conditions, these results indicate a detrimental role for the combination of 
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erythropoietin treatment and radiotherapy through the stimulation of tumour cell metabolism, 
inhibition of apoptosis and stimulation of tumour spread, and seem to indicate that rhEPO 
treatment negatively modulates RT efficacy. 
KEYWORDS: EPO, radiotherapy, apoptosis, metastasis, glucose transporter 
INTRODUCTION 
Anaemia adversely affects the clinical condition of cancer patients and contributes to the 
development of tumour hypoxia which in turn adversely affects response to radiotherapy. 
Since erythropoietin (EPO) is a well recognized and effective treatment for anaemia, this 
pleiotropic cytokine, which is involved in the proliferation and differentiation of the erythroid 
lineage, has been used to correct cancer-related anaemia and improve tumour hypoxia (1-7). 
Data available on this subject are, however, conflicting. On the one hand, in various clinical 
trials conducted in diverse groups of cancer patients it was found that treatment with 
recombinant human EPO (rhEPO) significantly increased the quality of life and survival rate 
of cancer patients, respectively by increasing their haemoglobin levels and by reducing the 
need for potentially risky red blood cell transfusions (8,9). However, a recent meta-analysis of 
57 of such trials performed, including 9353 patients, suggested that treatment of anaemia with 
rhEPO may have no impact on overall survival in patients with cancer (10). In addition, recent 
experimental findings have advocated a role for EPO as a strong anti-apoptotic agent in 
multiple non-erythroid tissues but also in neoplastic tissues. Also, the discovery of EPO 
receptors (EPO-R) on malignant cells, suggests that EPO may act as a tumour growth factor 
(1-3). Finally, contrary to initial findings, more recently, a number of randomized clinical 
trials, reported that rhEPO might actually adversely affect cancer survival rates of cancer 
patients treated by means of radiotherapy, mainly due to tumour progression (11,12). While 
strongly criticized for methodological pitfalls, these studies led the FDA to force a "black 
label" warning concerning the use ofrhEPO in cancer patients. 
In the light of these conflicting results, the influence of rhEPO either alone or in combination 
with radiotherapy on tumour oxygenation was studied in a rat colorectal cancer model given 
both treatment options may profoundly influence tumour oxygenation. Subsequently, the 
influence of rhEPO either alone or in combination with radiotherapy on the expression pattern 
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of several proteins related to tumour metabolism, survival and spread was studied in the same 
model. 
MATERIALS AND METHODS Animal and Tumour Model 
Male Wag/Rij rats were bought from Harlan (Horst, The Netherlands). The CC531 cell line is 
a 1,2-dimethylhydrazine-induced, moderately differentiated, and weakly immunogenic colon 
adenocarcinoma, syngeneic with W AG/Rij rats. This cell line is well studied and has been 
proven to provide a tumour-host model similar to human colorectal carcinogenesis (13). Cells 
were grown in plastic culture flasks in RPMI 1640 medium, buffered with HEPES (20 mM) 
(Invitrogen Corporation, Gibco, Ghent, Belgium) additionally supplemented with 10 % fetal 
calf serum, 4 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin at 37 °C in a  
humidified atmosphere with 5 % CO2 in air. The cells were transferred at 95 % confluency. 
Two million cells suspended in 0,2 ml of saline were injected subcutaneously (s.c.) in the 
proximal hind leg. Tumours reached a size of 0,5 - 1 cm after a period of 4 weeks. All the 
experiments with rats were approved by the institutional ethical committee and animal 
handling was done according to institutional guidelines for animal care. Experimental Therapy 
Animals were randomly divided into two groups in which some of the animals received RT: a 
control group (n = 20) in which 11 animals received RT and a rhEPO group (n = 26) receiving 
rhEPO in which 16 animals received RT. rhEPO (Eprex, Janssen Cilag, Beerse, Belgium) was 
administered at a dose of 3 x 0, 1 ml (286 IU) s.c. per week. The dosage was based on a dose­
finding study during which five or eight rhEPO administrations weekly resulted in an 
excessive haematocrit rise and important mortality ( data not shown). Recombinant human 
EPO has been shown to bind to the rodent EPO receptor (14). Rats were longitudinally 
studied during 3 weeks using the following timeframe: start of rhEPO administration ( day 1 ); 
first oxygenation measurement ( day 8); fractionated RT 5 x 5 Gy ( day 13 - 17); second 
oxygenation measurement, and killing by anaesthesia overdose and excision of tumours for 
histology (all on day 22). Radiotherapy 
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Rats were not sedated and the tumour-bearing hind leg was immobilised using a purpose-built 
Plexiglass holder, as described previously (15,16). Briefly, rats were placed in the holder in 
prone position. The hind legs were pulled through an opening in the holder and immobilised. 
Before each fraction, a radiation field was simulated encompassing the tumour with a margin 
of 1,5 cm. Photon irradiation was performed with a 5MV linear accelerator (Elekta, Crawley, 
UK). Five fractions of 5 Gy (total dose 25 Gy) were delivered on five consecutive days. As 
the tumours were inoculated s.c., they were covered with tissue-equivalent silicone bolus of 
1cm to prevent the build-up effect under the skin. One single direct field at a fixed source-skin 
distance of 100 cm was used. The dose was calculated to the midpoint of the tumours 
according to their volume in each individual animal, as obtained during simulation. Tissue pOz-measurements 
Tissue oxygenation was measured with a fibre-optic probe based on fluorescence quenching 
(OxyLite, Oxford Optronix, Oxford, UK) ( 17, 18). A precalibrated fibreoptic probe was 
inserted 5 mm deep into the tumour using a Seldinger technique; the probe was then 
withdrawn in 40 steps of 100 mm each over a total distance of 4 mm using a 
micromanipulator (model MN151, Narishige International Ltd, London, UK). After each 
micromanipulator movement, measurements were started as soon as a stable reading was 
obtained. Tissue pO2 was sampled every 2 s. Tissue pO2 was expressed in mmHg. 
Oxygenation measurements were performed in the animals that received RT, 5 days before 
and 5 days after the completion of RT. lmmunohistochemistry 
Formalin fixed, paraffin embedded tissue samples were used for immunohistochemistry with 
the appropriate antibodies. Sections of 4 µm thick were mounted on SuperFrost® microscope 
slides (Menzel-Glaser, Braunschweig, Germany), which were deparaffinized in xylene and 
rehydrated in a downgraded series of ethanol. After flushing in water, heat induced antigen 
retrieval was performed for 20 minutes with the appropriate buffer (EDT A pH = 8.0 or CIT 
pH = 6.0), after which the tissue slides were cooled down for 20 minutes and then flushed in 
water for 10 minutes. The endogenous peroxidase activity was blocked for 5 minutes with 0,3 
% hydrogen peroxide (DAKO, Glostrup, Denmark) on each tissue slide. Primary antibodies 
were than incubated for 1 hour at room temperature; the appropriate antibodies with their 
corresponding dilution factors (primary antibody diluted in 1 % BSA/PBS) are indicated in 
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Table 1 (see Table 1). After washing, the tissue sections were incubated for 30 minutes at 
room temperature with a labelled polymer-HRP anti-rabbit secondary antibody (DAK.O, 
Glostrup, Denmark). The colour reaction was developed using the chromogen 3,3-
diaminobenzidine+ (DAB) (DAKO, Glostrup, Denmark) for 10 minutes. After washing, the 
tissue sections were counterstained with Mayer's haematoxylin. 
Phosphate-buffered saline with 1 % BSA instead of the primary antibody was used as negative 
control on each slide in order to exclude false positive responses from non-specific binding of 
the secondary antibody. Prior to staining the specimens, an isotype control was performed to 
estimate the non-specific binding of target primary antibodies to cell surface antigens. Non­
specific binding is due to Fe receptor binding or other protein-protein interactions. 
Antibody Company Pretreatment Dilution + control tissue 
GLUT 1 ABC AM, ab 15309 EDTA 1/100 internal REC 
GLUT 3 Santa Cruz Biotechnology, s c-30107 CIT 1/50 testis 
GLUT 4 Santa Cruz Biotechnology, sc-7938 EDTA 1/100 placenta 
GLUT 8 cr,.Diagnostics International, GT81-A CIT 1/10 testis 
GLUT 9 cr,.Diagnostics International, GT91-A EDTA 1125 p ancreas c a  
HK I Santa Cruz Biotechnology, s c-28885 EDTA 1/500 liver 
HK II Santa Cruz Biotechnology, s c-28889 EDTA 1/100 liver 
HK III Santa Cruz Biotechnology, s c-28890 EDTA 1/400 liver 
SGLT-1 Fitzgerald, 70R-SR005 CIT 1/20 kidney 
N-CAD ABCAM, abl2221 CIT 1/100 brain 
TABLE 1. The different antibody dilutions and heat induced pre-treatment methods needed 
for the immunostainings. For each antibody the correct positive control tissues were used to 
optimize the immunostainings. (EDT A = ethylenediaminetetraacetic acid, CIT = citrate) Immunohistochemical Analysis 
The intensity and amount of positive tumour cells in the immuno-reaction were scored 
independently by two experienced observers, blinded to the clinical results. The percentage of 
tumour cells that were positive on the immuno-reaction were scored as follows : 0% (score 0), 
0-20% (score 1), 20-40% (score 2), 40-60% (score 3), 60-80% (score 4) and 80-100% (score 
5). Intensities of staining were categorized as absent (score 0), faint (score 1), average (score 
2) or strong (score 3). Positive tumour cells were counted per high-power field (final 
magnification, 400 X). An estimation of intensity and % positive tumour cells was made after 
counting ten high-powerfields. A final histological score was calculated as following: Hscore 
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= [{al x i l )  + (a2 x i2)] /2, where i = the score of intensity, a = the score of amount tumour cells that stained positive and 1 and 2 refer to the scores of the two observers. 
Statistical Analysis SPPS for Windows, version 1 5.0 was used for statistical analysis. Differences between two groups of continuous data were analysed with the Student's t-test (two-tailed, pared or unpaired as appropriate). To assess differences between the four different experimental groups, one-way analysis of variance (ANOVA) was performed with post-hoc Fisher's protected least significant differences (FLSD) on each variable. P value < 0.05 was considered significant. 
RESULTS 
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FIGURE 1. Mean pO2 values in the control group before (2, 1; sd 1,3) and after (3,9; sd 3,0) RT. Mean pO2 values in the rhEPO group before (6,7; sd 4,5) and after (11,5; sd 7,7) RT. Both before (p = 0,007; Student's t-test) and after (p = 0,01 5; Student's t-test) RT, pO2 values were significantly higher in the rhEPO treated rats. In the rhEPO group RT induced a reoxygenation (p = 0,019; Student's t-test). 69 
Effects of rhEPO Treatment on Haematocrit 
Data in this study were acquired from material which was part of larger set of data from 
another study.38 In this study, haematocrit values were tested before starting the experiment 
and on day 8. In rhEPO-treated rats, mean haematocrit showed a 25% increase from 50,7 ± 
0,4% before therapy to 62,6 ± 0,4% on day 8 (p < 0,00 1 ). In the control group, haematocrit 
values remained unchanged. 
Effects ofrhEPO Treatment and RT on Expression ofGLUTl , GLUT3, 
GLUT4, GLUT8, GLUT9 and SGLTl 
Mean Hscores for GLUTI expression for the different experimental groups were respectively: 
ctrl: 7,9 (range 4,0 to 1 2,0; sd 2,4), rhEPO: 1 1 , 1  (range 1 ,5 to 1 5 ;  sd 4,9), ctrl+RT: 9,0 (range 
4,0 to 1 3,5 ; sd 3 , 1 ), rhEPO+RT: 9,0 (range 2,5 to 1 3 ,5; sd 3 ,0). Mean Hscores for GLUT3 
expression for the different experimental groups were respectively: ctrl: 5 ,6 (range 1 ,5 to 9,0; 
sd 3 ,2), rhEPO: 4,7 (range 3 ,0 to 9,0; sd 1 ,9), ctrl+RT: 5 ,9 (range 1 ,5 to I 3,5; sd 3 ,5), 
rhEPO+RT: 7,9 (range 2,5 to 1 2,0; sd 2,9) (Fig. 2). Mean Hscores for GLUT4 expression for 
the different experimental groups were respectively: ctrl: 3 ,9 (range 1 ,0 to 9,0; sd 2, 7), 
rhEPO: 5,7 (1 ,5 to I O, O; sd 2,9), ctrl+RT: 4,9 (range 2,5 to 8,0; sd 2,3), rhEPO+RT: 5 ,2 
(range 2,5 to I 0,0; sd 2,5). Mean Hscores for GLUTS expression for the different 
experimental groups were respectively: ctrl: 7,3 (range 1 ,0 to 1 2,0; sd 3, 1 ), rhEPO: 5,8 (range 
1 ,5 to 1 2,0; sd 3,3), ctrl+RT: 7,7 (range 3 ,0 to 1 5 ,0; sd 4, 1 ), rhEPO+RT: 7,7 (1 ,5 to 1 5 ,0; sd 
3 ,6). Mean Hscores for GLUT9 expression for the different experimental groups were 
respectively: ctrl: 1 , 1  (range 0,5 to 2,5 ; sd 0,7), rhEPO: 2,2 (range 0,5 to 4,0; sd 1 , 1 ), ctrl+RT: 
3 ,1 (range 0,5 to 1 0,0; sd 3 ,5), rhEPO+RT: 2,4 (range 0,5 to 7,0; sd 1 ,8). Mean Hscores for 
SGL Tl expression for the different experimental groups were respectively: ctr I: 1 2,3 (range 
3 ,5 to 1 5,0; sd 3, 7), rhEPO: 1 0, 1 (range 0,5 to 1 5,0; sd 6,0), ctrl+RT: 9,3 (range 0,0 to 15,0; 
sd 5, 1 ), rhEPO+RT: 1 1 ,9 (range 0,5 to 1 5 ,0; sd 5 , 1 ). Immunostaining of GLUTI was mainly 
membranous and negative controls showed no staining. Immunostaining of GLUT3, GLUT4, 
GLUTS, GLUT9 and SGL Tl was cytoplasmic and negative controls showed no staining. 
A significant increase in GLUT3 expression was observed in the rhEPO group upon RT 
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FIGURE 2. Mean Hscores for GLUT3 expression for the different experimental groups were respectively: ctrl: 5,6 (range 1,5 to 9, 0; sd 3,2), rhEPO: 4,7 (range 3, 0 to 9, 0· sd 1,9), ctrl+RT: 5,9 (range 1,5 to 13,5; sd 3,5), rhEPO+RT: 7,9 (range 2,5 to 12, 0; sd 2,9). A significant increase in GLUT3 expression was observed in the rhEPO group upon RT treatment (p = 0, 01 ). 
FIGURE 3. Immunohistochemical analysis of Glut3 expression: an example comparing a sample with a high Hscore and a sample with a low Hscore. Panel A: Sample of rat that received RT and rhEPO (Hscore 12, 0) (2 00x). Panel B: Sample of rat that received no treatment (Hscore 2,5) (2 00x). 
Effects ofrhEPO Treatment and RT on Expression ofHKI, HK.II and HK.III Mean Hscores for HK.I expression for the different experimental groups were respectively: ctrl: 8,6 (range 3,5 to 1 0, 0; sd 2, 0), rhEPO: 8, 0 (range 1, 0 to 13,5; sd 3,3), ctrl+RT: 1 0,7 (range 7, 0 to 15, 0; sd 3,2), rhEPO+RT: 11,7 (range 8, 0 to 15, 0; sd 2,9) (Fig. 4). Mean Hscores for HK.II expression for the different experimental groups were respectively: ctrl: 7,7 (range 2,5 to 13,5; sd 3,4), rhEPO: 7, 1 (range 0, 0 to 1 0, 0; sd 3,2), ctrl+RT: 7,5 (range 0, 0 to 13,5; sd 3,5), rhEPO+RT: 9, 1 (range 0, 0 to 13,5; sd 3,3). Mean Hscores for HK.III expression for the different experimental groups were respectively: ctrl: 0,9 (range 0, 0 to 2, 0; sd 0,6), rhEPO: 71 
1 ,3 (range 0,0 to 2,5; sd 0,8), ctrl+RT: 0,9 (range 0,0 to 2,5; sd 0,7), rhEPO+RT: I ,0 (range 
0,0 to 2,5; sd 0,6). Immunostaining of the hexokinases was cytoplasmatic and negative 
controls showed no staining. 
A significant increase in HK.I expression was observed in the rhEPO group upon RT 
treatment (p = 0,003; ANOV A). Additionally, HK.I expression in the rhEPO group that 
received RT was significantly higher than in the control group that didn't receive RT (p = 
0,0 16; ANOV A) and HK.I expression in the control group that received RT was significantly 
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FIGURE 4. Mean Hscores for HK.I expression for the different experimental groups were 
respectively: ctrl: 8,6 (range 3 ,5 to I 0,0; sd 2,0), rhEPO: 8,0 (range I ,0 to I 3 ,5; sd 3 ,3), 
ctrl+RT: 1 0,7 (range 7,0 to 1 5,0; sd 3,2), rhEPO+RT: I 1 ,7 (range 8,0 to 15,0; sd 2,9). A 
significant increase in HK.I expression was observed in the rhEPO group upon RT treatment 
(p = 0,003). Additionally, HK.I expression in the rhEPO group that received RT was 
significantly higher than in the control group that didn't receive RT (p = 0,02) and HK.I 
expression in the control group that received RT was significantly higher than in the rhEPO 
group that didn't receive RT (p = 0,03). 
FIGURE 5. Immunohistochemical analysis of HK.I expression: an example comparing a 
sample with a high Hscore and a sample with a low Hscore. Panel A: Sample of rat that 
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received RT and rhEPO (Hscore 1 5,0) (200x). Panel B: Sample of rat that received no 
treatment (Hscore 3,5) (200x). 
Effects of rhEPO Treatment and RT on Expression ofN-cadherin 
Mean Hscores for N-CAD expression for the different experimental groups was respectively: 
ctrl: 6,6 (range 3,5 to 10,0; sd 2,4), rhEPO: 6,8 (range 3,5 to 1 0,0; sd 2,6), ctrl+RT: 9,6 (range 
3,5 to 1 5,0; sd 4,5), rhEPO+RT: 9,9 (range 1 ,5 to 1 5,0; sd 3,9) (Fig. 6). Immunostaining ofN­
cadherin was mainly cytoplasmatic and negative controls showed no staining. 
A significant increase in N-cadherin expression was observed in the rhEPO group upon RT 
treatment (p = 0,037; ANOVA). Additionally, N-cadherin expression in the rhEPO group that 
received RT was significantly higher than in the control group that didn't receive RT (p = 
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FIGURE 6. Mean Hscores for N-CAD expression for the different experimental groups was 
respectively: ctrl: 6,6 (range 3,5 to 10,0; sd 2,4), rhEPO: 6,8 (range 3,5 to 1 0,0; sd 2,6), 
ctrl+RT: 9,6 (range 3 ,5 to 1 5,0; sd 4,5), rhEPO+RT: 9,9 (range 1 ,5 to 1 5,0; sd 3,9). A 
significant increase in N-cadherin expression was observed in the rhEPO group upon RT 
treatment (p = 0,04). Additionally, N-cadherin expression in the rhEPO group that received 
RT was significantly higher than in the control group that didn't receive RT (p = 0,03). 
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FIGURE 7. lmmunohistochemical analysis ofN-cadherin expression: an example comparing 
a sample with a high Hscore and a sample with a low Hscore. Panel A: Sample of rat that 
received RT and rhEPO (Hscore 1 5 ,0) (200x). Panel B: Sample of rat that received no 
treatment (Hscore 5 ,0) (200x). 
GLUT3 HKI N-CAD 
ANOVA QM Q.J!1 QM 
ctrl H rhEPO 0 ,49 0 ,62 0 ,88 
ctrl H ctrl + RT 0 ,85 0 ,1 1  0 ,06 
ctrl H rhEPO + RT 0 ,07 Q..Q2 � 
rhEPO H ctrl + RT 0 ,36 � 0 ,08 
rhEPO H rhEPO + RT Q.J!1 0.003 o..M 
ctrl + RT H rhEPO + RT 0 ,09 0 ,42 0 ,85 
TABLE 2. Significant differences were found between the different experimental groups in 
the expression of GLUT3, HK.I and N-CAD. Overview of the p-values of the different 
comparisons. No significant differences were found between the different experimental 
groups in the expression of GLUTI (p = 0,24; ANOV A), GLUT4 (p = 0,48; ANOV A), 
GLUTS (p = 0,54; ANOV A), GLUT9 (p = 0,23; ANOV A), SGL Tl (p = 0,44; ANOV A) HK.II 
(p = 0,45 ; ANOVA) and HKIIJ (p = 0,49; ANOVA). P value :'.S 0,05 was considered 
significant. 
DISCUSSION 
The aim of this study was to investigate the expression of several proteins related to tumour 
metabolism and invasion in a rat colorectal cancer model receiving RT in combination with 
rhEPO treatment. This was done to assess a possible influence of EPO and RT on tumour cell 
metabolism and invasion either through a direct effect on the tumour cells or by an indirect 
effect by changes in the oxygenation status of the tumour. A statistically significant 
upregulation of hexokinase I (HK.I), N-cadherin, and glucose transporter 3 (GLUT3) was 
found when rhEPO treatment was combined with RT. 
Our results first of all indicate that rhEPO treatment increases tumour oxygenation. To date, 
the mechanisms by which rhEPO improves tumour oxygenation remain unclear. Besides its 
effect on haemoglobin levels, several direct effects of rhEPO have been described by which 
rhEPO can influence tumour oxygenation. Blackwell et al. found that systemic rhEPO 
administration to non-anaemic rats bearing mammary adenocarcinoma flank tumours 
improved tumour oxygenation independent of the effects on haemoglobin levels (1 7). Tovari 
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et al. found that rhEPO had profound effects on tumoural blood vessels in human epidermoid 
and colorectal cancer xenograft models through changes in vascular endothelial growth factor 
(VEGF) expression and microvessel morphology (19). Although there are several reports that 
RT alone causes an increase in tumour oxygenation, our results did not indicate this (20,21 ). 
We did find however, that RT causes an increase in tumour oxygenation when rhEPO is 
administered, possibly indicating a synergistic effect of both treatments. 
We further found a significant increase in GLUT3 glucose transporter expression in the 
rhEPO group upon RT treatment. Facilitative glucose transporters (GLUTs) mediate the 
transport of glucose and other monosaccharides across the plasma membrane of mammalian 
cells. The whole family of human GLUT proteins consists of 14 members with different 
substrate specificities, kinetic properties and tissue expression profiles. GLUT3 is a high 
affinity glucose transporter (Km = 10,6 mM) that is mainly expressed in the brain where it 
mediates glucose transport into neurons. As GLUT3 is believed to operate more efficiently at 
lower substrate concentrations than other isoforms, it is expected to supplement GLUTl in 
tissues with a high energy demand (22). Besides glucose, GLUT3 also transports galactose, 
mannose, maltose, xylose or dehydroascorbic acid. Upregulation of GLUT3 has frequently 
been described in human tumours, where it is believed to be involved in fulfilling the high 
energy demand of the tumour (23 ,24 ). Because of its high affinity for glucose and its ability to 
transport other energy substrates besides glucose, it's tempting to view an upregulation of 
GLUT3 as a stress reaction of the tumour cell in an effort to absorb as much energy from its 
environment as possible. As such, an upregulation of GLUT3 may be seen as a survival 
benefit allowing the tumour cell to cope with its compromised situation more efficiently. 
Our results also indicate a significant increase in HK.I expression in the rhEPO groep upon RT 
treatment. Additionally, HK.I expression in the rhEPO group that received RT was 
significantly higher than in the control group that didn't receive RT and HK.I expression in 
the control group that received RT was significantly higher than in the rhEPO group that 
didn't receive RT. HK.I is a metabolic enzyme belonging to the family of the hexokinases 
which comprises 4 members (HK.I, HK.II, HK.III, and HK.IV or glucokinase ). Hexokinases 
have a role in glucose metabolism, converting glucose to glucose-6-phosphate. 
Overexpression of HK is a common feature in cancer as it allows the tumour cell to maintain 
a high rate of glycolysis by maintaining the downhill concentration gradient necessary to 
move glucose into the cell through glucose transporters. The overexpressed form of HK is 
preferentially bound to the outer mitochondrial membrane. This interaction markedly reduces 
the enzyme's sensitivity to product inhibition by glucose-6-phosphate, provides preferred 
75 
access to mitochondrial generated ATP, and protects against proteolytic degradation (25-27). 
In addition to their role in glucose metabolism by augmenting cellular energy supply and 
levels of glucose-6-phosphate, HK.I and HK.II are also believed to play an active role in 
regulating cell death. In vitro and in vivo studies have shown that HK.I and HK.II play a role in 
protecting against mitochondrial regulated apoptosis through direct interaction with 
mitochondria and, more specifically, with the voltage-dependent anion channel (VDAC) 
through their N-terminal hydrophobic regions. A mechanism has been proposed in which 
binding of HK to VDAC induces channel closure leading to the prevention of cytochrome C 
release, which represents the mitochondrial phase of apoptosis (26,28-30). In this respect, 
HK.I overexpression in U-93 7 cells protected against apoptotic cell death induced by 
staurosporine and HK.I and II overexpression in HEK.293 cells protected against apoptotic cell 
death induced by hydrogen peroxide (28,31 ). Again, the increase in HK.I expression upon 
treatment with rhEPO and RT suggests activation of an anti-apoptotic mechanism in the 
remaining tumour cells allowing them to survive in compromised conditions. 
Finally, our results indicate a significant increase in Neural (N) - cadherin expression in the 
rhEPO group upon RT treatment. Additionally, N-cadherin expression in the rhEPO group 
that received RT was significantly higher than in the control group that didn't receive RT. The 
cadherin family of adhesion molecules regulates cell-cell interactions during development and 
during normal tissue homeostasis. N-cadherin is a cell-adhesion molecule belonging to the 
family of the cadherins that is normally found in fibroblasts and neural cells and has a role in 
tumour cell invasion and metastasis. Metastasis is a complex multistep process involving a 
series of tumour-host interactions that finally result in colonization of distant tissue. While E­
cadherin, which is responsible for maintaining interactions of epithelial cells, is frequently 
downregulated during tumour progression, N-cadherin is frequently upregulated during 
tumour progression and increases the invasiveness of tumour cells (32). This switch in 
cadherin expression, often referred to as the cadherin switch, can be the result of an epithelial 
to mesenchymal transformation (EMT) of tumour cells. EMT plays a critical role in the 
progression of tumours towards a more aggressive phenotype that is associated with increased 
motile and invasive capability (33). A number of studies described upregulation ofN-cadherin 
expression in several invasive tumour cell lines and tumour tissues from different origins (34). 
Additionally, its exogenous expression in tumour cells induces a scattered morphology and 
heightened motility, invasion and metastasis (35-37). This N-cadherin upregulation provides 
tumour cells with a way to permeate local and distant tissues and facilitate its survival by 
interacting with N-cadherin expressing host cells of the stroma or the endothelium through a 
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homophillic interaction (32,34). Therefore, the increase in N-cadherin expression upon 
treatment with rhEPO and RT suggests that the remaining tumour cells are enhancing their 
metastatic capacities enabling them to spread from their primary site to one or more 
metastatic sites. Upon visual confirmation of this changing phenotype, we observed a shift 
towards a poorly differentiated form with highly anaplastic cells and an increase in abnormal 
mitotic figures. 
The effects of rhEPO treatment on response to RT, chemotherapy or photodynamic therapy 
remain a matter of debate. Whereas some studies indicate that rhEPO treatment has beneficial 
effects on radiosensitivity ( 5-7) and leads to a survival benefit (8,9), other studies report on a 
diminished survival in case of rhEPO treatment (11,12). Although the latter studies were 
strongly criticized for study design, conduct and post-trial analysis, there are indeed 
increasing reports on the modulation of the effects of RT by rhEPO treatment. The 
mechanism by which this occurs remains unclear. In a recent study by Ceelen et al., an 
attempt was made to clarify these mechanisms. It was concluded that rhEPO treatment 
resulted in spatially heterogeneous modulation of RT effects on tumour microvessels. 
Treatment with rhEPO prevented RT-induced changes in microvascular permeability and 
tumour vascular volume, accompanied by a larger microvessel diameter and altered spatial 
complexity (38). The results seen in this study seem to confirm the unfavourable effects of 
rhEPO treatment on RT efficacy. 
To conclude, our results indicate a detrimental role for the combination of rhEPO treatment 
and RT through the stimulation of tumour cell metabolism, inhibition of apoptosis and 
stimulation of tumour spread. A significant upregulation ofHKI, N-cadherin and GLUT3 was 
observed after treatment with RT in combination with rhEPO treatment. These three proteins 
have distinct functions in protecting the cell in compromised conditions. As a consequence, 
these results seem to confirm the results of other groups whereby rhEPO treatment seemed to 
modulate the effects of RT on the tumour. The mechanism by which this occurs, remains 
largely unclear and needs further clarification. 
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ABSTRACT 
Introduction: Tumor hypoxia and tumor metabolism are linked through the activation of metabolic genes following HIF-1 activation. This raises the question whether this relation can be exploited to improve [ 18F]FDG-PET imaging. To do this, [ 18F]FDG-uptake was investigated after chemical induction of hypoxia and chemical activation of HIF-1 in an in 
vitro and in vivo model of a human colorectal carcinoma. 
Methods: [ 18F]FDG-uptake, HIF-la. protein levels and mRNA expression of GLUTl , HK2, HIF-l a and CA IX were determined in HT29 cells after treatment with 2 00µM CoCh and 5 00µM DMOG. In a HT29 xenograft, the distribution of endogenous and exogenous markers of hypoxia was investigated using immunohistochemistry and tumor [ 18F]FDG-uptake was determined after treatment with a single dose of 5 mg/kg hydralazine and 8 mg DMOG. 
Results: Treatment of HT29 cells with CoCh and DMOG induced functional HIF-1 and resulted in increased [ 18F]FDG-uptake. In a HT29 xenograft, a similar spatial distribution of pimonidazole, CA IX and GLUTl was found and treatment with DMOG resulted in significant increases in SUVmax and SUVmean using [ 18F]FDG-PET imaging. 
Conclusion: Chemical activation ofHIF-1 can increase in vitro and in vivo [ 18F]FDG-uptake. Imaging after pharmacological HIF-1 activation might possibly increase tumor [ 18F]FDG­uptake when using [ 18F]FDG-PET imaging. 
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INTRODUCTION 
2-Deoxy-2-[ 18F]fluoro-D-glucose ([ 18F]FDG) is the most widely used positron emission 
tomography (PET) radiotracer in oncology. This non-invasive imaging method, which is 
routinely used for cancer detection, staging and monitoring of response and recurrence in 
several tumor types, is based on the accumulation of a radiolabeled glucose analogue in tumor 
cells as a consequence of their enhanced glucose uptake and glycolysis. Although the precise 
determinant remains unclear, major factors considered to play a key role in the higher 
[
1 8F]FDG-uptake by malignant cells appear to be overexpression of different types of glucose 
transporters (GLUTs), a high hexokinase (HK) activity and a low glucose-6-phosphatase 
(G6P) activity (1,2). Despite its widespread use, a number of problems and limitations still 
exist. First of all, because glucose is used as an energy substrate throughout the body, 
[
18F]FDG-uptake in some benign tissues and certain physiological processes is common and 
complicates its oncological use: high uptake in normal brain tissue complicates brain tumor 
detection, aspecific bladder activity interferes with bladder and prostate cancer diagnosis, and 
inflammation and infection processes are known to be highly [ 18F]FDG avid. Secondly, some 
tumors such as prostate carcinoma, mucinous carcinoma and hepatocellular carcinoma display 
low [ 18F]FDG-uptake due to low metabolic rates or elevated G6P levels (3,4). In these 
patients, the lack of identification of sites of malignant invasion or underestimation of the 
disease may result in insufficient or lack of treatment, adversely affecting patient outcome. 
It is becoming more and more clear that tumor hypoxia, a characteristic feature of locally 
advanced solid tumors, plays an important role in tumor metabolism and as a result in 
[
1 8F]FDG-PET imaging. As hypoxic conditions aggravate the already profound and inherent 
dependence of malignant cells on glycolysis (5) through the Pasteur effect, cancer cells adapt 
to these hypoxic conditions by the induction of target genes involved in glucose metabolism 
ensuring necessary energy supply. Many of these adaptations are coordinated by the 
transcription factor hypoxia-inducible factor (HIF) - 1, which has been verified as a master 
regulator of oxygen homeostasis under hypoxic conditions (6). HIF-1 is a heterodimer 
consisting of HIF-la and HIF-l B, whose biological activity is determined by the expression 
and activity of HIF-1 a, which is constantly expressed and subsequently rapidly destroyed 
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under normal oxygen conditions. This involves a mechanism where posttranslational hydroxylation by specific prolyl hydroxylases (PHD) allows binding of the von Hippel­Lindau protein (VHL) tumor suppressor protein, which in turn leads to ubiquitination and proteasomal degradation. Under hypoxic conditions however, stabilization of HIF-la occurs through inactivation of the PHDs, allowing it to translocate to the nucleus where it can bind with the constitutively expressed HIF-1 � to form a functional transcription factor that will transactivate several target genes (7 ,8). As a number of these genes are involved in tumor glucose metabolism and consequently in the uptake and trapping of [ 1 8F]FDG, tumor hypoxia and functional imaging using [ 1 8F]FDG-PET are inherently linked. As a result, artificially induced tumor hypoxia or chemical HIF-1 activation might provide a means to increase tumor 
[
1 8F]FDG-uptake and improve tumor detection using [ 1 8F]FDG-PET imaging. Several approaches exist to induce tumor hypoxia in an in vitro and an in vivo setting. In vitro approaches comprise either the use of hypoxic chambers or either a direct chemical activation of HIF-1 using hypoxia mimics like cobalt chloride or chemicals inhibiting PHDs like dimethyloxalylglycine (DMOG) (9). A commonly used in vivo approach uses a peripheral vasodilator named hydralazine hydrochloride which, through indirect inhibition of tumor blood flow, causes tumor hypoxia (1 0). In this manuscript we studied the relationship between tumor hypoxia and [ 1 8F]FDG-uptake and investigated whether this relationship could be exploited to improve [ 1 8F]FDG-PET imaging. To do this, [ 1 8F]FDG-uptake was investigated after chemical induction of hypoxia and chemical activation of HIF-1 in an in vitro and in vivo model of human colorectal carcinoma. 
MATERIALS AND METHODS HT29 Cell Culture HT29 human colorectal carcinoma cells (ACC 299, DSMZ, Braunschweig, Germany) were cultured in McCoy's 5A medium (Invitrogen Corporation, Gibco, Merelbeke, Belgium) supplemented with 1 0% fetal bovine serum (Invitrogen Corporation), 4 mM L-glutamine, 50  µI/ml penicillin and 5 0  µg/ml streptomycin (lnvitrogen Corporation) and incubated at 37°C in a humidified atmosphere of 5% CO2 in air. Cells were kept in exponential growth phase by 84 
routine passage every 3-4 days (split ratio of 1/4 -1/6). Glucose concentration of McCoy's 5A 
medium is 3000 mg/L (16.67 mM). 
[ 
1 8F]FDG Uptake Experiments 
For radiotracer uptake experiments, 2.5 x 105 HT29 cells were seeded in a cavity of a 12-well 
plate (Multiwell™, BD Falcon®, Becton Dickinson, Franklin Lakes, NJ USA) and cultured in 
a humidified atmosphere of 5% CO2 in air at 37 °C in cell culture medium. Cells were 
incubated with 200µM cobalt chloride (CoCh) (Merck, Darmstadt, Germany) and 500µM 
dimethyloxalylglycine (DMOG; Echelon Biosciences, Salt Lake City, UT USA) for 5, 12 and 
24 hours. Phosphate buffered saline (PBS) was used to dissolve CoCb and DMOG. Control 
samples were treated with vehicle alone (PBS) and comparisons were made to vehicle-treated 
controls at each time point. After incubation, 0.74 MBq [ 18F]FDG was added to each well. 
After a 60 minutes incubation period at 37°C and 5% CO2, cells were washed three times with 
ice-cold PBS and lysed in 0.5 ml RIPA-buffer (Thermo Scientific, Rockford, IL USA). Cell 
lysates were counted using an automated gamma counter (Cobra II series, Canberra-Packard, 
Meriden, CT USA). Protein concentration of each sample was determined using the BCA 
protein assay kit (Pierce, Rockford, IL USA) according to the manufacturer's 
recommendations and bovine serum albumin was used as protein standard. Uptake/well was 
corrected for protein concentration. Quantitative Real-Time PCR 
After an identical experimental set-up like the [18F]FDG-uptake experiments, HT29 cells were 
lysed in RLT-buffer (Qiagen, Westburg BV, The Netherlands) and needle homogenization 
was performed. Total RNA was extracted using the RNeasy Mini Kit (Qiagen) according to 
manufacturer's instructions. One microgram of total RNA was converted to single strand 
complementary DNA ( cDNA) by reverse transcription (Superscript, Invitrogen) with 
Oligo(dT) priming. cDNA was used in real-time quantification using the SYBR green kit (GC 
Biotech, Alphen aan den Rijn, The Netherlands) and 250 nM of each primer. A two-step 
program was run on the LightCycler 480 (Roche, Vilvoorde, Belgium). Cycling conditions 
were 95°C for 10 min, 40 cycles of 95°C for 15 s and 60°C for 1 min. Melting curve analysis 
confirmed primer specificities. All reactions were run in duplicate and normalized to the 
geometric mean of human HMBS and SDHA. The efficiency of each primer was calculated 
using a standard curve of reference genomic or cDNA (Roche). Amplification efficiency was 
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determined using the formula 10-1/slope. For the actual calculations, the base of the 
exponential amplification function was used. ( e.g. 2.04 in case of 104% amplification 
efficiency). Forward and reverse sequences of all reference genes and target genes are shown 
in Table 1. 
Gene symbol Forward Primers (5' - 3') Reverse Primers (5' - 3') 
hHIF-1 a TGCCAGCTCAAAAGAAAACA ACCAACAGGGTAGGCAGAAC 
hCA IX TGACTTCAGCCGCTACT CAGCATCACTGTCTGGTTA 
hGLUT1 AAATGCTTGTGGATTGAGGG GTCGAAGTCTAAGCCGTTGC 
hHK2 CCCTGCCACCAGACTAA GGATCAGAGCCACAACG 
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG 
HMBS GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC 
TABLE 1. Sequences of used qRT-PCR primers. hHIF-la, human hypoxia inducible factor 
1 a; hCA IX, human carbonic anhydrase IX; hGLUTl, human glucose transporter 1; hHK2, 
human hexokinase 2; SDHA, succinate dehydrogenase complex subunit A; HMBS, 
hydroxymethylbilane synthase Enzyme-Linked lmmunosorbent Assay (ELISA) 
After an identical experimental set-up like the [ 18F]FDG-uptake experiments, HT29 cells were 
lysed using lysis buffer. Levels ofHIF-la in HT29 cell lysates were measured using a human 
HIF-la ELISA kit (R&D Systems DYC1935, Minneapolis, MN, USA) according to 
manufacturer's instructions and normalized to total protein content of cell lysates. Animal Model 
Four-to-six week old Female CD-1 ® nude mice were purchased from Charles River (Brussels, 
Belgium) and housed in a standard facility at the Department of Animal Sciences, Ghent 
University Hospital. All procedures were carried out in accordance with the guidelines and 
regulations for use and care of animals and approved by the local ethical committee, Faculty 
of Medicine, Ghent University (EC nr. 08/40). One million cells suspended in 0.1 ml of PBS 
were injected subcutaneously (sc) in the proximal hind leg. Tumor growth curves were 
obtained using calliper measurement and the estimate volume formula V = 1/2 ( a2b ), where a 
and b represent the short and long axis of the tumor, respectively. Experiments were initiated 
when tumors had reached approximately 10 mm in diameter, generally 14 days after 
implantation. When used, pimonidazole hydrochloride (H ypoxyprobe TM -1, Chemicon 
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International, Billerica, MA USA) was administered intraperitoneally (ip) to mice one hour 
before sacrification at a dosage of 60 mg/kg according to the manufacturers' instructions. Immunohistochemistry 
After resection of the tumors, the specimens were routinely processed, formalin fixed and 
paraffin embedded. Tissue sections of 5 µm thick were mounted on SuperFrost® microscope 
slides (Menzel-Glaser, Braunschweig, Germany), which were deparaffinized in xylene and 
rehydrated in a downgraded series of ethanol. After washing the slides in the appropriate 
buffer (tris-buffered saline {TBS) with 0.1 % Tween 20), heat induced antigen retrieval was 
performed for 20 minutes with citrate buffer (pH = 6.0), after which the slides were cooled 
down for 20 minutes. The endogenous peroxidase activity was blocked for 5 minutes with 0.3 
% hydrogen peroxide (Dako, Glostrup, Denmark). Slides were then incubated with primary 
antibodies diluted in PBS with 1 % bovine serum albumin (BSA) for 1 hour at room 
temperature (GLUTl ABCAM ab15309, 1/200; GLUT3 ABCAM ab1531 l, 1/50; HK2 Santa­
Cruz sc-28889, 1/100; CAIX ABCAM ab 15086, 1/1500; HIF-la ABCAM abl 14977, 1/100). 
After washing, the tissue sections were incubated for 30 minutes at room temperature with a 
HRP-labeled anti-rabbit secondary antibody (Dako ). The colour reaction was developed using 
the chromogen 3,3-diaminobenzidine+ (DAB) (Dako) for 30 seconds. The tissue sections 
were counterstained with Mayer's haematoxylin. In order to exclude false positive responses 
from non-specific binding of the secondary antibody, negative controls were incubated with 
1 % PBS-BSA instead of the primary antibody. Prior to staining the specimens, an isotype 
control was performed to estimate the non-specific binding of target primary antibodies to cell 
surface antigens. Immunohistochemical Analysis 
An Optronicscolor digital camera (Olympus Corporation, Tokyo, Japan) and specialized 
software (Cell D Olympus Imaging Solutions, Munster, Germany) was used to analyse 
immunohistochemical stainings. The intensity and percentage of positive tumor were scored 
independently by two experienced observers. The percentage of tumor cells that were positive 
were scored as follows : 0% (score 0), 0-20% (score 1), 20-40% (score 2), 40-60% (score 3), 
60-80% (score 4) and 80-100% (score 5). Intensities of staining were categorized as absent 
(score 0), faint (score 1), moderate (score 2) or strong (score 3). An estimation of intensity 
and percentage of positive tumor cells was made after counting ten high-powerfields (200x). 
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A final histological score (Hscore) was calculated as following: Hscore = [(al x il) + (a2 x 
i2)] /2, where i = the score of intensity, a = the score of amount tumor cells that stained 
positive and 1 and 2 refer to the scores of the two observers. A previously described 
semiquantitative scoring system was used to score pimonidazole staining: absent (score 0), > 
0 to 5% (score 1), > 5 to 1 5% (score 2), > 15 to 30% (score 3), >30% (score 4) (11 ). pOrMeasurements 
Tumor oxygenation after hydralazine treatment was measured with a fibre-optic probe based 
on fluorescence quenching (OxyLite, Oxford Optronix, Oxford, UK) ( 12). After anaesthesia 
was initiated using a constant flow of 2% isoflurane, a precalibrated fibreoptic probe was 
inserted 5 mm deep into the tumor using a Seldinger technique and kept in that same position 
for the duration of the experiment using a micromanipulator (model MN15 1 ,  Narishige 
International Ltd, London, UK). Animals were kept under anaesthesia for the duration of the 
experiment. Measurements were started and after approximately one hour to one hour and a 
half, a single dose of 5 mg/kg hydralazine hydrochloride (Sigma Aldrich, Schnelldorf, 
Germany) was injected ip. Tissue pO2 was sampled every second. Tissue pO2 was expressed 
in mmHg. After approximately three hours, measurements were stopped and animals were 
sacrificed. 
[
1 8F]FDG-PET Imaging 
[
1 8F]FDG-PET examinations were performed on 3 consecutive days (day 0, 1 and 2), using 
the first scan as a baseline scan before treatment. On day 1 and day 2 mice were treated with: 
a single ip dose of 5 mg/kg hydralazine 3h or 8h before [ 18F]FDG administration, a single ip 
dose of 8mg DMOG 8h before [ 18F]FDG administration, or a single ip dose of vehicle alone 
(PBS) 8h before [ 18F]FDG administration. Each experimental group consisted of 5 animals. 
Mice fasted for 6h before an intravenous (iv) injection with 3.7 MBq of in-house produced 
[
1 8F]FDG. One and a half hour post-injection, mice were anaesthetized with a mixture of 100 
mg/kg Ketamine and 10  mg/kg Xylazine. When mice were sedated, they were positioned side 
by side in the field of view (FOV) of a conventional PET camera (Allegro TM, Philips Medical 
Systems, Eindhoven, The Netherlands). After a 5 min transmission scan, a 10 min one-bed 
position PET acquisition was obtained. Images were reconstructed by a 3D-RAMLA 
technique using blobs as basis functions and with a pixel size of 2x2x2 mm. Attenuation and 
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scatter correction were applied during reconstruction and images were transferred to a remote 
workstation for further image analysis. 
Volumes of interest (VOi) were drawn around the tumor using PMOD 3.0 software (PMOD 
Technologies, Zurich, Switserland) and SUVmax and SUVmean (Standardized Uptake 
Values) were calculated. VOis from baseline scans were copied onto the treatment scans. 
[
1 8F]FDG uptake was also determined in a reference tissue (brain) to ensure that changes in 
tumor SUV were not a consequence of differences in injection technique or due to varying 
systemic clearance of the radiotracer from the body. Brain was chosen as it allowed easy and 
reproducible placement of VOis. Briefly, a spherical VOi (5mm diameter) was placed central 
in the brain using PMOD 3.0 software (PMOD Technologies) and SUVmax and SUVmean 
were calculated. Statistical Analysis 
All statistical analyses were performed using SPPS software (version 15.0; SPSS Inc., 
Chicago, IL, USA). Correlation analysis was performed using the Spearman rank test. 
Differences between three or more urtmatched groups were analyzed using one-way analysis 
of variance (ANOV A). Differences between two paired groups were analyzed using a paired 
t-test. Differences between two unpaired groups were analyzed using an unpaired t-test. A P  
value < 0.05 was considered statistically significant. 
RESULTS CoCh and DMOG Induce Functional HIF-1 
HIF-la. protein levels and mRNA expression levels of GLUTl ,  HK2, HIF-la. and CA IX 
were determined after incubation ofHT29 cells with 200µM CoCb and 500µM DMOG for 5,  
12 and 24h. Results are summarized in Figure 1 and 2.  These results indicate that functional 
HIF-1 is induced through HIF-l a. protein stabilisation after treatment with CoCb and DMOG 
resulting in increased transcription of GLUTl , HK2 and CA IX genes. As opposed to CoCli, 
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FIGURE 1. Protein expression levels of HIF-la in HT29-cells after treatment with 200µM 
CoCh and 500µM DMOG for 5h (white bars), 12h (hatched bars) and 24h (black bars). Fold 
changes are shown as mean ± SEM (n = 8) and are shown relative to control samples treated 
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FIGURE 2. mRNA expression levels of GLUTI ,  HK2, HIF-la and CA IX genes in HT29-
cells after treatment with 200µM CoCh and 500µM DMOG for 5h (white bars), 12h (hatched 
bars) and 24h (black bars). Fold changes in transcription levels are determined by SYBR 
Green qPCR using the geometric mean of hHMBS and hSDHA as reference genes. Fold 
changes are shown as mean ± SEM (n = 5) and are shown relative to control samples treated 
with vehicle (PBS) at each time point. * p < 0.05, ** p < 0.01, *** p < 0.001 
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Chemical Activation of HIF- 1 Increases In Vitro [ 1 8F]FDG Uptake 
[
18F]FDG-uptake was determined after incubation of HT29 cells with 200µM CoCh and 
500µM DMOG for 5, 1 2  and 24h. Results are summarized in Figure 3. Treatment with 
200µM CoCh for 1 2h and 24h resulted in a significant increase in [ 18F]FDG-uptake (p < 
0.001 ). Incubation for 5h had no effect. Treatment with 500µM DMOG for 5h, 1 2h and 24h 
resulted in a significant increase in [ 18F]FDG-uptake (p < 0.00 1 ). Treatment with 200µM 
CoClz and 500µM DMOG for 5, 1 2  and 24h did not result in significant changes in protein 
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FIGURE 3. [ 18F]FDG-uptake in HT29-cells after treatment with 200µM CoCh and 500µM 
DMOG for 5h (white bars), 1 2h (hatched bars) and 24h (black bars). Fold changes are shown 
as mean ± SEM (n = 9) and are shown relative to control samples treated with vehicle (PBS) 
at each time point. *** p < 0.001 
In Vivo Detection of Hypoxia in a HT29 Xenograft 
We compared the distribution of the exogenous hypoxia marker pimonidazole with the 
expression of GLUTl, GLUT3, HK2, HIF-la and CA IX in a HT29 xenograft. A total 
number of 1 8  tumor specimens was investigated. Mean pimonidazole score was 1 .9  ± 0. 1 9. 
Mean Hscore for GLUTl expression was 7.3 ± 0.69. Mean Hscore for GLUT3 expression 
was 8.6 ± 0.75. Mean Hscore for CA IX expression was 6.3 ± 0.64. Mean Hscore for HK.2 
expression was 1 .6 ± 0.22. Mean Hscore for HIF-la expression was 7.6 ± 0.82. A low but 
significant correlation was found between pimonidazole staining and CA IX - Hscore (R = 
0.491 ;  P = 0.038). Further, a significant correlation was found between GLUTl - Hscore and 
CA IX - Hscore (R = 0.746; P = 0.001 ). Expression of HK.2 was cytoplasmic and low. 
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Expression of GLUTI ,  GLUT3 and CA IX was membranous. A uniform, low expression of 
GLUT3 in the entire tumor section was observed. HIF- l a  expression was cytoplasmic and 
more or less uniformly expressed throughout the entire tumor section with a number of 
hotspots. Pimonidazole staining and expression of CA IX were localized around areas of 
necrosis, although a more diffuse and patchy staining was observed in areas away from 
necrosis as well. GLUTI expression was seen throughout the entire tumor section with the 
highest expression colocalizing with pimonidazole and CAIX. Overall, upon visual inspection 
we observed that although an absolute spatial colocalization was absent, pimonidazole 
staining and expression of GLUTl and CA IX showed a strong overlap and a similar pattern 
(see Figure 4). 
FIGURE 4. Immunohistochemical staining in HT29 xenograft: pimonidazole (Al 40x; A2 
l O0x; A3 200x), CA IX (Bl 40x; B2 l O0x; B3 200x), GLUTl (Cl 40x; C2 l O0x; C3 200x). 
Chemical Activation of HIF- 1 Increases In Vivo [ 1 8F]FDG Uptake 
Tumor [ 18F]FDG-uptake was determined after treatment with 5 mg/kg hydralazine and 8 mg 
DMOG in a HT29 xenograft. Tumor pO2-measurements were conducted in 3 animals after a 
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single dose of 5 mg/kg hydralazine hydrochloride to verify its mechanism of action. After 
insertion of the probe in the tumor, pOrvalues showed considerable variation. A steep drop in 
tumor pO2-values was observed immediately after administration of a single dose of 5 mg/kg 
hydralazine (see Figure 5). In all three animals, tumor oxygenation levels were significantly 
lower after hydralazine treatment (p < 0.00 1 ). [ 18F]FDG-PET examinations were performed 
on 3 consecutive days ( day 0, 1 and 2), using the first scan as a baseline scan before treatment. 
Results are summarized in Figure 6. Baseline tumor SUVmax and SUVmean (day 0) were not 
significantly different between the control and the treatment groups. No significant changes in 
tumor SUV max and SUV mean were observed in the control group during the length of the 
experiment. Treatment with a single dose of hydralazine caused a minor decrease in tumor 
SUVmax and SUVmean. After treatment with a single dose of 8 mg/kg IP of DMOG, we 
observed an increase in tumor SUVmax and SUVmean which was statistically significant on 
day 1 (p = 0.0 1 3  and p = 0.0 14, respectively). Brain [ 18F]FDG-uptake was also determined. 
Baseline brain SUVmax and SUVmean (day 0) were not significantly different between the 
control and the treatment groups. No significant changes in brain SUVmax and SUVmean 
were observed in the control, DMOG and hydra 8h groups during the length of the 
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FIGURE 5. Tumor oxygenation values in three animals. Arrows indicate the moment when a 
single dose of 5mg/kg hydralazine ip was administered. In all three animals, tumor 
oxygenation levels were significantly lower after hydralazine treatment (p < 0.001). Mean 
93 
mmHg animal I :  pre-hydra: 8.78, post-hydra: 5.03 ; mean mmHg animal 2: pre-hydra: 1 5 .57, 
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FIGURE 6. Tumor and brain SUVmax and SUVmean on day O (white bars), day I (hatched 
bars) and day 2 (black bars). Data are expressed as mean ± SEM (n = 5) and as a percentage 
change compared to baseline scans. After treatment with a single dose of 8 mg/kg DMOG ip, 
we observed an increase in tumor SUVmax and SUVmean which was statistically significant 
on day I (p = 0.0 13  and p = 0.0 I 4 respectively). After treatment with a single dose of 5 mg/kg 
hydralazine ip 3h before C8F]FDG administration, we observed an decrease in brain SUVmax 
which was significant on day 2 (p = 0.042). * p < 0.05 
DISCUSSION 
In this manuscript we studied the relationship between tumor hypoxia and [ 18F]FDG-uptake 
and investigated whether this relationship could be exploited to improve [ 18F]FDG-PET 
imaging. To do this, [ 18F]FDG-uptake was determined after chemical induction of hypoxia 
and chemical activation of HIF-1 in an in vitro and in vivo model of a human colorectal 
carcinoma. 
We first investigated whether chemical stabilization of HIF-la  under normoxic conditions 
could increase [ 18F]FDG-uptake in vitro. Treatment of HT29 cells with CoCh and DMOG 
resulted in induction of HIF-1 through HIF-la  protein stabilisation. This resulted in an 
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increased transcription of GLUTl, HK2 and CAIX genes. As opposed to CoClz, DMOG does 
not increase HIF-1 a mRNA levels, which is in line with its mechanism of action. Our results 
showed significant increases in [ 1 8F]FDG-uptake when HT29 colorectal carcinoma cells were 
treated with CoCh and DMOG. CoCh is a well known chemical inducer of hypoxia that has 
been successfully used in several studies. Its mechanism of action is not entirely clear and 
several hypotheses exist to explain its action (13-15). DMOG is a non-specific 2-oxoglutarate 
(OG) -dependent dioxygenase inhibitor. The 2-OG dioxygenase family includes PHDl-3 and 
factor inhibiting HIF-1 (FIH-1 ). Inhibition of these proteins results in stabilization of HIF-1 a 
and activation of HIF-1 (16). As confirmed in this study, both chemicals provide an easy 
platform to study the hypoxic response in an in vitro setting. Whereas CoCh-induced 
stimulation of [ 1 8F]FDG-uptake seems to increase as a function of time, the DMOG-induced 
stimulation appears to have an early set-on and remain constant throughout time. These 
results thus indicate a different mechanism of action of CoCh and DMOG. Numerous in vitro 
studies in different types of cancer cell lines have reported an increase in [
3H]FDG- or 
[ 18F]FDG-uptake after exposure to decreasing oxygen atmospheres (17-20). Some of these 
studies reported an increase in expression of GLUTl and GLUT3 (17,19) while one study 
observed no changes in cellular levels of GLUTl, GLUT3, HK2, HIFla and attributed the 
increase in uptake to an increase in GLUT-activity (18). Studies reporting on glucose-uptake 
after a chemical induction of hypoxia are limited. Two studies in Clone 9 rat liver cells 
reported on an increase in 3-O-methyl D-glucose transport after treatment for 24h with 250 
µM CoCh which was associated with an increase in GLUTl mRNA and protein content 
(21,22). Similar results were obtained in BeWo choriocarcinoma cells and articular 
chondrocytes (23,24). 
In a next step, we compared the distribution of endogenous and exogenous hypoxic markers 
in the tumors of non-treated HT29 xenografts. After injection, the exogenous hypoxia marker 
pimonidazole is reduced under hypoxic conditions and the resulting adducts are irreversibly 
bound to thiol-containing proteins in viable hypoxic cells (pO2 < 10 mm Hg) (25). 
Pimonidazole staining and expression of CA IX were localized in perinecrotic areas and a 
more diffuse and patchy staining pattern was observed in areas away from necrosis as well. 
Both showed a strong colocalization and a weak, but significant correlation was found 
between pimonidazole staining and CA IX-Hscore, confirming the role of CA IX as one of 
the most reliable endogenous markers of tumor hypoxia. Given the timeframe of CAIX 
expression (26), this would confirm that CAIX as well as pimonidazole mainly demonstrate 
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chronic hypoxia. Two other studies previously reported a similar spatial distribution between 
pimonidazole staining and CA IX expression in a HT29 xenograft (27 ,28). GLUTl was 
expressed throughout the entire tumor section with highest expression colocalizing with 
pimonidazole and CAIX. Although GLUTl is also believed to be mainly a marker of chronic 
hypoxia (29), its expression might occur at higher oxygen levels than CA IX expression and 
pimonidazole reduction. HIF-la was more or less uniformly expressed throughout the whole 
tumour section with a number of hotspots independent of areas of necrosis. Taken together, 
these results confirm hypoxic activation of HIF-1 downstream proteins in our in vivo model. 
To test whether or not artificial hypoxia or chemical activation of HIF-1 could induce an 
increase in [ 18F]FDG-uptake in an in vivo situation, HT29 xenografts were treated with 
DMOG and hydralazine hydrochloride. Several studies reported that hydralazine causes tumor 
hypoxia through a process of preferential arterial vasodilation in normal versus tumor tissue 
concomitant with a reduction in blood pressure ('steal phenomenon') (10,30-32). In this study 
as well, a sigriificant decrease in tumor pO2-values was observed in the HT29 xenograft after 
administration of a single dose of 5 mg/kg hydralazine. After treatment with a single dose of 
hydralazine we observed a minor decrease in tumor [ 18F]FDG-uptake. Although one can 
hypothesize that this is the consequence of the decreased tumor perfusion that characterizes its 
mode of action, other studies do not indicate an effect on tracer delivery and subsequent 
binding as soon as thirty minutes after hydralazine treatment (30-32). These studies 
successfully used hydralazine to confirm the pO2 dependence of several hypoxia-selective 
PET imaging agents. Possibly, the relative lack of selectivity that characterizes [ 18F]FDG as 
compared to more selective tracers used in these studies, taken together with the peripheral 
vasodilatation after hydralazine treatment, may explain the results. 
As opposed to hydralazine, DMOG has no direct effects on tumor oxygenation but directly 
stabilizes HIF-la  through PHD inhibition. Systemic administration of DMOG has been 
described previously (33-35). After treatment with a single dose of DMOG we observed a 
sigriificant increase in tumor [
18F]FDG-uptake. We hypothesize that this increase is the 
consequence of tumoral HIF-1 activation with an associated transcription of metabolic genes 
resulting in an increase in glucose/[ 18F]FDG uptake. As proposed by Cummins et al., DMOG 
may be primarily active at the sites of acute insults. Indeed, they showed that systemic 
administration of DMOG did not alter basal myeloperoxidase activity and cytokine levels in 
normal colon tissue, but counteracted inflammation in colon subjected to inflammatory insults 
(33). Another study observed similar effects when systemic administration ofDMOG induced 
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increased expression of HIF-la and downstream VEGF in muscle that was subjected to ischemic insult, but not in normal muscle (34). If this would be the case, tumor specific activation of HIF-1 can indeed be achieved with associated increase in glucose transport. We hereby propose a role for PHO-inhibitors as a potential tool to increase tumor [ 18F]FDG­uptake in order to enhance sensitivity using [ 18F]FDG-PET. Indeed, although [ 18F]FDG-PET imaging is successful in detecting most types of cancer, there are a number of situations were 
[
18F]FDG-PET imaging is less successful due to low [ 18F]FDG-avidity (e.g. hepatocellular carcinoma and prostate cancer) or a low or decreased tumor-to-background ratio ( e.g. brain tumors due to high physiological glucose uptake in normal brain, bladder and prostate tumors due to [ 18F]FDG excretion through the urinary system) (3,4). In these cases [ 18F]FDG-PET imaging after a single treatment with PHO-inhibitors might possibly increase sensitivity. Whereas systemic use of DMOG in experimental animals to explore its effect in models of ischemic heart, renal and muscle disease and inflammatory bowel disease indicated no adverse effects (9,32-35), systemic use of DMOG in humans has not been reported. However, other prolyl hydroxylase domain-containing protein inhibitors are currently under development for the treatment of anaemic and ischemic conditions in humans (36,37). Although some of these compounds are currently undergoing phase I and phase II clinical trials, their oncological use has not been explored and deleterious effects on tumor progression thus need to be investigated as it is generally known that hypoxia impairs the effectiveness of therapy and negatively affects prognosis (38). Further studies thus will indicate whether the benefit of an increased detection is worth the transient activation of HIF-1. 
CONCLUSION We observed significant increases in [ 18F]FDG-uptake following chemical activation of HIF-1 in an in vitro and in vivo model of a human colorectal carcinoma. In cases [ 18F]FDG-PET imaging is less successful, imaging after pharmacological HIF-1 activation might possibly increase sensitivity and provide a means to improve imaging. 
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ABSTRACT Given its importance in human and canine tumour biology, a profound understanding of tumour hypoxia is of paramount importance. Therefore, the aim of this work was to investigate the relationship between tumour hypoxia and the expression of a number of hypoxia-induced proteins that play a role in tumour metabolism. The hypoxia marker pimonidazole was administered to dogs affected by spontaneous mammary carcinoma and compared with immunohistochemical staining for GLUTI and 3, HK 2 and CA IX. A statistically significant correlation was found between pimonidazole staining and GLUTI ­expression ( R  = 0.6 07; p = 0. 001 ). These results indicate a strong interaction between tumour hypoxia and tumour metabolism by the induction of proteins essential to maintain a stable tumour microenvironment. 
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The occurrence of heterogeneously distributed hypoxic and/or anoxic areas is a characteristic 
feature of locally advanced solid tumours and has been described in a wide range of human as 
well as canine malignancies (1). These areas of acute and chronic hypoxia are the result of an 
abnormal structure and function of the tumoural microvessels, increased diffusion distances 
between the nutritive blood vessels and the tumour cells, and disease- or treatment- related 
anaemia. Recent studies have demonstrated a clear relationship between this hypoxic 
microenvironment and tumour-associated metabolic alterations. In this respect, tumour 
hypoxia has been associated with an aggressive tumour phenotype, poor response to therapy, 
and worse prognosis in a wide range of human malignancies (2-4). Cancer cells adapt to 
hypoxic conditions by the induction of target genes involved in glucose metabolism, 
angiogenesis, erythropoiesis and apoptosis in an effort to overcome their compromised 
condition. Many of these adaptations are coordinated by the transcription factor hypoxia­
inducible factor (HIF) - I, which has been verified as a master regulator of oxygen 
homeostasis under hypoxic conditions (5). To compensate for the hypoxia-induced drop in 
mitochondrially produced ATP, cells will increase their glycolytic ATP-production (Pasteur 
effect) which is inherently inefficient when compared to aerobic degradation of glucose 
(Krebs cycle), leading to an increase in glucose transport and consumption. This is further 
enhanced by aerobic glycolysis (Warburg effect) (6). Several approaches, non-invasive and 
invasive, exist for the detection of tumour hypoxia (4). Numerous studies have investigated 
tumour hypoxia in a prospective and retrospective manner by studying the expression and 
localisation of endogenous and exogenous markers of hypoxia. Several different candidates 
have emerged as possible endogenous markers of hypoxia of which the most important are 
HIF-la, carbonic anhydrase IX (CA IX), glucose transporter (GLUT) I and 3. None of these 
have however, proven their selectivity for hypoxia as their expression is believed to be 
influenced by other parameters than merely hypoxia (7). The most relevant marker for 
qualitative and quantitative determination of tumour hypoxia in experimental and clinical 
circumstances is the exogenous hypoxia marker pimonidazole. This 2-nitroimidazole reagent 
is reduced under hypoxic conditions and the resulting adducts are irreversibly bound to thiol­
containing proteins in viable hypoxic cells (pO2 < 10 mm Hg) (8). Pimonidazole is a robust 
marker of hypoxia and its microregional distribution correlates with oxygen concentration at 
the cellular level (9, 10). The objective of this study was to investigate the relationship 
between tumour hypoxia and the expression of a number of hypoxia-induced proteins that 
play a role in tumour metabolism in a spontaneous canine mammary carcinoma. 
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Privately owned dogs with a spontaneous mammary carcinoma and no other concurrent 
disease were eligible for the study at the Faculty of Veterinary Medicine, Ghent University. 
All dog owners signed an informed consent form and all procedures were approved by the 
local ethical committee. This spontaneous canine model was chosen because of its high 
incidence, easy resection and the common occurrence of multiple tumours. Pimonidazole 
hydrochloride (HCl) powder (Hypoxyprobe™-1, Chemicon International) was dissolved in 
0.9% NaCl, filtered (0.2 µm) and given intravenously (i.v.) at a dosage of 0.28 g/m2 as 
previously described (11). To decrease the amount of product needed in this study a weight 
limit for the dogs was set at 20kg. Tumours were resected 14 hours later (plasma half life of 
Hypoxyprobe™-1 in dogs is approximately 90 minutes). This timing was chosen for practical 
considerations to allow an overnight stay of the animals in the clinic after injection of 
pimonidazole HCl. This timing however, does not exceed the turnover rate of hypoxic cells, 
nor the stability of pimonidazole adducts in the tissue of interest (11,12). After resection of 
the tumours, the specimens were formalin fixed and paraffin embedded. 
Immunohistochemical staining of tissue sections was performed as previously described (13) 
with the appropriate primary and secondary antibodies (Table 1 ). 
Antibody Company DIiution Pos. Co1111ol Tissue lsotypa conltol Secontla1y Re,19enl Tertl,1rv Reaqent 
Hypoxyprobe-1 Mabl ChemIcon International 1 /50  tumour Mouse lgG, (Dako) B1otin-conjuaated F(ab)2 (Dako) LSAB92 Streptavidin-HRP (Dako) 
GLUT1 ABCAM, ab15319 11200 brain (vascular) Rabbit lgG (Dako) Envision+ System-HRP (Dako) I 
GLUl3 ABCAM, ab15311 1/50 brain (neuronal) Rabbit lgG (Dako) Envision+ System-HRP (Dako) I 
HK2 Santa-Cruz, sc-28889 1/100 smooth muscle Rabbit lgG (Dako) Vectastam ABC sytem (Vector Labs) I 
CAIX ABCAM, ab15006 1/100 tumour Rabbit lgG (Dako) Vectastam ABC sytem (Vector Labs) I 
TABLE 1. The used primary and secondary antibodies with their corresponding dilution 
factors (primary antibody diluted in lx PBS with 1% BSA). (Hypoxyprobe-1 Mabl: 
monoclonal antibody against pimonidazole, GLUTl: glucose transporter 1, GLUT3: glucose 
transporter 3, HK2 : hexokinase 2, CA IX :  Carbonic anhydrase 9) 
The intensity and percentage of positive tumour cells in the immuno-reaction were scored 
independently by two experienced observers. The percentage of tumour cells that were 
positive was scored as follows: 0% (score 0), 0-20% (score 1), 20-40% (score 2), 40-60% 
(score 3), 60-80% (score 4) and 80-100% (score 5). Intensities of staining were categorized as 
absent (score 0), faint (score 1), moderate (score 2) or strong (score 3). An estimation of 
intensity and percentage of positive tumour cells was made after counting ten high­
powerfields. A final histological score (Hscore) was calculated as following: Hscore = [(al x 
i 1) + ( a2 x i2)] /2, where i = the score of intensity, a = the score of amount tumour cells that 
stained positive and 1 and 2 refer to the scores of the two observers. A previously described 
semiquantitative scoring system was used to score pimonidazole staining: absent (score 0), > 
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0 to 5% (score 1 ), > 5 to 1 5% (score 2), > 1 5  to 30% (score 3), >30% (score 4) ( 14). SPPS for 
Windows, version 1 5.0 was used for statistical analysis. Data are expressed as mean ± SEM 
(standard error of the mean). Correlation analysis was performed using the Spearman rank 
correlation test. Differences between two groups of paired data were analyzed using the 
Wilcoxon test. A p value < 0.05 was considered significant. 
Ten female animals, weighing 3.5 kg to 1 3  kg participated in the study. All these animals had 
multiple tumour nodules. After unilateral mastectomy was performed, 36 mammary gland 
tumour specimens were harvested. After reviewing the specimens by a trained veterinary 
pathologist, 1 1  benign tumours (9 mammary adenomas, 1 lipoma and 1 leiomyoma) and 25 
malignant tumours (1 1 mammary adenocarcinomas grade I, 1 mammary adenocarcima grade 
II and 1 3  mammary complex carcinomas grade I) were identified. Only the malignant 
tumours were included in this study. 
Overall pimonidazole staining was modest and patchy (Fig. 1 - A) and mean score was 0.5 ± 
0. 1 5. Immunostaining of GLUTI ,  GLUT3 and CA IX was membranous (Fig. 1 - B,C,E). 
Mean Hscore for GLUTl expression was 1 .5 ± 0.41. Mean Hscore for GLUT3 expression 
was 6. 1 ± 0.56. Mean Hscore for CA IX expression was 8.4 ± 0.75. Immunostaining of HK.2 
was cytoplasmic (Fig. 1 - D) and mean Hscore was 8.2 ± 0,40. A significant correlation was 
found between pimonidazole staining and GLUTI -expression (R = 0.607; p = 0.001 ). 
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FIGURE 1. Immunohistochemical staining in canine specimens: pimonidazole (A, l O0x), 
GLUTI (B, 200x), GLUT3 (C, 200x), HK2 (D, 200x), CA IX (E, 200x). 
Pimonidazole is widely accepted as a reliable marker of hypoxia and has been successfully 
used in several types of cancer (9,10). It provides hypoxia measurements with a high spatial 
resolution and as reduction only takes place in viable cells with functional nitro-reductase 
enzymes, dead cells do not generate a signal. After it has been reduced and bound in tumour 
tissue, loss of the marker mainly occurs through cell loss (12). It shows a steep increase in the 
amount of reduction below a pO2 of I O  mmHg (8). This was confirmed in a study by Raleigh 
et al. in which pimonidazole binding was compared with micro-electrode pO2 measurements 
(1 5). Other studies that compared pimonidazole binding with invasive oxygen measurements 
have given inconsistent results (1 6- 1 8). Necrosis is thought to be the main confounding factor. 
To our knowledge, only two studies have previously investigated tumour hypoxia in canine 
tumours using pimonidazole. Azuma et al. quantified the longevity of pimonidazole adducts 
as an estimate of the lifetime of hypoxic cells and Kleiter et al. investigated the oral 
administration of pimonidazole as a means of minimizing invasiveness (1 1 ,19). Both studies 
illustrated the feasibility to demonstrate tumour hypoxia in spontaneous canine tumours using 
pimonidazole. In this study, a significant correlation was found between pimonidazole 
staining and GLUTI -expression (p = 0.001 ,  Spearman rank). A similar correlation has been 
described previously in two studies that found a strong spatial colocalization and correlation 
between GLUTI -expression and pimonidazole staining, respectively in human bladder and 
cervical cancer (20,21 ). Contrary to these findings, studies trying to show a relationship 
between GLUT I -expression and invasive oxygen measurements have failed to demonstrate a 
strong correlation (22-24). Again, necrosis is thought to be a main confounding factor 
together with the influence of other m icroenvironmental parameters than merely hypoxia. 
While a significant correlation was found only between pimonidazole staining and GLUTI ­
expression, the histological scores of GLUT3 proved higher than those of GLUTI (p = 0.001, 
Wilcoxon) indicating a possible higher impact of GLUT3 on tumour glucose metabolism 
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when compared to GLUTl in this tumour type. Overexpression of GLUT3 has been reported 
in a variety of human cancers (25), confirming its importance for tumour metabolism. 
To conclude, we found a significant correlation between pimonidazole staining and GLUTI­
expression in a spontaneous canine mammary carcinoma. This indicates a strong interplay 
between tumour hypoxia and tumour metabolism by the hypoxia-driven induction of proteins 
essential to maintain a stable tumour microenvironment. 
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ABSTRACT Tumour cells are characterized by an increased rate of glucose consumption and glycolysis. This increased glucose consumption leads to tumour acidification, which represents a major obstacle for several therapeutic strategies. Tumour cells have adapted to this acidification by upregulation of several H+-extruding transporter systems and proteins to cope with this compromised situation. One of these proteins is carbonic anhydrase IX which catalyzes the reversible hydration of carbon dioxide to carbonic acid outside the cell, leading to an acidic extracellular pH and an physiological intracellular pH. The aim of this paper was to study semiquantitatively the expression of carbonic anhydrase IX in non-small cell lung cancer and to assess the existence of a possible relationship between carbonic anhydrase IX expression and tumour FOG-uptake, reflecting glucose metabolism. The levels and the extent of carbonic anhydrase IX expression were estimated in immunohistochemical stained formalin fixed, paraffin embedded tissue samples from 18 patients with non-small cell lung cancer and compared with FOG-uptake in FDG-PET imaging. We found a statistically significant correlation between carbonic anhydrase IX Hscores and SUVmax and SUVmean values of the primary tumour. This relationship found provides indirect evidence for co-transcription of glucose transporters and hexokinases that drive tumour hyperglycolysis, and carbonic 1 12 
anhydrase IX governed by HIF-1 and suggests that in the future it may be possible to identify 
non-small cell lung cancer patients that are most likely to benefit from carbonic anhydrase IX 
targeting therapy on the basis ofFDG-PET imaging. 
Keywords: CA IX, NSCLC, FDG-PET, pH 
INTRODUCTION 
As first described by Warburg more than 50 years ago, tumour cells utilize more glucose than 
normal cells and maintain a high glycolytic rate, even in conditions of adequate oxygen 
supply (aerobic glycolysis) (1). A major consequence of the Warburg effect and the 
accompanying aerobic glycolysis is tumour acidification because of the accumulation of lactic 
acid (2,3). Importantly, tumour acidification is associated with the acquisition of a metastatic 
phenotype and chemoresistance to weakly basic anticancer drugs such as vinca-alkaloids and 
anthracyclines (4). While the acidification process results in a drop of pH in the interstitial 
space, the intracellular pH in solid tumour cells remains close to the physiological value. This 
suggests that malignant cells extrude protons more avidly than their untransformed 
counterparts. Indeed, several W-extruding transporter systems appear to be upregulated in 
cancer cells, respectively the monocarboxylate carrier which exports lactate and W, the Na+­
W antiporter and H1" channels (5). 
In addition to an increased H1" efflux, a wide variety of tumour types, including non-small cell 
lung carcinoma, show increased expression of the transmembrane zinc metalloenzyme 
carbonic anhydrase IX (CA IX /  CA 9). CA IX catalyzes the reversible hydration of carbon 
dioxide to carbonic acid outside the cell (6). Carbonic acid is subsequently transported inside 
the cell by HCO3- /Cr anion exchangers where it may buffer H+, while the H1" generated 
remains outside the cell contributing to the build up of the extracellular acid environment 
(5,7-9) Given the role of CA IX in the acidification of the extracellular tumour 
microenvironment and its neutralizing effect on the intracellular pH on the one hand and the 
association of tumour acidification with tumour invasion and chemoresistance, CA IX is an 
attractive target for cancer therapy. 
Importantly, the genes encoding for the glucose transporter and hexokinases that drive tumour 
hyperglycolysis, and CA IX are both under the control of hypoxia-inducible factor-I (HIF-1) 
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(10-12). Accordingly, the aim of this study was to study semiquantitatively the expression of 
CA IX in non-small cell lung cancer (NSCLC) and to assess the existence of a possible 
relationship between CA IX expression and tumour FOG-uptake, reflecting glucose 
metabolism by primary NSCLC. Such relationship, if existing, could provide a rationale for 
selection of those patients suffering from NSCLC whom may benefit from CA IX inhibition 
treatment, based on FDG-PET imaging. 
MATERIALS AND METHODS Patients 
Eighteen patients in whom substantial biopsy material or a surgical resection specimen of a 
primary NSCLC was available and that had also undergone an FDG PET-CT scan one week 
before the intervention or biopsy-procedure were included. The diagnosis of NSCLC was 
histologically confirmed in all patients. CA IX expression was scored and related to FDG 
SUVmean and SUVmax ofthe primary tumour. FDG-PET 
Whole body FDG-PET scans were acquired on a dedicated PET-CT scanner (Gemini, Philips) 
from the neck to the pelvis. Patients were required to be fasting for a minimum of 4 hours 
prior to FDG injection. Blood glycaemia was monitored with a portable capillary glucometer. 
Patients received a dose of FDG based on their body weight using the following formula 
((body weight/10)+1))*37 MBq. The mean delay from FDG injection to imaging was 60 
minutes, minimally 50 minutes. Images were acquired in a 3 -dimensional mode and 
reconstructed with attenuation correction ( CT-based) using OSEM ( ordered subset 
expectation maximization). Data were processed using MIMVISTA software. Maximum FDG 
SUV was derived from a region of interest (ROI) drawn over the tumour lesion on the slice 
containing the most intense tumour signal, using CT as a reference. The mean tumour SUV 
value was defined using region growing using the voxel with the maximum value as seeding 
voxel and a threshold of 75% of the maximum value. The 75 % threshold was chosen in order 
to largely exclude regions of tumour necrosis that may significantly influence the mean SUV 
value. 1 14 
Immunohistochemistry 
Routinely processed, formalin fixed, paraffin embedded surgical pathology specimens were 
used for immunohistochemistry. Sections of 4 µm thick were mounted on SuperFrost® 
microscope slides (Menzel-Glaser, Braunschweig, Germany), which were deparaffinized in 
xylene and rehydrated in a downgraded series of ethanol. After flushing in water, heat 
induced antigen retrieval was performed for 20 minutes with the appropriate buffer (EDTA 
pH = 8.0), after which the tissue slides were cooled down for 20 minutes and then flushed in 
water for 10 minutes. The endogenous peroxidase activity was blocked for 5 minutes with 0,3 
% hydrogen peroxide (DAKO , Glostrup, Denmark) on each tissue slide. Primary antibody 
(anti-CAIX, ABCAM ab15086, 1/2000 in 1% BSA/PBS) was than incubated for 1 hour at 
room temperature. After washing, the tissue sections were incubated for 30 minutes at room 
temperature with a labelled polymer-HRP anti-rabbit secondary antibody (DAKO , Glostrup, 
Denmark). The colour reaction was developed using the chromogen 3,3-diaminobenzidine+ 
(DAB) (DAKO , Glostrup, Denmark) for 10 minutes. After washing, the tissue sections were 
counterstained with Mayer's haematoxylin. 
Phosphate-buffered saline with 1 % BSA instead of the primary antibody was used as negative 
control on each slide in order to exclude false positive responses from non-specific binding of 
the secondary antibody. Prior to staining the specimens, an isotype control was performed to 
estimate the non-specific binding of target primary antibodies to cell surface antigens. Non­
specific binding is due to Fe receptor binding or other protein-protein interactions. Immunohistochemical analysis 
The intensity and percentage of positive tumour cells in the immuno-reaction were scored 
independently by two experienced observers. Only membranous staining was scored 
(intensity and percentage of positive cells). The percentage of tumour cells that were positive 
on the immuno-reaction were scored as follows : 0% (score 0), 0-20% (score 1), 20-40% 
(score 2), 40-60% (score 3), 60-80% (score 4) and 80-100% (score 5). Intensities of staining 
were categorized as absent (score 0), faint (score 1), average (score 2) or strong (score 3). An 
estimation of intensity and percentage of positive tumour cells was made after counting ten 
high-powerfields. A final histological score was calculated as following: Hscore = [(al x il) + 
(a2 x i2)] /2, where i = the score of intensity, a = the score of amount tumour cells that stained 
positive and 1 and 2 refer to the scores of the two observers. 1 1 5 
Statistical analysis. 
SPPS for Windows, version 15.0 was used for statistical analysis. Correlation analysis was 
performed using the Spearman rank test ( a P value < 0.05 was considered significant). 
RESULTS Patients 
Patient results are shown in Table 1. There were 14 men and 4 women, mean age was 67 
years, range: 52-82 years. Four patients presented with stage I disease, 3 presented with stage 
II disease, 7 patients with stage III disease and 4 patients suffered from stage IV disease. 
FDG-PET data: FDG SUVmax values of the primary tumour ranged from 0.7 to 22.1 (mean 
10.0). FDG SUVmean values of the primary tumour ranged from 0.6 to 19 (mean 8.7). 
Nb. Gender Age T TtiM: 
FDG FDG CAIX 
SUVmean SUVmax Hscore 
1 F 55 3 2 5.4 6.2 3 
2 M 58 3 3 4. 6 5. 2 3 
3 M 79 2 2 13 . 5  1 6.7 4. 5 
4 M 82 2 1 1 2. 1  1 3 . 0  6 
5 M 78 2 1 1 9  22. 1 7. 5 
6 M 79 2 4 0 . 6 0.7 0 . 0 
7 F 73 2 1 3  8.4 1 0. 1  7. 5 
8 M 69 2 1 6 . 3 7 .6  4 .5  
9 M 78 2 3 5. 2 6 . 6 0. 0 
1 0  F 56 2 2 6 . 1 7 .2  1 . 5  
1 1  M 52 2 3 5. 8 6.7 2. 0 
1 2  M 80 2 3 8 . 1 9. 6 4. 5 
1 3  M 62 2 4 9 . 1 1 0 . 9  2 . 5 
14 M 6 1  2 4 5 .4 6 .4 1 . 5  
1 5  M 6 1  2 1 1 5 . 2  1 6 . 1 9 . 0 
1 6  M 65 2 3 1 1 . 0  1 2. 9  3. 0 
17 M 65 3 3 6.4 7. 5 5. 0 
1 8  F 57 2 4 14. 0 15 . 0  4. 5 
TABLE 1. T= T-stage, TNM= TNM stage 1 16 
CA IX expression 
Membranous tumour cell CA IX expression was detected in 16 (88 %) patients (see Figure 1 ). 
Mean Hscore for CA IX expression in the total group was 3 ,9 (range 0,0 to 9,0; sd 2,8). CA 
IX expression was not related to tumorsize (T-stage) 
FIGURE 1. Immunohistochemical 
staining of CA IX (200 X). Staining 
was typically confined to the cell 
membrane and had a strong intensity. 
Correlation Between CA IX Hscores and FDG SUVmax and SUVmean Values 
A statistically significant correlation was observed when plotting CA IX Hscores against FDG 
SUVmax and FDG SUVmean values of the primary tumour, respectively r = 0.7 16  (p = 
0,00 1 )  and r = 0.758 (p = 0.000 1 )  (see Figures 2, 3, 4). 
\ 
FIGURE 2. Shows high FDG uptake in the primary NSCLC of patient nb. 1 5  and 
corresponding intense CA IX staining on histology 
1 1 7 
I 
FIGURE 3. Shows moderate FDG uptake in the primary NSCLC of patient nb. 12 and 
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FIGURE 4. Scatterplot of the relationship between CA IX (CA9) Hscores and their 
corresponding FDG SUV mean values (Tmean) and FDG SUV max values (Tmax). 
DISCUSSION 
The aim of this study was to investigate the expression of CA IX in NSCLC and to determine 
a possible relationship with FDG-uptake in FDG-PET imaging. 
In our series, 88 % of the tumours investigated showed positive membranous staining for CA 
IX. Other studies investigating CA IX expression in NSCLC yielded varying numbers of 
positive cases, respectively varying from 24,6 % to 81,8 % (13- I 7). In most of these studies, 
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however, a different scoring methodology was used. Vermylen et al. differentiated between 
cytoplasmic, cytoplasmic with membranous reinforcement or membranous only staining 
pattern and used a three-point scoring system for the intensity of staining. Immunostaining 
proved positive in 52 of 65 tumour samples with the percentage of stained cells in positive 
tumours being highly variable (13). Giatromanolaki et al. only made a distinction between 
negative, weak cytoplasmic and strong membrane/cytoplasmic staining. In their series, 39 out 
of 107 cases studied showed strong membrane/cytoplasmic expression of CA IX (14). 
Swinson et al. assessed the percentage of cells with membranous and cytoplasmic expression 
and divided CA IX expression into quartiles depending on the percentage of cells that stained 
positive (15). Kon-no et al. classified NSCLC tumours into CA IX positive or negative using 
a cut-off of 20 % of positive cancer cells showing an unequivocal strong membranous and/or 
cytoplasmic reaction; using this criterion, 33 out of 134 cases studied were CA IX positive 
(16). Finally, in the study by Kim et al. a similar scoring system to the one used in the study 
reported was used and a comparable percentage of patients, respectively 54 of 75 patients (72 
% ) showing CA IX expression, reported ( 17). Of interest, in four out of five studies the 
prognostic relevance of CA IX expression was studied ( 14-17). In three out of these four 
studies, respectively the studies by Giatromanolaki et al., Swinson et al. and Kim et al. CA IX 
expression was related to poor prognosis in both univariate analysis and multivariate analysis 
whereas in the study by Kon-no et al. CA IX expression was significantly associated with 
overall and disease-free survival in univariate analysis only ( 14-17). 
In the series presented, a statistically significant correlation was observed between CA IX 
Hscores and SUV max and SUV mean values of the primary tumour. This relationship found 
provides indirect evidence for co-transcription of glucose transporter and hexokinases, that 
drive tumour hyperglycolysis, and CA IX governed by HIF-1 (10-12). To date, only one other 
study, respectively by van Baardewijk et al. reported simultaneously on FOG-uptake and CA 
IX expression in patients suffering from NSCLC. However, the purpose of this study was to 
address the prognostic value of FDG-PET imaging and several markers related to hypoxia 
(HIF-la and CA IX), proliferation (Ki-67) and glucose metabolism (GLUTl and GLUT3). 
Accordingly, the scoring system used (a 4-point score system only taking into account the 
percentage of positive cells) was not optimized for correlation analysis and hence correlation 
analysis was not performed (18). 
Chemotherapeutic drugs that are weakly ionized, e.g. vinca-alkaloids such as vinorelbine 
which is currently used in an adjuvant setting as well as in advanced NSCLC, will enter cells 
by passive diffusion in their non-ionized form. In this form, they will tend to partition 
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preferentially across the cell membrane into the compartment where their ionized form predominates. Accordingly, increasing the pH of tumours will enhance the uptake of such agents by the tumour cell, increasing their therapeutic potential. To date, many classes of highly effective in vitro CA IX inhibitors have been developed and the pharmacological evaluation of some of them has recently begun, e.g. the sulphonamide indisulam which is currently being tested in phase II clinical trials ( 4, 19,2 0). The relationship found between CA IX expression and FDG-PET in this study suggest that in the future it may be possible to identify NSCLC patients that are most likely to benefit from CA IX targeting therapy on the basis of FDG-PET imaging. In conclusion, our results show a statistically significant correlation between FOG-uptake in FDG-PET imaging and CA IX expression providing indirect evidence for co-transcription of glucose transporter and hexokinases, that drive tumour hyperglycolysis, and CA IX governed by HIF-1. Based on this finding, studies assessing the predictive value of FDG-PET imaging for CA IX therapy may prove worthwhile to pursue. 
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ABSTRACT 
Given its importance for a tumor's survival and growth, several therapeutic strategies rely on 
the selective inhibition of angiogenesis and the destruction of existing tumor vasculature. This 
raises the need for a non-invasive tool to evaluate tumor vasculature. We describe the 
radiosynthesis and evaluation of a novel imaging tracer that specifically binds tumor 
subendothelial collagen and thereby images tumor vasculature. 
Methods: 99mTc-tricarbonyl was prepared and labeled with His-CNA35. After in vitro 
specificity testing, in vivo biodistribution and dosimetric studies were performed in healthy 
nude mice via planar imaging. 99mTc-(C0)3 His-CNA35 was evaluated for in vivo imaging of 
tumor vasculature in a HT29 colorectal carcinoma xenograft. 
Results: The labeling procedure yielded a compound with 95-99% radiochemical purity and 
good in vitro stability. An in vitro binding test confirmed specificity and functionality. 99mTc­
(C0)3 His-CNA35 rapidly cleared from the blood and predominantly accumulated in the 
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kidneys and liver. The effective dose for a proposed single-injection of 500 MBq 99mTc-(CO)3 
His-CNA35 is 3,70 mSv (per organ) or 2,01 mSv (per gram tissue). Tumors were successfully 
visualized and uptake correlated with ex vivo immunohistochemical staining of tumor 
vasculature. 
Conclusion: 99mTc-(CO)3 His-CNA35 may be a useful novel radioligand for the in vivo 
detection of tumor vasculature through subendothelial collagen binding. A non-invasive 
method of imaging tumor vasculature that could provide a reliable assessment of tumor 
vasculature would allow evaluation of the effectiveness of commonly used antiangiogenic 
therapies as well as determination of their optimal dosing and scheduling. 
Key words: CNA35, tricarbonyl, tumor vasculature, HT29 
As a tumor mass grows beyond the support capacity of the vasculature it relies on, the need 
for new blood vessels arises. This is achieved through the process of angiogenesis in which, 
through a multistep process that relies on the tumor-driven production of pro-angiogenic 
factors, new blood vessels are formed from existing ones. These resulting new blood vessels 
however, are structurally and functionally deficient when compared to normal ones. They are 
disorganized, tortuous and leaky which leads to heterogeneous blood flow, hypoxia, acidosis 
and elevated interstitial fluid pressure (IFP) with a disturbed tumor microenvironment as a 
result (1). Nevertheless, this neovascularization allows the tumor to grow and plays an 
important role in tumor invasiveness and metastasis. Given its importance, a number of 
therapeutic strategies rely on the selective inhibition of angiogenesis and destruction of tumor 
vasculature. In several types of cancer, antiangiogenic therapy alone or in combination with 
standard chemotherapeutic strategies have led to an improvement of survival (2,3). As the 
importance of these therapies increases, non-invasive methods are needed to provide a reliable 
assessment of tumor vasculature and thus provide a means for the management and planning 
of antiangiogenic therapy. 
A possible mechanism to target tumor vasculature is based upon the selective exposure of 
collagen in these vessels due to their aberrant endothelial lining. Collagen-binding adhesion 
protein 35 (CNA35) is a 35 kDa collagen binding domain of specific bacterial adhesion 
proteins from Staphylococcus aureus where it participates in its infectious process. The 
collagen binding properties of these domains are well characterized and overexpression can 
be attained in Escherichia Coli in large quantities ( 4,5). CNA35 has previously been labeled 
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with a number of fluorophores in order to visualize collagen in tissues and life cell cultures 
and has a moderate affinity (Kct ~ 0,5 µM) for a variety of different collagen types (5-7). The 
proposed mechanism of binding involves the wrapping of the CNA35 protein around the 
triple helix of collagen ( 4). Collagens are an important component of the extracellular matrix 
(ECM), an interconnected molecular network providing mechanical support for cells and 
tissues and regulating certain biochemical and cellular processes. Up till now, 19 different 
collagens have been identified which are categorized into fibrillar and non-fibrillar collagens. 
Collagen IV is the major component of the vascular basement membrane, a specialized form 
of ECM that lines the blood vessels and separates epithelia from its underlying mesenchyme 
(8). In contrast to normal blood vessels, tumor vasculature displays an abnormal, incomplete 
endothelial lining that is characterized by large inter-endothelial junctions and an increased 
number of fenestrations (1). This allows CNA35 to penetrate the endothelial lining and bind 
the underlying collagen layer. In normal vessels these abnormalities do not exist in this 
degree, preventing major infiltration of the endothelial lining and subsequent binding of the 
underlying collagen layer. As a result, specific targeting of tumor vasculature is possible and 
non-invasive imaging of tumor vasculature is feasible when labeling CNA35 with a 
radioactive molecule. 
The aim of this study was to radioactively label CNA35 and evaluate this marker of tumor 
vasculature in order to selectively image tumor vasculature non-invasively. 
MATERIALS AND METHODS 
99mTc-( CO )3 His-CNA3 5 Preparation 
Preparation of the labeling precursor 99mTc-tricarbonyl ([99mTc(CO)J(OH2)3t) was performed 
according to manufacturer's instructions. One ml of eluted 99mTcO4- (1480 - 2590 MBq) (GE 
Healthcare, Buckingshamshire, England) was added to the IsoLink™ vial (lsoLink™ kits 
were kindly provided by Mallinckrodt Medical B.V., The Netherlands) containing the 
following lyophilized products: 4.5 mg sodium boranocarbonate, 2.85 mg sodium 
tetraborate.1 0H2O, 8.5 mg sodium tartrate.2H2O. The vial was placed in a water bath for 30 
minutes at 95 - 100°C after which the reaction vial was cooled down to room temperature. 
The precursor was brought at pH 7 by addition of IM HCI. His-CNA35 (50 - 60 µg) 
(provided by Prof. Dr. C. Reutelingsperger, Department of Biochemistry, University 
Maastricht) was added to the precursor and incubated at 37°C for 1 to 1.5 hours while blown 
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dry with nitrogen (N2) gas to reduce the reaction volume. Protein LoBind Tubes (Eppendorf, 
Hamburg, Germany) were used to prevent adhesion of the protein to the vial wall. The vial 
was washed with physiological saline (0.9% NaCl) and the reaction mixture was purified on a 
Sephadex ™ G-25 medium PD-I O  column (GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden) which was activated with phosphate-buffered saline (PBS) containing 0.5% bovine 
serum albumin (BSA, Sigma-Aldrich-Fluka, Bomem, Belgium) and eluted with fractions of 
500 µl PBS. The radioactivity of each fraction was measured in a dose calibrator (VIK.-202, 
Veenstra, The Netherlands). Radiochemical Analysis 
The radiochemical purity of the 99mTc-(CO)3 His-CNA35 was determined by instant thin­
layer chromatography (ITLC) with silica gel-coated fiberglass sheets (Life Sciences, Pall 
Corporation, Zaventem, Belgium) using physiological saline as the mobile phase. Samples of 
radiolabeled His-CNA35 were tested for their in vitro stability at 4h and 24h after preparation 
at 4°C and 37°C in: PBS, McCoy's 5A cell medium supplemented with 10% fetal bovine 
serum (FBS) and human blood serum. Fifty microliter of 99mTc-(CO)3 His-CNA35 was mixed 
with 50 µl PBS, cell medium or serum and ITLC was carried out to assess the radiochemical 
purity. At both time points, 5 µl of the samples were spotted on ITLC strips and radioactivity 
was counted using an automated gamma counter (Cobra II series, Canberra Packard, Meriden 
CT USA). High-pressure liquid chromatography (HPLC) was performed to analyze the 
integrity and radiochemical purity of the radiolabeled CNA35 with a size exclusion Shodex 
KW 802.5 column (7.8x 300 mm; Thomsom Instrument Company, Oceanside, CA USA) 
connected to a UV-VIS spectrometer A 280 nm (SPD-6AV, Shimadzu, Deurne, Belgium) and 
a Nal y counter (Model 2200, Ludlum, Sweetwater, TX USA). Elution was performed at a 
flow rate of0.8 ml/min with a 0.1 M Potassium Phosphate buffer pH 7 and a Waters 510 dual 
head pump. The purity of the unlabeled and labeled compound was further analyzed with 
SOS-PAGE performed according to the method of Laemmli (9). The labeled (0.04 MBq) 
99mTc-(CO)3 His-CNA35 and unlabeled (5µg) His-CNA35 were mixed with an equal volume 
of Laemmli sample buffer (2x) and loaded on to a 15% SOS-PAGE gel. Ten µl of a protein 
ladder (10-250 kDa) from Biolabs was treated the same way. Electrophoresis was performed 
at 200V (Protean III system, Bio-Rad, Nazareth Eke, Belgium) until the dye front reached the 
bottom of the gel. Visualization of the separated proteins was done either with Coomassie 
Briliant Blue R-250 staining (Bio-rad) or either by exposure of a superresolution film for I 
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min to the radioactive gel after which visualization of the radioactive protein was effected 
with Cyclone Storage Phosphor equipment (PerkinElmer, Boston, USA). In Vitro Solid-Phase Binding Assay 
Collagen I -, collagen IV -, laminin - and fibronectin - coated multiwell plates (BD, Franklin 
Lakes NJ, USA) were blocked with 3% PBS/BSA for 3h at 37 °C, aspirated and washed three 
times with PBS. Afterwards, increasing concentrations of 99mTc-(CO)3 His-CNA35 were 
added to each well and incubated for 3h at 37 °C. Supernatant was removed and wells were 
washed 2 times with PBS. Supernatant was measured using an automated gamma counter 
(Cobra II series, Canberra Packard) and uptake was calculated. To asses non-specific binding, 
uptake was measured in a noncoated multiwell plate (BD, Franklin Lakes NJ, USA) as well. 
All assays were done in triplicate. HT29 Cell Culture 
HT29 human colorectal carcinoma cells (ACC 299, DSMZ, Braunschweig, Germany) were 
cultured in McCoy's 5A medium (Invitrogen Corporation, Gibco, Merelbeke, Belgium) 
supplemented with 10% fetal bovine serum (Invitrogen Corporation), 4 mM L-glutamine, 50 
µ1/ml penicillin and 50 µg/ml streptomycin (Invitrogen Corporation) and incubated at 37°C in 
a humidified atmosphere of 5% CO2 in air. Cells were kept in exponential growth phase by 
routine passage every 3-4 days (split ratio of 1/4 - 1/6). Animal Model 
Four-to-six week old female CD-1® nude mice were purchased from Charles River (Brussels, 
Belgium) and housed in a standard facility at the Department of Animal Sciences, Ghent 
University Hospital. All procedures were carried out in accordance to the guidelines and 
regulations for use and care of animals and approved by the local ethical committee, Faculty 
of Medicine, Ghent University (EC nr. 09/14). One million (1.106) HT29 human colorectal 
carcinoma cells suspended in 0.1 ml of PBS were injected subcutaneously (sc) in the proximal 
right hind leg. Tumor growth curves were obtained using calliper measurement and the 
estimate volume formula (mm3) = 1/2 (a2b), where a and b are the short and long axis of the 
tumor respectively. Experiments were initiated when tumors reached approximately 10 mm in 
diameter, generally 14 days after implantation. 
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Biodistribution and Dosimetry ofRadiolabeled CNA35 
For biodistribution and dosimetry studies, 4 healthy nude mice were positioned on the 
gamrnacamera and were maintained under isoflurane anaesthesia (2%) for the duration of the 
experimental procedure while body temperature was maintained. Following bolus tail-vein 
administration of37 MBq (approximately 4µg) 99mTc-(CO)3 His-CNA35 in 150 µl, mice were 
imaged during the first 100 minutes ( dynamic study, one hundred frames of one minute) 
followed by planar images of ten minutes at 4, 8 and 23 h after injection of the radiotracer for 
evaluation of the biodistribution of 99mTc-(CO)3 His-CNA35 in vivo. Mice were imaged using 
a conventional triple-head gamma camera (Triad, Trionix, Twinsburg, OH USA) operated in 
planar mode with the animals positioned on one of the three detectors. Regions of interest 
(ROI) were drawn over the total body, liver, right kidney, left kidney, heart and part of the left 
hind leg (= background) using PMOD 3.0 software (PMOD Technologies, Zurich, 
Switserland). ROI's were drawn on early images and the shape and size (number of pixels) 
were kept constant over all subsequent images per mouse. Total body retention was estimated 
using the no-excretion approach, that is total counts collected during the first minute of the 
dynamic study were assumed to correspond to the total injected dose (ID). Total counts from 
a later whole-body scan at time ti were used to estimate percentage ID: %ID = ( counts ti / 
counts (first frame) x 100%). Following correction for background radiation, decay correction 
and, when needed, correction for residual activity in the tail, uptake in the organs was 
expressed as percentage of the injected dose. 
Based upon quantification of whole body images (0-100 minutes, 4 h, 8 h, and 23 h) from the 
biodistribution studies, dosimetry of 99mTc-(CO)3 His-CNA35 was estimated using MIRDose 
3.1. Organ residence time was obtained by integrating the organ activity curve that was 
normalised with the injected activity, but not corrected for physical decay. For liver, right 
kidney, left kidney and the remainder of the body, time-activity curves (TAC) were 
constructed from the dynamic (first 100 min) and static planar scans at later time points. The 
TAC's were fitted to bi-exponential functions and residence times were calculated. Based on 
these, organ dose and effective dose were calculated with MIRDose 3.1. Data obtained from 
mice were converted to a 68-kg human reference adult, both using an activity per organ and 
an activity per mass approach. In Vivo Imaging of Tumor Vasculature in a Human HT29 Colorectal Tumor Xenograft Model 
1 3 1  
For in vivo imaging of tumor vasculature, 10 HT29 colorectal carcinoma xenografts were 
injected intravenously (iv) with 18.5 MBq (approximately 2µg) 99mTc-(CO)3 His-CNA35 in 
150 µl. Three hours post-injection (pi), mice were brought under isoflurane anaesthesia (2%) 
for the duration of scan while body temperature was maintained. A planar, static scan of 20 
minutes was performed using a conventional triple-head gammacamera (Triad, Trionix, 
Twinsburg, OH USA) with the animals positioned on one of the three detectors. A syringe 
with a known amount of radioactivity was scanned along with the mice to allow 
semiquantification of the results using ROI analysis. ROis were copied from the tumor­
containing right hind leg to the left hind leg and data were expressed as tumor-to-background 
ratio's (T/B ratios) using the left hind leg as background. Directly after the scan, the animals 
were killed by cervical dislocation, tumors were removed, formalin fixed and paraffin 
embedded. Detection of Tumor Vasculature by lmmunohistochemistry 
Tumor vasculature was evaluated using immunohistochemical markers for endothelial cells 
(CD105/Endoglin, R&D AF1320, 1/50), blood vessel basement membrane (collagen IV, 
Abeam ab6586, 1/500), and mural cells, i.e., pericytes and vascular smooth muscle cells 
(alpha smooth muscle actin, Abeam ab5694, 1/200). Tissue sections of 5 µm thick were 
mounted on SuperFrost® microscope slides (Menzel-Glaser, Braunschweig, Germany), which 
were deparaffinized in xylene and rehydrated in a downgraded series of ethanol. After 
washing the slides in the appropriate buffer (tris-buffered saline (TBS) with 0.1 % Tween 20), 
heat induced antigen retrieval was performed for 20 minutes in citrate buffer (pH = 6.0), after 
which the slides were cooled down for 15 minutes. The endogenous peroxidase activity was 
blocked for 5 minutes with 0.3 % hydrogen peroxide (Dako, Glostrup, Denmark). Slides were 
then incubated with the primary antibody overnight (CD105) or for 1 hour (collagen IV and 
aSMA) at room temperature (primary antibody diluted in PBS with 1 % BSA). After washing, 
the tissue sections were incubated for 30 minutes at room temperature with a HRP-labeled 
anti-rabbit secondary antibody (Dako) or the combination of a biotinylated link and 
streptavidin-HRP (Dako). The colour reaction was developed using the chromogen 3 ,3-
diaminobenzidine (DAB) (Dako) for 30 seconds. After washing, the tissue sections were 
counterstained with Mayer's haematoxylin. In order to exclude false positive responses from 
non-specific binding of the secondary antibody, negative controls were tested with 1 % PBS­
BSA instead of the primary antibody. Prior to staining the specimens, an isotype control was 
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performed to estimate the non-specific binding of target primary antibodies to cell surface 
antigens. Immunohistochemical Analysis 
An Optronicscolor digital camera (Olympus Corporation, Tokyo, Japan) and specialized 
software (Cell D Olympus Imaging Solutions, Munster, Germany) was used to analyse 
immunohistochemical stainings. MVD was assessed in sections stained for CD 105 using the 
criteria of Weidner et al. (10). Briefly, the entire tumor section was scanned at low power 
(magnification x40) to identify vascular hot spots, which are the areas of highest 
vascularisation. Individual microvessels were then counted under high power (magnification 
x200) to obtain a vessel count in a defined area, and the average vessel count in five hot spots 
was taken as the MVD. Any brown stained endothelial cell or endothelial cell cluster that was 
clearly separated from adjacent microvessels, tumor cells, and other connective tissue 
elements was considered a single, countable microvessel. The same hotspots were used to 
count a-SMA and collagen IV positive vessels using the same procedure. A ratio of a-SMA to 
CD 105 was used to calculate the vessel maturity index (VMI) which provided a percentage of 
mature vessels (11). Statistical Analysis 
All statistical analysis was performed using SPSS software (version 15.0; SPSS Inc., Chicago, 
IL, USA). Spearman correlation test was used to calculate correlations between 99mTc-(CO)3 
His-CNA35 tumor uptake and immunohistochemical stainings in the tumor. Data were 
considered statistically significant when a two-tailed p-value of< 0.05 was reached. 
RESULTS Radiochemical Profile of 99mTc-( CO)r His CNA35 
His-tagged CNA35, with a N-terminal extension containing six histidine residues, was 
successfully labeled with 99mTc-(CO)3 • Incubation of the His-CNA35 with the 99mTc-(CO)3 
occurred at physiological pH (pH = 7) and at a temperature of 37°C for about 1 - 1.5 hours. 
Although specialized vials were used to prevent adhesion of the protein to the vial wall, 
considerable residual activity was noted in the reaction vial. Radiochemical yields of 40-50% 
and specific radioactivities of approximately 8.9 - 10.4 MBq/µg protein were obtained. 99mTc-
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(C0)3 His-CNA35 was purified on a calibrated PD-10 gel permeation colwnn using PBS as 
eluent. The radiochemical purity of the labeled CNA35 was evaluated by ITLC with 
physiological saline as mobile phase. Radiochemical purities of 95 - 99% were obtained with 
the remainder being free 99mTc pertechnetate (1 - 4%). HPLC was performed to characterize 
the radiolabeled His-CNA35. 99mTc-(C0)3 His-CNA35 was eluted at a retention time of 9.8 
min. The SOS-PAGE showed a band of36 kDa representing the radiolabeled His-CNA35. No 
other small molecules were identified. In vitro, no significant degradation of the product was 
noted for up to 24 hours, at 4°C and 3 7°C in: PBS, cell medium supplemented with 10% FBS 
or human blood serum. The stability tests thus demonstrated that 99mTc-(C0)3 His-CNA35 has 
good thermodynamic stability in PBS, cell medium and human blood serum. In Vitro Solid-Phase Binding Assay 
Binding of 99mTc-(C0)3 His-CNA35 to collagen I -, collagen IV -, laminin - and fibronectin -
coated multi well plates was studied in order to confirm the specificity and functionality of the 
labeled molecule. Results are summarized in Figure 1. Binding of 99mTc-(C0)3 His-CNA35 
to collagen I and IV was observed. Negligible binding was observed to laminin- , fibronectin­
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FIGURE 1. Binding of 99mTc-(C0)3 His-CNA35 to collagen 1-, collagen IV-, laminin-, 
fibronectin- and noncoated multiwell plates. Data are expressed as mean ± SEM (n = 3). 
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Biodistribution 
Following bolus tail-vein administration of 37 MBq 99mTc-(CO)3 His-CNA35, mice were 
imaged during the first 100 minutes (dynamic study, one hundred frames of one m inute) 
followed by planar images of ten minutes at 4, 8 and 23 h after injection of the radiotracer. 
The biodistribution of 99mTc-(CO)3 His-CNA35 in four healthy nude mice is summarized in 
Table 1 and Figure 2. Following intravenous injection 99mTc-(CO)3 His-CNA35, the 
radiotracer was rapidly cleared from the blood (6,54 ± 1 ,47 %ID during the first minute and at 
1 hour pi only 1 ,86 ± 0, 1 4  %ID remained in the blood). Liver and kidneys showed the highest 
radiotracer uptake throughout the biodistribution experiment (see Table I ,  Figure 2 and 3). At 
all time points, the right kidney showed a higher uptake when compared to the left kidney. 
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FIGURE 2. Decay-corrected 99mTc-(CO)3 His-CNA35 uptake vs time curves for bloodpool, 
liver, right kidney and left kidney. Planar scans were made from 0- 100 min (dynamic study, 
100 frames of I min) and at 4 h, 8 h and 23h pi (static study, I O  min). Kidneys show the 
highest radiotracer uptake (right kidney more than left), followed by the liver. A rapid 
clearance of the tracer from the blood was observed. 
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Time pi Blood Liver Right kidney Left kidney 
(min) (% ID ± SD) (%ID ± SD) (%ID ± SD) (%ID ± SD) 
1 6.54 ± 1 .47 1 7.30 ± 7.01 1 8 . 1 0  ± 4.32 8.79 ± 0.97 
10  3.41 ± 0 .35 1 8 .47 ± 6.52 1 9.73 ± 4.20 1 1 .06 ± 0.65 
20 2.66 ± 0. 1 9  1 7.41 ± 5.97 20. 1 7  ± 4.06 12 .71 ± 0.64 
30 2.33 ± 0.23 1 6. 1 0  ± 5.37 20.58 ± 4.02 1 3 .64 ± 0.82 
40 2 . 1 2  ± 0.22 1 5.47 ± 5.30 20.99 ± 4. 1 5  14.27 ± 0.92 
50 1 .95 ± 0. 1 6  1 5.05 ± 4.99 21 .00 ± 4. 1 2  14.64 ± 0.80 
60 1 .86 ± 0. 1 4  1 4.55 ± 4.90 20.91  ± 4.09 1 4.87 ± 0.90 
70 1 .79 ± 0. 1 5  14. 1 9  ± 4.70 2 1 . 1 8 ± 4. 1 2  1 5. 1 9  ± 1 .04 
80 1 .72 ± 0.20 1 3 .89 ± 4.74 21 .05 ± 3.96 1 5.38 ± 0.96 
90 1 .72 ± 0. 1 3  1 3.66 ± 4.41 20.73 ± 4.04 1 5.48 ± 1 . 1 5  
1 00 1 .69 ± 0. 1 5  1 3.30 ± 4.32 20.73 ± 4. 1 0  1 5.72 ± 1 . 1 8  
240 1 .73 ± 0.34 8.23 ± 2 .74 1 9.85 ± 4.20 1 3.96 ± 0.53 
480 1 .67 ± 0.33 9 .34 ± 2.31 1 7 .07 ± 3.24 1 5.40 ± 2.71 
1 380 1 .49 ± 0.25 7. 1 4 ± 1 . 1 2  12 .23 ± 2.83 1 2 .06 ± 2.36 TABLE 1. Biodistribution (%ID) of 99mTc-(CO)3 His-CNA35 in nude mice (n = 4) at 
different time points post-injection. Pi, post-injection; ID, injected dose; SD, standard 
deviation 
FIGURE 3. Posterior view of planar images showing in vivo biodistribution of 99mTc-(CO)3 
His-CNA35 in a healthy mouse (37 l'v1Bq 99mTc-(CO)3 His-CNA35 injected), during first 
minute (A) and 1 00 minutes (B) after injection of the radiotracer (acquisition time of 1 
minute); and 4h (C), 8h (D) and 23h (E) after injection of the radiotracer (acquisition time of 
1 36 
1 0  minutes). Liver and kidneys show the highest radiotracer uptake. L = liver, Kr = right kidney, Kl = left kidney, B = bladder, PI = place of injection 
Dosimetry To translate the mice biodistribution data into estimates of patient dose, the organ values were extrapolated from the data derived from the biodistribution data to a 68-kg man using the standard Medical Internal Radiation Dose (MIRD) scheme and S-tables. A summary of dosimetric parameters for the main excretory organs and total body is given in Table 2. Kidneys clearly had the highest absorbed dose, followed by the liver. The effective dose equivalent (EDE) and the effective dose (ED), when calculations were done per organ, were 0.0 1 29 mSv/MBq and 0.00739 mSv/MBq, respectively. The EDE and the ED, when calculations were made per gram tissue, were 0.006 1 2  mSv/MBq and 0.00402 mSv!MBq, respectively. The total ED for a proposed single-injection of dosage of 500 MBq 99mTc-(CO)3 His-CNA35 will be 3,70 mSv (ED per organ) or 2,0 1 mSv (ED per gram tissue). MIRDose 3. 1 also gives estimates of the dose in other organs, for example absorbed dose (per organ) for the lungs, ovaries, testes and uterus (radiation-sensitive organs) are 0.003 1 7, 0.00294, 0.00 1 56 and 0.00289 mGy/MBq, respectively. 
Per organ Per gram tissue 
Site Residence Time Absorbed Dose Residence Time Absorbed Dose 
(h) (mGy/MBq) (h) (mGy/MBq) 
Kidneys 2.74 0. 1 38 1 .05 0.0538 
Liver 0.91 0.0145 0.33 0.00593 
Total Body 7.56 0.00378 7.56 0.00252 
TABLE 2. Dosimetric data for intravenously administered 99mTc-(CO)3 His-CNA35. 
In Vivo Imaging of Tumor Vasculature in a Human HT29 Colorectal Tumor 
Xenograft Model Three hours after intravenous injection of 99mTc-(CO)3 His-CNA35, a planar, static scan was made. Radiotracer uptake in the tumors was calculated by ROI-analysis and expressed as T/B ratios. In all 1 0  HT29 human colorectal carcinoma xenografts, tumors were visually determinable and showed a heterogeneous uptake of the radiotracer (see Figure 4). T/B ratios varied considerably among the different animals (mean 3.03 ± 0.88). 99mTc-(CO)3 His-CNA35 137 
uptake was correlated with MVD (R = 0.733, p = 0.016) and blood vessel-associated collagen 
IV (R = 0.758, p = 0.011) as determined by immunohistochemistry (see Figure 5). 
Additionally, we found a significant inverse correlation between 99mTc-(CO)3 His-CNA35 
uptake and the VMI (R = - 0.709, p = 0.022) (see Figure 5). 
FIGURE 4. In vivo imaging of tumor vasculature in 2 HT29 human colorectal carcinoma 
bearing mice (right hind leg) showing respectively a mouse (left) with high tumor uptake (T/B 
ratio 3.94) and a mouse (right) with low tumor uptake (T/B ratio 2.63). 
FIGURE 5. Immunohistochemical staining of CD105/Endoglin (A, 200x), Collagen IV (B, 
200x), and a-SMA (C, 200x) in HT29 tumors. 
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DISCUSSION 
In this manuscript, the successful radioactive labeling and validation of a new marker of 
tumor vasculature is described. This marker is based upon binding of tumor subendothelial 
collagen due to the structural deficits that characterize tumor vasculature. 
This is the first report of the successful radioactive labeling of CNA35 to detect tumor 
vasculature non-invasively. Several studies have labeled CNA35 with fluorophores in order to 
detect collagen in an in vitro setting. Krahn et al. investigated the binding properties of 
CNA35-0G488 and confirmed binding to collagen types I-VI with various affinities and no 
binding to other ECM proteins (5). In the following in vitro study, collagen formation around 
HVS cells was successfully demonstrated (5). Using the same molecule, Boerboom et al. 
successfully obtained high resolution images of collagen in samples of HVS myofibroblast 
cell cultures, mouse carotid artery vessels and engineered cardiovascular constructs (6). The 
only in vivo study to our knowledge successfully performed fluorescent collagen labeling 
after intravenous injection of CNA35-OG488 (7). 
In our study, labeling yields of approximately 40-50% and high radiochemical purities (2: 
95%) were obtained. The incubation of CNA35 with the 99mTc-tricarbonyl took place at a 
temperature of 3 7°C at physiological pH and the radiotracer remained stable for up to 24h, at 
4°C and 37°C, in physiological solution, cell medium and human blood serum. Overall, 
preparation of 99mTc-(CO)3 His-CNA35 was straightforward and resulted in a pure product 
with a good stability. The functionality and specificity of the labelled molecule were 
confirmed in an in vitro solid phase binding assay where binding of 99mTc-(CO)3 His-CNA35 
to collagen I and IV was observed with negligible binding to fibronectin and laminin. These 
results confirm those obtained in a previous study (5). 
The biodistribution study performed in 4 healthy nude mice revealed that the radiotracer 
rapidly cleared from the blood following iv injection and was predominantly retained in the 
liver and the kidneys indicating a urinary excretory pathway. Uptake in the right kidney was 
higher than in the left kidney at all time points. This may be explained by a partial overlap of 
the right kidney with the liver, or due to the position of the right kidney in relation to the 
camera. The high uptake in the liver and the kidneys may be due to the nature of the 
endothelial lining in these organs. Unlike in other organs, the blood vessels in the liver have a 
discontinuous endothelial coverage and the blood vessels of the kidneys have a fenestrated 
endothelium (12,13). As a result, labeling of collagen in the subendothelial layers of these 
blood vessels can occur. Megens et al. described a similar phenomenon when they studied the 
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uptake of a fluorescently labeled variant of CNA35 in healthy and atherosclerotic arteries of 
mice after both ex vivo and in vivo administration (7). Administration of 99mTc-(CO)3 His­
CNA35 to patients would cause an effective dose of 0.00739 mSv/MBq corresponding to a 
total effective dose of 3.70 mSv (ED per organ) for a patient dose of 500 MBq. These 
numbers are in the low range when compared to other tracers used in a clinical setting (14). 
However, allometric scaling from laboratory animals to humans was performed on the basis 
of body/organ weight which assumes that the biokinetics of compounds depends primarily on 
the metabolic rate of the animal which in turn is a function of the body weight or body surface 
area. The effective doses obtained in this study merely give an estimation of the effective dose 
that would be obtained in human patients. A detailed study in humans for a reliable estimation 
of the effective dose is still recommended. 
To image tumor vasculature in vivo, human colorectal carcinoma xenografts were imaged 3 
hours after injection of 99mTc-(CO)3 His-CNA35 to allow sufficient bloodpool clearance. A 
heterogeneous uptake of the radiotracer was seen in all tumors. A significant correlation 
between 99mTc-(CO)3 His-CNA35 uptake and MVD was demonstrated. Further we found a 
significant correlation between 99mTc-(CO)3 His-CNA35 uptake and collagen IV that was 
associated with blood vessels. Additionally, we found a significant inverse correlation 
between 99mTc-(CO)3 His-CNA35 uptake and the VMI. This VMI gives an estimate of the 
percentage of vessels that is associated with mural cells and thus an estimate of the maturity 
of the vessels. These results indicate that imaging using CNA35 gives a reliable estimate of 
existing tumour vasculature and confirm the proposed mechanism of binding in which the 
characteristic leakiness and immatureness of tumor blood vessels allows binding of 
subendothelial collagen IV and selective imaging of tumor vasculature. A limitation to our 
approach is the existence of capillaries with a fenestrated and/or discontinuous endothelium in 
a number of tissues like kidneys, endocrine glands, gastrointestinal tract and liver (12,13). 
Although biodistribution studies did not indicate much binding of our molecule to other 
organs except kidneys and liver and all tumors were visually determinable, future studies will 
have to assess the extent of non-specific binding in these organs. Discontinuous endothelium 
(or sinusoids) that can be found in the liver usually have an incomplete or absent basement 
membrane, which would prevent major binding (12,13). 
Besides histological and circulating markers of tumor angiogenesis, a number of non-invasive 
markers of tumor vasculature and angiogenesis have been reported that use different imaging 
modalities. Compounds that specifically target VEGF (vascular endothelial growth factor) and 
its receptors together with compounds that target integrins are the best studied candidates to 
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image tumor vascularisation. Although several of these tracers have been tested in a pre­clinical and clinical setting where they successfully visualized several types of tumors and their metastases (15, 16), none of these are routinely used in clinic and few have been used to detect antiangiogenic therapy response. In two studies, response to antiangiogenic therapy was successfully detected using 99mTc-HYNIC-VEGF and 89Zr-ranibizumab ( 17, 18). However, due to the long biological half-life of VEGF, labeling of VEGF or VEGF-targeting molecules with long-lived isotopes like 89Zr or 1 1 1 1n is needed (18, 19), resulting in high radiation exposures. Using RGD (asparagine-glycine-aspartic acid) - peptide based tracers, several studies also successfully evaluated treatment response to antiangiogenic therapy (2 0-22). However, as integrins are expressed not only on endothelial cells but on tumor cells as well (2 0,23), and are minimally expressed on normal quiescent endothelial cells (24), RGD­peptide based tracers might not be truly representive of existing tumor vasculature. Furthermore, high uptake of 1 8F-galacto-RGD in inflammatory lesions has been reported (25). In future studies, we will assess the potential of 99mTc-(CO)3 His-CNA35 to evaluate the effectiveness of commonly used antiangiogenic drugs. Additionally, we will attempt to label CNA35 with PET labels such as Gallium-68 (68Ga), which has the advantage of a generator­based production and a convenient half-life (68min). Given its mechanism of action we further propose a role for radio labeled CNA3 5 in evaluating the vascular normalisation window which follows antiangiogenic therapy (26). Non-invasive evaluation of the time frame of this normalisation window would allow selection of the appropriate timing to administer chemotherapy. 
CONCLUSION His-tagged CNA35 was successfully labeled with 99mTc-(CO)3 and this resulted in a pure, functional product with a good stability. The biodistribution study demonstrated a rapid blood clearance and a predominantly renal excretion. Tumors were successfully visualized and uptake correlated with ex vivo immunohistochemical staining of blood vessels and basement membrane and was inversely correlated with vessel maturity. Further research will determine whether or not 99mTc-(CO)3 His-CNA35 can provide a reliable tool for the management and planning of antiangiogenic therapy. 141 
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As the proteins responsible for [ 18F]FDG-uptake are under control of HIF-1, the master 
regulator of the hypoxic response, the degree of [ 18F]FDG-uptake might indirectly reflect the 
degree of tumor hypoxia and vice versa. Therefore, in this work we explored the relation 
between tumor oxygenation and tumor metabolism, and evaluated the possible consequences 
and benefits of this relation for functional imaging using [ 18F]FDG - PET. In a second part of 
this work a new radiotracer of tumor vasculature was evaluated. As tumor vasculature and 
tumor hypoxia are highly interconnected, non-invasive imaging of tumor vasculature might 
provide insights into tumor hypoxia. 
In Chapter 2. partim 2.1, the effects of an increase in tumor oxygenation on tumor metabolism 
were studied by investigating changes in expression of proteins important for tumor 
metabolism, survival and spread in a rat colorectal xenograft after treatment with rhEPO. 
Tumor pO2-measurements confirmed that pO2-values were significantly higher after treatment 
with rhEPO. To date, the mechanisms by which rhEPO improves tumor oxygenation remain 
unclear. Several direct effects of rhEPO have been described by which rhEPO can influence 
tumor oxygenation independent of the effects on hemoglobin levels or through changes in 
vascular endothelial growth factor (VEGF) expression and microvessel morphology 
(Blackwell et al. 2003, Tovari et al. 2005). Although rhEPO-treatment increased tumor 
oxygenation, we did not find significant differences in the expression of GLUTl, GLUT3, 
GLUT4, GLUTS, GLUT9, SGLTl, HKI, HKII, HKIII and N-cadherin between experimental 
groups receiving rhEPO and experimental groups that didn't. We did on the other hand, find 
significant increases in the expression of GLUT3, HKI and N-cadherin when rhEPO was 
combined with radiotherapy. As these proteins have distinct anti-apoptotic and pro-metastatic 
functions by increasing energy supply, preventing cytochrome C release and increasing tumor 
invasiveness, these findings substantiate results of earlier studies that reported that rhEPO 
might actually adversely affect survival rates of cancer patients treated by radiotherapy 
(Henke et al. 2003, Leyland-Jones et al. 2005) by acting as an anti-apoptotic agent and a 
growth factor not only on endothelial cells but on tumor cells as well (Hardee et al. 2006, 
Sinclair et al. 2007, Jelkmann et al. 2008). The mechanism by which this occurs remains 
largely unclear and needs further clarification. 
In Chapter 2, partim 2.2, the effects of a decrease in tumor oxygenation or a direct HIF-1 
activation on tumor metabolism were studied by investigating [18F]FDG-uptake in an in vitro 
and in vivo model of human colorectal carcinoma. We first investigated the effects of 
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chemical activation of HIF-1 on [ 18F]FDG-uptake in human HT29 colorectal carcinoma cells. Treatment of HT29 colorectal carcinoma cells with the hypoxia mimicking chemicals CoCh and DMOG resulted in induction of HIF-1 through HIF-l a protein stabilization which resulted in increased transcription of GLUTl , HK2 and CA IX genes. As opposed to CoCh, DMOG did not increase HIF-1 a mRNA levels, which is in line with its mechanism of action where DMOG inhibits breakdown of HIF-1 a protein. Treatment of HT29 colorectal carcinoma cells with the hypoxia mimicking chemicals CoCh and DMOG resulted in significant increases in [ 1 8F]FDG-uptake. Both chemicals are hypoxia mimics that, as confimed in this study, provide an easy platform to activate HIF-1 and investigate the hypoxic response in an in vitro setting. Whereas CoCh-induced stimulation of [ 18F]FDG-uptake seems to increase as a function of time, the DMOG-induced stimulation appears to have an early set­on and remain constant throughout time. These results thus indicate a different mechanism of action of CoCh and DMOG. Although numerous in vitro studies in different types of cancer cell lines have reported on an increase in [3H]-FDG or [ 18F]-FDG uptake after exposure to decreasing oxygen atmospheres (Clavo et al. 1 995, Burgman et al. 2 001 , Pedersen et al. 2 001 , Oswald et al. 2 007), studies reporting on glucose-uptake after a chemical induction of hypoxia are limited. Two studies in Clone 9 rat liver cells reported on an increase in 3-O-methyl D­glucose transport after treatment for 24h with CoCh which was associated with an increase in GLUTl rnRNA and protein content (Behrooz et al. 1 997, Hwang et al. 2 002). Similar results were obtained in Be Wo choriocarcinoma cells and articular chondrocytes (Baumann et al. 2 007, Peansukmanee et al. 2 008). In a next step, we investigated [ 18F]FDG-uptake after induction of artificial hypoxia and chemical activation of HIF-1 in an in vivo xenograft model of human colorectal carcinoma. Comparison of endogenous and exogenous hypoxic markers in control animals showed a significant correlation between pimonidazole staining and CA IX expression, confirming the role of CA IX as one of the most reliable endogenous markers of tumor hypoxia. Given the timeframe of CA IX expression (Vordermark et al. 2 005), this would confirm that CA IX as well as pimonidazole mainly demonstrate chronic hypoxia. Upon visual inspection we observed that, although an absolute spatial colocalization was absent, expression of CA IX and GLUTl showed a strong overlap with pimonidazole staining and a similar staining pattern. To create artificial hypoxia in our in vivo tumor model, we used the peripheral vasodilator hydralazine hydrochloride which, through indirect inhibition of tumor blood flow ('steal phenomenon'), causes tumor hypoxia (Fisker et al. 1 991). In this study as well, a 1 48 
significant decrease in tumor pO2-values was observed in the HT29 xenograft after 
administration of a single dose of hydralazine. There have been several attempts to modulate 
tumor oxygenation in order to overcome RT resistance and improve response. Only a few 
studies have looked at the effects of this modulation on [ 18F]FDG-PET imaging. In a study by 
Chan et al., a significant increase in [ 18F]FDG-uptake was found in SCCVII tumor bearing 
mice breathing normal air when compared to carbogen, only when the highest uptake regions 
of the tumor were considered (Chan et al. 2006). Comparable results were obtained by 
Bentzen et al. (Bentzen et al. 2000). Another study by de Geus-Oei et al. found that 
[
18F]FDG-PET with hyperoxygenation in 22 patients suffering from head-and-neck cancer 
induced a profound, but variable metabolic change ( de Geus-Oei et al. 2006). To our 
knowledge, only one study evaluated 1 4C-2-deoxyglucose uptake in an hypoxic tumor model 
created by use of a tourniquet and observed a decrease in uptake as compared to the control 
tumor on the other thigh (Kubota et al. 1999). In our study, treatment with a single dose of 
hydralazine caused a minor decrease in SUVmax and SUVmean. Perhaps the lack of effect 
that is seen after treatment with hydralazine is the consequence of the decreased tumor 
perfusion that characterizes its mode of action. Other studies, that successfully used 
hydralazine to confirm the pO2 dependence of several hypoxia-selective PET imaging agents 
did not indicate an effect on tracer delivery and subsequent binding as soon as thirty minutes 
after hydralazine treatment (Lewis et al. 2001, Kinuya et al. 2002, Lee et al. 2008). Another 
possibility is an incorrect timing of hydralazine administration. The timing used in this study 
was based on work by Fisker et al., where an almost 90% reduction in tumor levels of 86-
RbCl was observed within 15min following a single dose of 5 mg/kg hydralazine i.v. before 
slowly returning to control levels after about 8h (Fisker et al. 1991). We assumed that the 
ideal moment to inject [ 18F]FDG would be the moment were a partial or complete recovery of 
tumor blood flow was present. In other words, it was our intention to find the time point 
where the effects of reduction of blood flow would not hamper tracer delivery but at the same 
time would ensure the hypoxic effects that would be necessary to activate the HIF-1 system 
and induce downstream gene expression of glucose transporters, hexokinases, . . . . We 
therefore chose to determine [ 18F]FDG-uptake 3 hours and 8 hours after hydralazine 
treatment. To chemically activate HIF-1 in our in vivo tumor model, we used DMOG, which 
has no direct effects on tumor oxygenation but stabilizes and activates HIF-1 through PHD­
inhibition. Systemic administration of DMOG has been described previously without adverse 
effects (Cummins et al. 2008, Milkiewicz et al. 2004, Hill et al. 2008). In our study, we 
observed an increase in SUV max and SUV mean after treatment with a single dose of DMOG 
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which was statistically significant on day 1. We hypothesize that the increase in tumor 
[
1 8F]FDG-uptake after treatment with a single dose of DMOG is the consequence of tumoral 
HIF-1 activation with an associated transcription of metabolic genes resulting in an increase 
in glucose/[ 18F]FDG uptake. As proposed by Cummins et al., DMOG may be primarily active 
at the sites of acute insults. Indeed, they showed that DMOG did not alter basal 
myeloperoxidase activity and cytokine levels in normal colon tissue, but counteracted 
inflammation in colon subjected to inflammatory insults (Cummins et al. 2008). Another 
study observed similar effects when DMOG induced increased expression of HIF-la and 
downstream VEGF in muscle that was subjected to ischemic insult, but not in normal muscle 
(Milkiewicz et al. 2004). If this would be the case, tumor specific activation of HIF-1 can 
indeed be achieved with associated increase in glucose transport. 
In Chapter 2, partim 2.3, the distribution of the exogenous hypoxia marker pimonidazole was 
compared with the expression of GLUT 1 and 3, HK2 and CA IX in a spontaneous canine 
mammary gland carcinoma. This spontaneous canine tumor model was chosen because of its 
high incidence, easy resection and the common occurrence of multiple tumors. As described 
in Chaper 1, the exogenous hypoxia marker pimonidazole is the most relevant marker for 
qualitative and quantitative determination of tumor hypoxia in experimental and clinical 
circumstances. In this study a statistically significant correlation was found between 
pimonidazole staining and GLUTI expression confirming the strong interplay between tumor 
hypoxia and tumor metabolism. 
In Chapter 2, partim 2.4, the expression of CA IX was compared with [ 18F]FDG-PET 
SUVmax and SUVmean values in patients suffering from NSCLC. The transmembrane zinc 
metalloenzyme carbonic anhydrase IX (CA IX) catalyzes the reversible hydration of carbon 
dioxide to carbonic acid outside the cell and is involved in respiration and acid-base balance 
(Potter et al. 2004). As the gene for CA IX has been shown to be one of the most strongly 
hypoxia-inducible ones (Lal et al. 2001 ), it has emerged as one of the most reliable and 
frequently used endogenous hypoxia markers. In this study, a statistically significant 
correlation was found between CA IX expression and [ 18F]FDG SUVmax and SUVmean 
values of the primary tumor. Besides further confirming the strong interplay between tumor 
hypoxia and tumor metabolism, these results also suggest that in the future it may be possible 
to identify NSCLC patients that are most likely to benefit from CA IX targeting therapy on 
the basis of [ 18F]FDG-PET imaging. 
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In Chapter 3, a new radiotracer to detect tumor vasculature was evaluated. The radiolabeling 
of His-CNA35 with [99mTc] via tricarbonyl is described and its use in the detection of tumor 
vasculature is investigated. Overall preparation of 99mTc-(CO)3 His-CNA35 was 
straightforward and resulted in a pure product with a good stability. An in vitro solid-phase 
binding assay confirmed the functionality and specificity of the labeled molecule. This assay 
confimed binding of the molecule to collagen I and IV while negligible binding was observed 
to fibronectin-, laminin- and non-coated surfaces. These results confirm earlier results 
obtained in binding experiments perfomed with a fluorescently labeled variant of the CNA35 
molecule (CNA35-OG488) where a strong affinity of CNA35 for collagen I and IV and a lack 
of major binding to other extracellular matrix proteins besides collagens, was described 
(Krahn et al. 2006). Biodistribution studies indicated a rapid clearance from the blood and a 
predominantly urinary excretory pathway. Mice biodistribution data were translated into 
estimates of patient dose and effective doses are in the low range when compared to other 
tracers used in a clinical setting (ICRP 2008). The effective dose numbers obtained in this 
study however, merely give an estimate of the actual patient dose and therefore, a detailed 
study in humans is still recommended. After injection of 99mTc-(CO)3 His-CNA35 in 
untreated HT29 human colorectal carcinoma bearing mice, all tumors were visually 
determinable and showed a heterogeneous uptake of the radiotracer. Similar to biodistribution 
experiments, high uptake was seen in liver and kidneys which can be the result of the nature 
of the endothelial lining in these organs. Unlike in other organs, the blood vessels in the liver 
have a discontinuous endothelial coverage and the blood vessels of the kidneys have a 
fenestrated endothelium (Young et al. 2000, Aird et al. 2007). As a result, labeling of collagen 
in the subendothelial layers of these blood vessels can occur. In a study by Megens et al. that 
performed collagen imaging of a fluorescently labelled variant of CNA35 (CNA35-OG488) in 
normal wild-type mice and Apo K'- mice with induced atherosclerotic plaques after both ex 
vivo and in vivo administration, a similar phenomenon was described (Megens et al. 2007). To 
confirm uptake specificity, immunohistochemistry was performed on these animals and these 
results showed a significant correlation between T/B ratios and MVD (CD105/Endoglin) and 
blood vessel associated collagen IV. Further, an inverse correlation was found between T/B 
ratios and vessel maturity (VMI; aSMA). These results indicate that imaging using CNA35 
gives a reliable estimate of existing tumor vasculature and confirm the proposed mechanism 
of binding in which the characteristic leakiness and immatureness of tumor blood vessels 
allows binding of subendothelial collagen IV and selective imaging of tumor vasculature. 
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Several in vitro studies suggested that [ 18F]FDG-uptake is increased under hypoxic conditions 
(Clavo et al. 1995, Burgman et al. 2001, Pedersen et al. 2001, Oswald et al. 2007) and several 
studies performed in different xenograft models have described a correlation between 
[
18F]FDG-uptake and pimonidazole staining (Scigliano et al. 2008, Dearling et al. 2004, 
Pugachev et al. 2005). Likewise, our results suggest a strong interplay between tumor hypoxia 
and tumor metabolism. More specifically, we found a significant correlation between 
pimonidazole staining and CA IX expression in a colorectal carcinoma mouse xenograft, a 
significant correlation between pimonidazole staining and GLUTI expression in a 
spontaneous canine mammary gland carcinoma and a significant correlation between CA IX 
expression and [18F]FDG SUVmax and SUVmean values of the primary tumor of patients 
suffering from NSCLC. Whereas our results suggest that [ 18F]FDG-uptake might reflect 
tumor hypoxia, comparison of the distribution of [
18F]FDG with more specialized hypoxia 
tracers has yielded mixed results (see Chapter 1). It appears that in those tumors where HIF-1 
activation is mainly hypoxia-driven, the degree of [
18F]FDG uptake may be a surrogate 
marker of tumor hypoxia. Therefore, it seems questionable that [
18F]FDG can act as a reliable 
non-invasive marker of tumor hypoxia as several other hypoxia-independent 
microenvironmental parameters such as differentiation, pH, glucose availability, oncogene 
activation, . . .  affect the activation of HIF-1 and/or the expression of proteins downstream of 
HIF-1 that are involved in glucose metabolism. However, insight into the relationship 
between tumor hypoxia and tumor metabolism can create opportunities to increase [
18F]FDG­
uptake in situations where diagnostic accuracy is suboptimal: (i) tumors with a high 
differentiation and a low growth rate (prostate carcinoma, hepatocellular carcinoma and 
neuroendocrine tumors) often fail to take up [ 18F]FDG; (ii) the inability of [ 18F]FDG to 
evaluate lesions either in or adjacent to tissues with a high metabolic activity (brain) or 
physiological accumulation (urinary bladder); and (iii) the reduced specificity of [ 18F]FDG in 
the differentiation of malignant from an infective or inflammatory process (Kellof et al. 2005, 
Endo et al. 2006). In this work, [ 18F]FDG-uptake was increased in an in vitro and in vivo 
model of human colorectal carcinoma after chemical activation of HIF-1 using a PHD­
inhibitor. Possibly, in situations were [ 18F]FDG-PET imaging is less successful, imaging after 
a single treatment with PHO-inhibitors might increase sensitivity. Several of these prolyl 
hydroxylase domain-containing protein inhibitors are currently under development for the 
treatment of anaemic and ischemic conditions in humans (Yan et al. 2010, Bernhardt et al. 
2010). Although some of these compounds are currently undergoing phase I and phase II 
clinical trials, their oncological use has not been explored and deleterious effects on tumor 
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progression thus need to be investigated. Future studies will try to confirm the results obtained 
in the HT29 colorectal carcinoma xenograft using PI-ID-inhibitors in the spontaneous canine 
mammary carcinoma tumor model. 
In a second part of this thesis a new radiotracer of tumor vasculature was evaluated. The 
successful labeling and in vivo imaging properties are described. However, a limitation to our 
approach is the existence of capillaries with a fenestrated and/or discontinuous endothelium in 
a number of tissues like kidneys, endocrine glands, gastrointestinal tract and liver (Young et 
al. 2000, Aird et al. 2007). Although biodistribution studies did not indicate much binding of 
our molecule to other organs except kidneys and liver and all tumors were visually 
determinable, future studies will have to assess the extent of non-specific binding in these 
organs. 
Imaging of tumor vasculature is interesting for a number of reasons. Firstly, as the importance 
of anti-angiogenic chemotherapy increases, methods are needed to provide a reliable 
assessment of tumor vasculature and thus provide a means for the management and planning 
of anti-angiogenic therapy. Given the difficulties associated with invasive methods, a non­
invasive method is of major clinical interest. Several candidate markers have been labeled 
with PET and SPECT labels to image tumor vasculature of which compounds that specifically 
target VEGF (vascular endothelial growth factor) and its receptors together with compounds 
that target integrins are the best studied. Although several of these tracers have been tested in 
a pre-clinical and clinical setting where they successfully visualized several types of tumors 
and their metastases (Cai et al. 2008, Dijkgraaf et al. 2009), none of these are routinely used 
in clinic and few have been used to detect antiangiogenic therapy response. In one study by 
Blankenberg et al., 99mTc-HYNIC-VEGF was successfully used to detect response to low­
dose metronomic (antiangiogenic) and high-dose (tumoricidal) cyclophosphamide treatment 
in mice with 4Tl tumors (Blankenberg et al. 2006). Further, a recent study by Nagengast et al. 
successfully evaluated 89Zr-ranibizumab as a biomarker of dynamic angiogenic changes in 
tumors after treatment with sunitinib (Nagengast et al. 2011). However, due to the long 
biological half-life ofVEGF, labeling of VEGF or VEGF-targeting molecules with long-lived 
isotopes like 89Zr or 1 1 1In is needed (Nagengast et al. 2011, Nagengast et al. 2011), resulting 
in high radiation exposures. Using RGD (asparagine-glycine-aspartic acid) - peptide based 
tracers, several studies also successfully evaluated treatment response to antiangiogenic 
therapy (Jung et al. 2006, Morrison et al. 2009, Battle et al. 2011). However, as integrins are 
expressed not only on endothelial cells but on tumor cells as well (Jung et al. 2006, Beer et al. 
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2006), and are minimally expressed on normal quiescent endothelial cells (Brooks et al. 
1994), RGD-peptide based tracers might not be truly representive of existing tumor 
vasculature. Furthermore, high uptake of 1 8F-galacto-RGD in inflammatory lesions has been 
reported (Haubner et al. 2005). 99mTc-(CO)3 His-CNA35 provides a new means to target 
tumor vasculature and thereby image it. In future studies, the potential of this tracer to provide 
a reliable assessment of the efficiency of anti-angiogenic chemotherapy and thus a means for 
its management and planning, will be evaluated. Additionally, we will attempt to label 
CNA35 with PET labels such as Gallium-68 (68Ga). Whereas SPECT imaging with 99mTc 
offers the advantage of ready availability at a low cost and versatile chemistry, PET ensures a 
superior spatial resolution and more accurate quantification. Secondly, given its characteristic 
mechanism of action, CNA35 might also be a valuable tool to evaluate the vascular 
'normalisation window' that follows anti-angiogenic chemotherapy. This phenomenon states 
that careful application of antiangiogenic therapy can 'normalize' the abnormal tumor 
vasculature, resulting in more efficient delivery of drugs and oxygen to the targeted tumor 
cells and thereby enhancing RT and chemotherapy efficiency (Jain et al. 2005). Indeed, 
administration of antiangiogenic drugs as a single agent yielded only modest objective 
responses and no long term survival benefits in clinical trials. In contrast, when given in 
combination with chemotherapy, increases in survival were observed (Mia et al. 2008). It 
appears that antiangiogenic therapy can restore the imbalance between pro- and anti­
angiogenic factors and thereby partially restore the structural and functional deficiencies that 
characterize tumor blood vessels. These deficiencies, as mentioned in Chapter 1, lead to 
heterogeneous blood flow, hypoxia, acidosis and elevated interstitial fluid pressure (IFP) with 
a disturbed tumor microenvironment as a result. Because tumor vasculature labeling with 
CNA35 is based upon these abnormalities, restoration of a normal tumor vessel wall would 
inhibit binding of the molecule. As a consequence, imaging using CNA35 would allow 
evaluation of the 'normalisation state' of tumor blood vessels. As suggested by Jain, it is 
crucial to identify the time window during which the vessels initially become normalized, as 
well as an understanding of how long they remain in that state (Jain 2005). Given its 
mechanism of binding, CNA35 might be an ideal candidate to identify the time frame of this 
'normalisation window' and therefore the ideal moment to administer chemotherapy. Finally, 
as tumor vasculature and tumor hypoxia are highly interconnected, non-invasive imaging of 
tumor vasculature might provide insights into tumor hypoxia and allow estimation of the 
degree of tumor hypoxia. Few studies have reported on a comparison between tumor 
vasculature imaging agents and tumor hypoxia imaging agents. In one study by Picchio et al., 
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a substantial discordance was found between the tumor distribtion of [ 18F]FAZA and [251]­
Gluco-RGD in EMT6 tumor xenografts (Picchio et al. 2008). In several studies performed by 
the group from Nijmegen, the spatial distribution of exogenous markers of tumor hypoxia was 
compared with immunohistochemical markers of tumor vasculature. Whereas one study found 
only a weak and non-significant inverse correlation between hypoxic fraction and vascular 
density (Wijfels et al. 2000), another study found a significant inverse correlation between the 
hypoxic fraction and the density of perfused vessels (Rijken et al. 2000). Future studies will 
compare 99mTc-(CO)3 His-CNA35 uptake with uptake of a specialized hypoxia tracer. 
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